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The synthetic vitamin A derivative, fenretinide (4HPR) was developed in the 1970’s as a 
means to induce retinoid cancer preventive effects in cells and tissues devoid of the retinoic acid 
receptor, and has become an important compound for chemoprevention of a variety of cancers 
such as oral squamous cell carcinoma (OSCC).  However, OSCC chemoprevention clinical trials 
with orally delivered 4HPR have been unsuccessful likely due to extensive first pass metabolism, 
systemic toxicity, and sub-therapeutic levels of 4HPR at the target site. Local 4HPR delivery 
vehicles have the potential to deliver therapeutic doses while alleviating any systemic side 
effects.  Limited penetration distance of the drug in tissues, however, is one of the most prevalent 
challenges with the local delivery approach. To overcome these limitations and to increase drug 
exposure at the site of action, solubilizers and permeation enhancers were combined with 4HPR 
in local delivery depots, and their drug release kinetics in vivo and 4HPR’s tissue uptake in 
presence of solubilizers ex vivo were evaluated.  Long-acting release of 4HPR from injectable 
millicylindrical implants were prepared with poly(lactic-co-glycolic acid) and polyvinyl alcohol 
(PVA)/sucrose matrices as a function of drug loading and the presence of various excipients to 
enhance the release of the water-insoluble 4HPR. 4HPR was released from PLGA implants much 
slower in vivo than in the Tween 80-solubilizing media in vitro, with a 3-week lag phase 
followed by continuous release of  >2 months, and showed some release enhancement by 
addition of solubilizers. The water-soluble PVA/sucrose implant provided continuous drug 
release for up to 6 weeks in vivo. These 4HPR-PLGA formulations were further evaluated in an 
oral cancer xenograph mouse model, and shown to be effective at reducing rate of tumor growth 
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over 10 days. A remarkable solubility enhancing formulation was achieved with 4HPR 
amorphous solid dispersions (ASDs) prepared with polvinylpyrrolidone (PVP) polymer.  The 
PVP-4HPR ASD was loaded into PLGA implants and evaluated in vivo, and found to 
substantially improve release kinetics from previous crystalline 4HPR formulations.  Tissue 
binding kinetics was characterized in buccal epithelia and subcutaneous tissues in presence of 
various solubilizing and permeation enhancing media. Time of exposure, but not solubilizer or 
permeation enhancers, affected uptake and 4HPR exhibited a five-fold greater binding affinity to 
buccal epithelia relative to subcutaneous connective tissues. These optimized long-acting 4HPR 
millicylindrical implants were further evaluated in vivo over 2 weeks in rabbit buccal epithelia, 
for their ability to enhance drug-tissue distribution.  Quantitative Raman spectroscopic imaging 
was utilized to measure drug-tissue concentration gradients in excised tissue sections.  The 
implants released much faster in the mouth compared to our previous studies in s.c. tissue, and 
the drug penetration in the buccal tissues (i.e. distance to reach 10% of concentration at implant 
surface, or C10) was on the order of 0.5- 8 mm for all formulations.  The ASD of 4HPR in PLGA 
provided the greatest drug penetration through tissues, likely as a result of supersaturated drug 
concentrations next to the implant.  Hence, these approaches may be useful for local delivery of 
4HPR and OSCC chemoprevention.   
 
 






Chapter 1: Introduction 
1.1.  Oral Cancer Disease State and Treatment  
Oral squamous cell carcinoma (OSCC) is a worldwide health concern, and in 2016, 
~50,000 Americans were newly diagnosed with oral or pharyngeal cancer(1).  The risk factors 
associated with OSCC include smoking, alcohol consumption, human papillomavirus (HPV) 
infection, and Epstein-Barr virus(EBV) (2). The vast majority of oral cancers arise from 
malignant transformation of preneoplastic surface epithelial lesions(3). Despite treatment 
advances that include intraoperative radiation, the 5-year survival rates of persons with OSCC 
is discouraging low (50%) (2).  Following initial therapy, oral cancer patients are managed by 
close clinical follow-up often supplemented with imaging studies.  Despite vigilant monitoring 
and well-recognized risk factors for recurrence, over one third of patients develop life-
threatening and often untreatable recurrent OSCCs (4).  Replacement of the current “watchful 
waiting” strategy with well-tolerated and effective secondary OSCC chemoprevention could 
make a significant clinical impact for these individuals. As OSCC management requires 
extensive, often disfiguring surgery, treated OSCC patients often experience depression and 
reduced motivation.   
Development of an implantable delivery system capable of providing therapeutic drug 
levels while alleviating systemic side effects and improving patient compliance issues could 
advance secondary OSCC chemoprevention. The synthetic vitamin A derivative, 4-
hydroxy(phenyl)retinamide [fenretinide (4HPR)] was developed in the 1970s as a means to 




induce retinoid cancer preventive effects in cells and tissues devoid of the retinoic acid 
receptor (5).  Previous studies from our labs have demonstrated that 4HPR inhibits focal 
adhesion kinase (FAK)-ECM interactions and significantly reduces invasion, which is the 
ultimate step in OSCC development(6). To address OSCC’s redundant signaling cascades, 
secondary OSCC chemoprevention will ultimately require complementary agents (7).  Based 
on fenretinide’s multiple mechanisms of action including growth regulation and suppression of 
gratuitous signaling (8),  it is our intention to include fenretinide (4-HPR) in the secondary 
chemopreventive formulation.       
1.2.  Fenretinide (4HPR) for Oral Cancer Chemoprevention  
1.2.1.  4HPR Clinical Trial Results  
  One of the first studies utilizing 4HPR as a chemopreventive was done in 1994 by 
Tradati et al, where topical application (100 mg b.i.d. x 2 months) for treatment of oral 
leukoplakia/lichen planus resulted in regression of lesions, with no adverse side effects and 
minimal systemic drug levels (9).  The clinical trials (2005) with oral administration of 4HPR 
at low doses (100 mg p.o. b.i.d.), showed that 4-HPR protected against recurrent lesions, but its 
overall efficacy was unclear.  An additional study of low dose (200 mg p.o. q.d. x 3 months) 
given to non-excised oral epithelia dysplasia (OED) lesions showed reduction of lesion size in 
34% of patients (10).  In high dose studies (900 mg/m2 p.o. b.i.d. in 3 weeks cycles), low 
response rates led to discontinuation of the study (11). Despite some promising results of 
decreased lesion size in these clinical trials, the orally dosed route failed due to inability to 
achieve therapeutic levels, even at high doses(4).  These high doses often were associated with 
severe side effects, including nyctalopia, hyperlipidemia, and dry skin. These studies also 




failed to fully evaluate local pharmacokinetic (PK) parameters including tissue concentrations, 
metabolite formation, and drug stability and release kinetics(4).   
1.2.2.   4HPR Pharmacological Mechanisms 
In vitro, 4HPR demonstrated extensive cancer prevention (chemopreventive) promise 
by its abilities to induce terminal differentiation and/or apoptosis in a variety of epithelial and 
neural origin premalignant and malignant cells (12, 13).  In vitro efficacy did not translate, 
however, to clinical efficacy (14-16) where human OSCC chemoprevention clinical trials using 
oral/systemic 4-HPR delivery were unsuccessful (4). These findings likely reflect extensive 
4HPR inactivation during first pass metabolism coupled with an inability to achieve 
therapeutic levels in the oral cavity(4), while systemic side effects e.g. mucositis, nyctalopia 
and increased sera lipids were observed (16, 17).  4HPR can bind with high affinity to selected 
proteins e.g. retinol binding protein, focal adhesion kinase (6, 18), STAT3 (7), which opens the 
prospect that tissue bound 4HPR could serve as a local drug reservoir.  Furthermore, for 
optimal cancer prevention efficacy, 4HPR also needs to induce tumor suppressive effects on 
the connective tissue stroma and infiltrating inflammatory cells as well as the premalignant 
lesional cells (19).  4HPR has the antineoplastic effects of Vitamin A, but also has a decreased 
resistance-induction and toxicology profile (20).  4HPR has been shown to modulate thiol 
dependent proteins that are responsible for redox-signaling and growth regulation are important 
in chemoprevention (21-23).  Long-term efficacy with 4HPR is plausible due to its receptor-
independent induction of apoptosis.  It has been shown in vitro that high 4HPR concentrations 
(10 µM) induced apoptosis through a receptor-independent pathway, and low concentration (1 
µM) promoted epithelial differentiation through a receptor-mediated pathway (20).  




1.2.3.    4HPR Physiochemical Properties and Pharmacokinetics  
4HPR (Fig.1-1) is a highly lipophilic compound, with a logP of 6.31(24).  4HPR is 
nearly insoluble in aqueous solutions, making it a cumbersome compound to develop into an 
effective drug product. 4HPR has a phenyl-amide group that possesses three proton-accepting 
sites as well as two proton donors, that is connected to the parent retinoid structure of a 
conjugated poly-olefin chain and cyclohexenyl ring. This highly conjugated molecule gives 
rise to its bright yellow color, strong UV absorption at 365 nm with molar absorptivity (ε) of 
47,900 M-1·cm-1. The phenyl-amide group gives 4HPR more surface activity than other retinoids 
(25).  Discrepancies may arise from observed versus predicted solubilities due to tendency of 
retinoids to aggregate (25).  Additional formulation challenges can arise during in vitro 
experiments when high levels of surfactants are used for 4HPR solubilization, which do not 
produce physiologically meaningful data (26, 27).  Therefore it becomes difficult to predict 
release and tissue distribution behavior based on standard in vitro testing methods.  In addition 
to its low aqueous solubility, 4HPR is subject to photodegradation and oxidative degradation 
which is most pronounced in organic solvents.  4-HPR is stable in its solid state(24) and 
multiple polymorphs do exist.(28)   
 
Figure 1-1. Fenretinide (4HPR) chemical structure, a chemotherapeutic molecule. 
Human pharmacokinetic (PK) data obtained from previous 4-HPR clinical trials with 
200-1000 mg daily oral dosing demonstrated that 4HPR is retained in tissues (20%)(29), rapid 
equilibrium occurs in plasma (<24 h)(29), has greater preference for tissue than plasma, max 
plasma levels are achieved after 4 h (Tmax) (15), half live (t1/2) is 12-24 h (14-16) and is 




detected in blood even 6 mo. post-treatment indicating bioaccumulation (16). When dosed 
orally, 4HPR exhibits high first pass metabolism into its primary metabolites including the 
oxidized 4HPR (4-oxo-HPR), hydroxyl-4HPR (4-OH-HPR), methylated 4HPR (4-MPR), and 
glucuronidated 4-HPR.  4-MPR is inactive and is the primary outcome of 4-HPR as it passes 
through the liver. While the human oral cavity does not contain enzymes that can methylate 4-
HPR, it does possess the enzymes capable of oxidative bioactivation and the glucuroniated 
metabolite capable of enteric recycling. Nude mouse tissue, however, may be capable of 
methylating 4-HPR. The 4-oxo-HPR metabolite is active and has been shown to have 
chemotherapeutic properties.  Additionally, little or no free retinol, retinaldehyde or retinoyl 
esters are excreted from body following intravenous (IV) injection of 4HPR, indicating 
extensive metabolic degradation is occurring(30). 
 Poor therapeutic tissue levels of 4HPR can be related to its physicochemical properties 
and non-specific binding to tissue components.  Highly lipophilic drugs generally have greater 
tissue permeability due to partitioning and accumulation into the cells phospholipid bilayer.   
However, for extremely lipophilic drugs (logP >3.5), the permeation is actually decreased due 
to high aqueous insolubility and excessive accumulation in the subcutaneous (SC) fat deposits 
(29).  4HPR across Caco-2 monolayers was investigated, and where it was suspect that many 
factors could contribute to poor oral absorption of 4HPR, including low solubility/dissolution, 
paracellular transport component of passive diffusion, drug efflux by the transporter p-
glycoprotein (P-gp), transport via saturatable carrier-mediated transporters, degradation and 
metabolism, and accumulation in the cell membrane.(31)  The results of that study showed that 
transport of 4HPR through Caco-2 cells occurs by transcellular passive diffusion, and poor 




permeation of 4HPR was attributed to its accumulation in the lipophilic cell membrane and 
poor partitioning into the receiver medium (solubility issues)(31).    
Biological molecules, such as sera protein albumin, can stabilize drugs and prevent 
their clearance from tissue. The high propensity of 4HPR to precipitate with plasma proteins 
leads to a decrease of active drug at the target site.  This high plasma binding is characteristic 
of retinoids, such as retinol, where little to no free retinol is transported in the body, due to its 
exclusive binding to the carrier protein retinol binding protein (RBP) present on cell surfaces 
(30).  4HPR displaces vitamin A on sera retinol binding protein with 100-fold greater affinity 
(17), results that demonstrate 4HPR is capable of high-affinity protein binding.  RBP then 
forms a complex with pre-albumin to prevent loss by ultrafiltration in the kidney, thereby 
contributing to slower clearance of the drug-protein complex (30).     
1.3. Oral Cavity Properties and Drug Formulation Considerations 
1.3.1.   Oral Epithelium Properties 
The oral cavity is an attractive site for local and systemic drug delivery routes due to a 
high degree of vascularization leading to greater permeability. In particular, the non-
keratinized tissues of the oral mucosa are preferred over keratinized sites. Nearly all 
compounds are capable of traversing these tissues, yet their rate depends upon their size and 
chemical nature.  The permeability of the oral mucosa is protected by several barriers, 
including intercellular boundaries caused by membrane coated granules in stratified squamous 
epithelium, basement membranes, lipids, and saliva containing high molecular weight mucins 
(MG1) (32).  The mucosal layer functions include: clearance mechanisms, water balance, ion 
transport and regulation, lubrication, diffusion barrier, creating a barrier to drug absorption 
(33).     




The surface area of the human oral mucosa is 200 cm2 and is highly vascularized, multi-
stratified, and is either keratinized or non-keratinized contingent upon location. Drug 
permeation through the mucosa occurs via both transcellular and paracellular routes (34).  The 
buccal region has three distinct tissue layers (Fig. 1-2): epithelium, basement membrane, and 
connective tissue. The thickness of the buccal epithelium (in humans) is 500-800 μm, or 8-10 
cells, and its turnover rate is 28 days (32). The mucus coating the buccal epithelium is 0.1-0.7 
mm thick. Three types of overlying stratified epithelium is present in different regions 
including: masticatory mucosa, lining mucosa, and buccal mucosa(32). Masticatory mucosa 
covers the gingival and hard palate and consists of keratinized epithelium closely resembling 
the epidermis of skin.  It is usually tightly attached to collagenous connective tissue. Lining 
mucosa covers all other regions except the dorsal surface of tongue, and has the ability to 
stretch, and is composed on non-keratinized stratified squamous epithelium. Lining epithelium 
is attached by loose, elastic connective tissue underlying structures. The buccal mucosa 
epithelium is the least permeable site, while the floor of the mouth has the highest 
permeability, and most extensive vascularity, hence it is a popular delivery site for sublingual 
medications. The lining regions of the floor of mouth and lateral border of tongue have been 
deemed high risk sites for OSCC. Additional layers of the epithelium in oral cavity include the 
corium and submucosa that contain minor salivary glands and other secretory glands, blood 
vessels, fat, fibrous tissue, and white blood cells. The types of cells present in healthy oral 
epithelium include melanocyte, Langerhans cells, and Merkel cells.  Following local trauma, 
infection, or an immune response, granulocytes, histiocytes and lymphocytes are also present. 





Figure 1-2. Structure of the oral mucosa, including the overlying oral epithelium and underlying connective tissue 
(lamina propria and submucosa) (32). 
 
1.3.2.   Factors Affecting Oral Mucosa Permeability 
 The permeability of the mucosa may be increased under certain circumstances, and is 
most often observed in undifferentiated epithelial cells that may be present near the teeth, 
during consumption of alcohol, through use of toothpastes containing surfactants, or in lesions 
that facilitate uptake of water.(32) Although premalignant oral lesions are most often seen in 
tobacco users, persons with negative social histories are still susceptible. Depending upon the 
lesion grade,  4 to 95% of the lesions can undergo malignant transformation(32).  Inflammation 
is a common condition that can occur in the mouth, and can lead to reduced keratinization, and 
subsequently greater permeability.  Age of an individual can affect the characteristics of the 
oral epithelium, and concerns of whether thinning skin or other changes can lead to decreased 




permeability are debatable. Cancer therapies including chemotherapeutics and radiation can 
limit the proliferative capacity of the epithelium making it thinner or ulcerated, as well as 
reduction of salivary mucins, both compromising barrier function(32).  Permeability of some 
drugs through the buccal mucosa was found to increase when their carrier system decreased the 
pH of the mucosa (35). 
1.3.3.    Animal Models for Studying Oral Drug Delivery 
 Rabbits, dogs, and pig animal models are ideal for studying delivery to oral cavity due 
to the histological similarities to humans (36). The mucosa in rabbits and dogs is non-
keratinized and the thickness of rabbit mucosa (600 µm) is similar to humans.  The epithelial 
cheek pouch in rabbits differs slightly from humans in that it is slightly keratinized, and the 
identification and isolation of non-keratinized regions can be difficult.  Nonetheless, the rabbit 
model provides ample surface area to work with and are more economical to use than dogs.  
Rats and mice are less ideal models to use due to a greater abundance of keratinized tissues 
present. Although the oral epithelium of dogs and monkeys is non-keratinized, it is much 
thinner than humans, and therefore more permeable.  Pig buccal mucosa is frequently used due 
to its similar molecular composition to human, as well as its ease and low cost of tissue 
acquisition (34). Separation of pig buccal mucosa epithelium from connective tissue results in 
epithelium thickness of 150 μm(34).  Table 1-1 below outlines the various characteristics of 
buccal mucosa in different mammals. 
 
 




Table 1-1. Comparison of buccal mucosa of different mammals (34) 
Animal Model Tissue structure Buccal 
membrane 
thickness (μm)  
Permeability constant for 
titrated water  
(x 107 cm/min)  
Human Non-keratinized 580 ± 90 579 ± 122 
Dog Non-keratinized 126 ± 30 1045 ± 37 
Hamster Keratinized 115.3 ± 11.5 n.d. 
Pig Non-keratinized 772 ± 150 634 ± 40 
Rabbit Partially keratinized 600 n.d. 
Rat Keratinized n.d. n.d. 
Monkey Non-keratinized 271 ± 50 1025 ± 154 
n.d.= not determined 
Data represents mean ± SD 
1.4.  Local Drug Delivery Systems 
Some cancers can metastasize throughout the body, making systemic drug 
administration necessary, while other types of cancer such as OSCC, are bound to specific 
visible locations and would most likely benefit from local delivery of chemotherapeutics.   
Notably, local delivery formulations provide a pharmacologic advantage via provision of 
therapeutic levels to the target site without eliciting systemic effects. One of the challenges of 
delivering a drug locally is the drug’s limited penetration distance in tissue.  Previous research 
done by the Saltzman group(37-41) found that the penetration distance of a the drug released 
from an implantable polymer device in the brain was at most 3 mm from center of the device, 
while the highest concentrations occurred at a penetration distance of only 1 mm.  In this 
research, we will be formulating millicylindrical implants for local delivery, so we will limit 
the discussion of types of local delivery vehicles to the following sections. 
 
 




1.5.  Factors Affecting Drug-Tissue Distribution  
1.5.1. Overview  
 Limited penetration distance is the most prevalent challenge encountered during local 
drug delivery (39, 42). Not surprisingly, there are many factors that govern drug distribution in 
tissues including: rates of diffusion, convection, elimination, protein binding, cellular uptake, 
capillary permeation, degradation and permeability into cell and subcellular components 
(which may lead to bioaccumulation), and finally intracellular metabolism and efflux (43). 
Upon administration of an implantable/injectable device, the drug moves from the devices’ 
matrix to the extracellular space (ECS) along a concentration gradient, or by convecting 
interstitial fluid.  Consumption of molecules occurs via binding to tissue elements (including 
target receptors and non-specific), which can then be internalized or metabolized.  
Additionally, drug molecules can permeate blood vessels and then be transported into systemic 
circulation, leading to biotransformation, or elimination.  Diffusion through tissue interstitium 
is a slow process, and during this period of migration extensive metabolism or clearance can 
occur(43).  As a result, the volume of tissue exposed to the delivered drug is small.  A drug’s 
fate can be described in detail in terms of absorption, distribution, metabolism, and elimination 
also known as ADME. 
1.5.2. Drug Absorption 
Regardless of the route of administration, a drug must cross several cell or basement 
membranes before it reaches its target tissue.  Drugs and other molecules move across cellular 
membranes by several processes such as: bulk flow or convection, passive diffusion, facilitated 
or active transport, and pinocytosis.  Of these, passive diffusion and convection is most 




important in xenobiotics.  Diffusion mediated processes are governed by movement of drug 
along a concentration gradient, while convection occurs along a bulk flow of a liquid.   
Convection processes have a significant effect on drug delivery to tumor vascular space. The 
change in concentration can be expressed as a sum of diffusion and convection processes in 
Ficks 2nd law: 
= +  
Small hydrophilic drugs (100-200 Da) generally travel through epithelium via 
paracellular transport (between adjacent cells), and movement of molecules is limited by 
presence of tight junctions (44). Permeation enhancers are often used to allow paracellular 
absorption of large hydrophillic molecules (44). Hydrophobic drugs are most likely to pass via 
a transcellular pathway (through the cells) (44).  Once the hydrophobic drug has partitioned 
into the cell membrane, it can be absorbed transcellularly via passive diffusion or by 
specialized transporters, such as P-glycoprotein (P-gp).  In some cases drugs can be absorbed 
by transcytosis, a process by which exogenous substances are engulfed into vesicles of 
polarized cells and released at other side of cell.  If, in this process, the vesicle fuses with 
lysosomes, the drug will be degraded.  Alternatively, a drug exhibiting similar structural 
homology to endogenous compounds, could bind to a receptor, resulting in endocytosis, and 
eventually leading to drug degradation.  
1.5.3. Drug Distribution 
Upon parenteral delivery of a drug, it comes into contact immediately with a vast 
number of capillaries.  Most of the 1013 cells in the body are within a few cell diameters of a 
blood vessel, thereby making delivery of oxygen and nutrients to and from tissues possible 




(45). Notably, while the human oral surface epithelia is directly exposed to oxygen it is 
avascular and therefore dependent upon the underlying connective tissue vasculature for 
nutrients.  Blood vessel properties affecting clearance include: total surface area, average 
separation between blood vessels, wall thickness (permeability), volume/blood flow profile in 
skin, and variability in these properties can occur at given depths of skin (46).  Highly 
lipophilic drugs will have high capillary permeability, leading to a greater drug elimination 
from injection site. Solutes traverse the pores in the capillary wall by a combination of 2 
processes:  diffusion and filtration. Diffusion is the primary mode of transport for lipid-
insoluble molecules.  Most drugs can rapidly permeate capillaries at a rate much faster than 
they can traverse other membranes, and thus the rate limiting step for the movement of 
molecules through tissue is based on rate of blood flow rather than capillary permeability.  
 Understanding and elucidating the microvascular patterns in regular and irregular 
tissues is important for prediction of drug delivery to those tissues.  The vascular network of 
oral mucosa was characterized by analysis of space-filing properties (local fractal dimension, 
D), tortuosity (fractal dimension of the minimum path, Dmin), and randomness (47).  Blood 
microvessels distribution in normal skin is most abundant approximately 0.1 mm below skin 
surface (46).  Total blood vessel area was found to decrease quasi-exponentially to a depth of 
approx. 0.75 mm, but can vary between sites.   
Absorption of an injected drug usually occurs within 30 min, however absorption can 
be delayed in presence of s.c. fat, which act as barriers to transport. Both the human buccal fat 
pad and the fatty zone of the anterior hard palate are lipid rich sites in the oral cavity. The rate 
of absorption can be prolonged by incorporation of vasoconstrictors, conversion of drug into a 
less soluble form, injection of depots or implants, or administration of insoluble 




microcrystalline suspension(48).  Cell membranes and macromolecules in extracellular space 
(ECS) are transport barriers that increase diffusion path length.  Therefore, differences are 
expected between free diffusion coefficient in solution (Df) and apparent diffusion coefficient 
in tissue (Db).  The ratio of Df to Db is defined as the square of the tortuosity (t2), and increases 
when more barriers to drug traveling through ECS are present.  Other factors that can affect 
diffusion include molecular size and shape, electrostatic interactions, and protein binding. 
After absorption into the blood stream, drugs can be distributed to all parts of the body.  
Compounds that can permeate freely through membranes are distributed in body water to both 
extracellular and intercellular fluids.  Compounds that are only able to permeate capillaries are 
only distributed into the extracellular space.  Often times, a drug is highly protein bound, and 
remains in the intravascular space after injection.  Drugs can be readily redistributed in the 
body where there is a rich vascular supply, such as the brain or within the tumor environment.  
Over time, the plasma concentration falls, and the drug diffuses back into circulation for 
redistribution.  The drug can also accumulate in lipid-rich tissues with poor blood supplies, and 
is especially true for highly lipophilic drugs.  Often, drugs are not distributed equally within the 
body, but rather accumulate in specific tissues.  For example, basic drugs tend to concentrate in 
areas with pH lower than the pKa and acidic drugs tend to concentrate in areas with a greater 
pH than the pKa. 
Drug-protein binding can enhance or detract from the drugs bioavailability and 
performance.  Only unbound drugs are able to freely move from one compartment to another 
and exert their pharmacological effect.  Drugs may bind to a wide variety of plasma proteins 
including: most commonly albumin, but also lipoproteins, glycoproteins, and globulins.  




Albumin is an alkaloid, so it will bind neutral or acidic molecules, but once it becomes 
saturated, molecules will begin to bind to lipoproteins.  Basic molecules are likely to bind to α1 
acid glycoproteins.  Generally, drugs that have low protein binding are able to penetrate the 
tissue better than those that have high protein binding, however lower binding can lead to 
faster clearance. As a rule of thumb, if drug-protein binding is < 90%, then it is likely to have 
good performance, however if it is >99% bound, it is likely to significantly impact 
performance.  For drugs that undergo slow metabolism, changes in unbound fraction of drug 
directly influence the clearance of the drug.  Changes in level of free drug change the volume 
of distribution (Vd) because free drug may distribute into tissue and lead to a decrease in 
plasma concentration.   The fraction of drug unbound (fu) can be expressed in terms of free 
drug [D] and drug-protein complex [DP]: 
=
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1.5.4. Drug Elimination 
Drugs can be eliminated from the active site by capillary transport and by cellular 
uptake leading to drug degradation or metabolism.  As already discussed, drugs with high 
binding affinity have slower elimination rates and longer half-lives due to the ability to evade 
clearance mechanisms.  An advantage of local drug delivery is the ability to bypass extensive 
degradation by eliminating the first-pass effect.  When a foreign molecule enters the cell, the 
cell has mechanisms for detoxifying and degrading it such as pH dependent degradation or 
enzymatic degradation.  The purpose of metabolic processes it to render the drug more 
hydrophilic and less potent so that it may be excreted from the system.  Degradation process 
can occur by either Phase 1 or Phase 2 metabolism; by oxidative/reductive reactions with 




CYP450 or other enzymes or through conjugation reactions (glucuronidation, sulfation, 
acetylation) respectively. 
1.5.5. Drug-Tissue Penetration Equations 
 Penetrability is defined as the ability of an agent to migrate through tissue, or more 
specifically, the ability of drug molecules deposited in interstitial space to navigate through 
tissue without loss of activity (43).  Drug penetration is a function of dispersivity and 
elimination.  Dispersivity can be characterized by the diffusion coefficient, rate of fluid flow in 
tissue, and extent of tissue binding. The relationship between these factors can be summarized 
by the diffusivity/elimination modulus, φ, and is an effective way to characterize drug 
penetration (49): 
=  ×   
where L is the half thickness of delivery device, k is the elimination rate constant, and D is the 
dispersivity constant.  Additionally, the effectiveness of local drug delivery (η) can be 
calculated based on the diffusion/elimination modulus(49): 
=
1
[1 − exp (− )] 
In vivo studies conducted to determine the drug penetration distance often involves 
determining drug concentration in thinly sliced tissue sections.  Using the semi-infinite slab 
model(50), the drug concentration in tissue sections can be transformed into infinite 
homogeneous space (where Co is the concentration tissue/device interface): 
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 The penetration distance is related to elimination/diffusivity modulus (φ).  At large φ 
values, elimination dominates over diffusion, while a lower φ favors diffusion, and 
consequently a larger penetration distance.  The modulus φ can be related to the treatment area, 
for example to find the area where drug concentration is greater than 10% of maximum value 
(C > 0.1C0 ), then the penetration distance equation becomes:  
 = − =
10
 
For most drugs, the concentrations decreases exponentially the further away from 
implanted medical device, and is typically on the order of 1-3 mm(50).  Research by Saltzman 
studied the penetration distance of the cytotoxic drug carmustine from a polymeric implant in a 
rat brain for glioblastoma treatment, and found the drug penetration distance is  maximized 
with a lower φ values, (diffusion is faster than elimination) with distances ranging from 1 mm 
to 6 mm, shown in Fig 1-3(43). 
 
 
Figure 1-3.  Drug (carmustine) tissue-penetration from locally 
delivered polymeric implant in rat brain, as a function of 
elimination/diffusion modulus (φ).   




In some cases, a three compartment pharmacokinetic model is used to describe 
distribution to the tissue adjacent to the delivery device including; extracellular matrix (ECM), 
intracellular space (ICS), and cellular membrane (CM). The  molar concentration of drug per 
total tissue volume, C, can be expressed as:(41) 
= ∙ + ∙ + (1 − − ) ∙  
Where α and β are the volume fractions of ECS and ICS, respectively; CECS0, CICS0 and CCM0 
indicate the moles of drug per phase volume.  Water soluble drugs distribute most readily in 
ECM and are therefore able to efficiently diffuse around cells.(45)  Conversely, lipid soluble 
drugs are usually able to have greater penetration into lipid membranes and be transported 
intracellularly.   
1.6. Tumor Targeting 
 The local environment of a tumor makes it difficult to target for drug delivery, due to 
its lack of vascular density, and thereby the cell's distance from blood vessels which supply 
nutrients and also transport drugs, is vastly larger (>100 μm) than normal tissue. The rapid 
proliferation of tumor cells force blood vessels apart, leading to irregular blood flow, 
compression of blood and lymphatic vessels by cancer cells, and ultimately hypoxic regions in 
the tumor(45).  Additionally, this poor organization of vasculature can cause increased 
interstitial fluid pressure (IFP), and decreased movement of molecules through the ECM due to 
reduced convection(45).  The ECM is known to have a rapid turnover rate, so modification of 
the ECM has the potential to alter penetration of drugs through tissue. To target the tumor 
extravascularly by the enhanced permeation and retention (EPR) effect, particles should be in 
the size range of 200-400 nm.  




It is expected that drug release rate from a local delivery vehicle into the tumor will be 
influenced by the type of tumor environment due to expansion or compression exerted on the 
implant (non-necrotic tumor > necrotic tumor > SC > in vitro) (51).  The convective forces in 
vivo are likely to increase solvent and drug efflux, leading to a greater release in vivo than in 
vitro.  Differences in tissue perfusion will also affect drug release rates, and is expected that the 
relatively avascular network of necrotic tumor will be slower than the more vascularized 
subcutaneous space due to increased drug elimination and a larger concentration gradient.  
1.7. Solubilization Strategies for Hydrophobic Drugs 
Many techniques have been employed in attempt to increase aqueous solubility of a 
poorly soluble drug molecule, including 4HPR and other retinoid derivatives, including:  
micellar solubilization(25, 52)  reduction in particle size via milling, conjugation with 
amphilphilic moieties(53, 54),  complexation to dextrans(55), PEGylation(52),  encapsulation 
into PLGA polymeric systems including microparticles (24,56,57), liposomes(58,59), lipid-
based emulsions, formation of drug-salt (54), or formation of co-crystals (60) to name a few 
(61). Previous work by our lab had determined 4HPR solubility parameters in selected organic 
solvents along with various excipients (24, 26, 27). A comprehensive compilation of 4HPR 
solubility in organic solvents, surfactants, polymers and proteins can be found in Appendix 1.  
Solubilization agents are classified as those that inhibit crystal formation by forming drug 
complexes (PVP, β-cyclodextran, PEG 8000), or micelle forming nonionic surfactants with 
high HLB values such as Tween80 and citrate esters (35).  The potential for excipient related 
toxicity should be taken into consideration, and pharmaceutical excipients acceptable for 
human use can be referenced in the Handbook of Pharmaceutical Excipients (by Rowe, 
Sheskey and Weller, 4th ed, 2003), or commercial approved product references such as USP 




30/NF 25 (2006), Physician’s Desk Reference (57th ed 2003), FDA’s website on inactive 
ingredient guide (IIG), or deemed Generally Regarded as Safe (GRAS) by FDA. When dosing 
SC, stricter guidelines must be followed compared to IV, such as smaller volumes, isotonicity, 
narrow pH range (4-8), and lower concentration of cosolvents (62). 
1.8. Permeation Enhancing Excipients 
Permeation or tissue penetration enhancers aim to increase the drug flux into the 
targeted tissues. The mechanisms to achieve higher permeation include: changing mucus 
rheology (in mucoadhesive systems), increasing fluidity of lipid bilayer, acting on components 
and tight junctions, overcoming enzyme barriers, and increasing thermodynamic activity of 
drugs (35). A list of penetration enhancer classes, examples, and their mechanisms of action 
can be found in Table 1-2, and include the classes of surfactants, bile salts, fatty acids, 
chelators, cyclodextrins, anionic polymers, and cationic compounds. The concentration of the 
permeation enhancer must be such that it facilitates the transport of drug, but does not cause 
intercellular swelling or edema of epithelium.   
Table 1-2 Penetration enhancers and their mechanisms of action 
Class 
 
Examples Mechanism of action 
Surfactants Anionic: Sodium lauryl sulfate 
Cationic: Cetyl pyridinium chloride 
Nonionic: Poloxamer, Brij, Span, Myrj, 
Tween 
Solubilization and perturbation 
of intercellular lipids and protein 
domain integrity 
Bile salts Sodium deoxycholate 
Fatty acids Oleic acid, Caprylic acid, Lauric acid, Lyso 
phosphatidyl choline, Phosphatidyl choline 
Increase fluidity of phospholipid 
bilayer 
Cyclodextrins α, β, γ, Cyclodextrin, methylated β –
cyclodextrins 
Inclusion of membrane 
compounds 
Chelators EDTA, Citric acid, Sodium salicylate, 
Methoxy salicylates  
Interfere with Ca2+ open tight 
junctions, decrease trans. epith. 
elect. resis. (TEER) Anionic Polymers Carbopol, polyacrylic acid 
Cationic 
Polymers &  
Compounds 
Chitosan, Trimethyl chitosan 
 
Poly-L-arginine, L-lysine 
Ionic interaction with negative 
charge on the mucosal surface 




1.9. Millicylinders Implants for Controlled Release (CR) Local Drug Delivery 
Local CR drug delivery systems are presumed advantageous over daily oral dosage 
forms in that the once monthly dosing could lead to better treatment outcomes, elimination of 
first-pass effect and patient compliance issues, lowered risk of systemic toxicity, and increased 
drug stability.  Preformed implants, including millicylinders are injectable delivery vehicles, 
and can be manufactured by extrusion or compression forces to design implants of various 
shapes and sizes.  The shape of the implant plays a large role in the release of the drug due to 
available surface area for pore formation and drug diffusion routes through the implant matrix.  
Preformed implants’ reproducible size lead to release profiles that can be easily controlled. The 
process of extruding can either utilize solvent extrusion or hot melt extrusion processes.  Hot 
melt extrusion is useful for low solubility or amorphous drugs with low melting points (63). A 
major factor dictating the drug release profile is the homogeneity of drug encapsulated in the 
polymer matrix.  For controlled release drug delivery over 1-6 mo., implants can be prepared 
from bioerodible polymers, such as poly(lactic-co-glycolic acid) (PLGA), and are useful for 
both local and systemic delivery of a large range of drugs including small molecules and 
biologics. However, it is known that the dissolution of a hydrophobic drug solid can be a slow, 
thermodynamic process, resulting in intrinsic controlled release properties of the drug, and so 
therefore polymer-free implants loaded with hydrophobic drug could exert the intended long-
acting release profiles as well.  Currently, there are several injectable FDA approved drug 
products that exhibit long-acting release based on dissolution including psychotropics and 
corticosteroids. 
 




1.9.1.   Rationale for Controlled Release PLGA Implants 
PLGA and poly-lactic acid (PLA) are still the biodegradable controlled release (CR) 
polymers of choice in injectable depots owing to its safety, biodegradability, ease of 
processing, and tailorable release by adjusting its molecular weight, end-group capping, and 
ratio of lactide:glycolide monomers, as shown in Fig. 1-4 (64-66).  To date, the FDA has 
approved several PLGA CR drug products including both systemic delivery products such as 
the Lupron Depot (leuprolide acetate microspheres for prostate cancer) and local delivery 
formulations including Ozurdex® (dexamethasone intravitreal implant for macular edema), 
and Atridox (doxycycline in situ forming implants [ISFIs] for periodontitis)(67).  For our 
studies we chose to formulate 4-HPR in PLGA millicylinders due to the ability to achieve high 
drug loading, lower burst release compared to microspheres and ISFIs developed previously 
for systemic delivery (24, 56).  Additionally, the millicylinder formulations are desirable for 
future evaluation of in vivo tissue penetration and efficacy studies, and will allow for precise 
drug-tissue distribution measurements from point of origin, and will stay in place so as to 
better target the local pre-cancerous region. Due to the small size of millicylinders (~ 5 mg, 0.8 
mm i.d. x 1 cm), they can be easily injected through a trocar syringe or surgically implanted.   
 
Figure 1-4.  Chemical structure of PLGA or poly(lactic-co-glycolic) acid, showing bio-erosion by hydrolysis into 
its monomer units. 
 




1.9.2.  PLGA Chemical Properties Provide Tailorable Drug Release 
In aqueous environments, PLGA can readily undergo hydrolysis and degrade into its 
glycolic acid and lactic acid counterparts which are later biodegraded in the citric acid cycle.  
The polymer properties, water uptake and degradation time, can be adjusted by careful 
selection of a polymer based on the following criteria:  molecular weight, polymer end-capping 
group, lactide/glycolide ratio, and crystallinity (D or L isomers) (64).  The composition of the 
ratio of glycolic: lactic acid monomer chains in PLGA are critical aspects for controlled release 
properties.  Common PLGA ratios are 50:50, 75:25, 85:15 or 100% lactic acid (PLA). 
Formulations with higher content of lactic acid have slower degradation due to having greater 
hydrophobicity than glycolic acid. Degradation of 40-70% PLGA is the fastest, and 50% 
PLGA is most commonly used for 2 month release applications. There are 2 different 
stereoisomer forms of PLGA/PLA, D and L. The D isomer is amorphous, while the L isomer is 
semi-crystalline and also has slower degradation. Common formulations use a mixture of D 
and L PLGA isomers. Hydrolysis occurs faster in amorphous parts of polymer matrix, due to 
greater mobility of the chains.  However, the oligomers formed during degradation have the 
ability to crystallize, and slow the drug release.    
 The molecular weight of PLGA, proportionally related to viscosity, can affect its 
degradation profile. Common molecular weights range from 10-200 kDa, and higher molecular 
weight polymers result in slower degradation, but higher burst release due to a greater free 
volume between the polymer chains(68). Water uptake is faster in lower molecular weight 
polymers which leads to formation of pores where the drug can diffuse through. Polymer 
blends have been used to facilitate drug release of a hydrophobic drug, such as combinations of 
higher molecular weight polymers blended with a small amount of low molecular weight 




polymer. A low molecular weight polymer may be desirable for a hydrophobic drug to 
minimize the lag phase(64). 
 PLGA polymers can also be tailored by varying the end-capping of the polymer chains, 
most commonly with ester or carboxyl groups.  PLGA is a moderately hydrophobic molecule, 
with very low aqueous solubility, and hydrophilic end-capping can induce plasticization of the 
polymer.  Carboxylated  PLGA’s have greater swelling than esters, and therefore lead to faster 
polymer degradation and drug release(69). The polymer acidic microenvironment is due to the 
buildup of lactic and glycolic acid monomers formed from polymer hydrolytic degradation.  
The acidic microenvironment has been shown to stabilize certain hydrophobic drugs with 
maximum stability below pH 4(64).   
The polymer concentration in the carrier solvent affects the drug release as well.  The 
initial burst release is inversely proportionate to polymer concentration, and a higher 
concentration of polymer can lead to slower drug release. Common carrier solvents used for 
formation of PLGA based delivery systems due to PLGA's high solubility in include: 
dichloromethane (DCM), ethyl acetate (EtOAc), tetrohydrofuran (THF), n-methylpyrrolidone 
(NMP), and acetone. The toxicity of the solvent is important for the operator, patient and 
regulatory approval of the drug product. Permissible levels of residual solvent are specified by 
the United States Pharmacopeia (USP) classifications. 
1.9.3.   Drug Release Mechanisms from PLGA 
 Drug release profiles from bioerodible PLGA systems are characterized by triphasic 
release patterns: an initial high rate of drug release in the burst release, followed by a slow lag 




phase where by drug release is controlled by diffusion, and finally by an increased drug release 
the occurs when  the polymer erodes.  Transport  through pores is the most common route for 
release, and can further be described as diffusion controlled or convection controlled (through 
osmotic pumping) (66).  Table 1-3 outlines the processes that may occur to influence release 
kinetics from PLGA matrices, and the characteristics of the triphasic drug release will be 
discussed in detail in the following sections (38). 
Table 1-3. Processes that influence the rate of drug release from bioerodible matrices  
Process Possible effect Effect on the release 
rate 
Hydrolysis Auto-catalysis Increase 
Erosion and pore formation 
Plasticizing effect of oligomers 
Crystallization of oligomers Decrease 
Polymer chain mobility and pore closure 
Drug–drug and polymer–drug interactions 
Erosion Pore formation Increase 
Loss of catalytic effect of acidic degradation products Decrease 
Water absorption Hydrolysis Increase 
Pore formation 
Increased pH Decrease 
Polymer chain mobility and pore closure 
Collapse of the polymer 
structure 
Cracks and new surfaces Increase 
Decreased porosity Decrease 
Phase 1: Burst Release 
The first phase of drug release from polymer matrix is considered the burst release, and 
can be defined as the quantity of drug that escapes the polymeric delivery system prior to onset 
of polymer erosion-mediated drug release(68).  The rate and extent of burst release is an 
interplay of drug solubility (thermodynamic) and transport (diffusion) properties of the system.  
Burst release is due to rapid release of drug molecules on the surface of the polymer, or those 
that are close to the surface and are easily accessible by hydration, and therefore correlates 
with the particle surface area.  The surface area can be affected by particle size distribution, 
irregularities in shapes, and cracks that serve as channels to increase effective surface area.(68)  




Phase 2: Drug Diffusion 
 Following the initial burst release phase, the drug release in Phase 2 is often the slow 
release or lag phase.  During this phase, the drug diffuses slowly out of the denser polymer 
matrix through the few existing pores.  It is a function of drug diffusivity through polymer 
matrix, drug loading, drug solubility, matrix dimensions (surface area), and porosity and 
tortuosity of diffusion pathway (70).  In the early stages of release, the polymer becomes 
hydrated and swells and the pore formation process begins.  Initially, these pores are small, so 
little drug is able to diffuse out.  Over time, a pore network begins to form and drug can diffuse 
from matrix.  Another component of drug release in this phase is drug diffusion through the 
polymer matrix, and is dependent upon the molecule size and matrix tortuosity.  
Phase 3: Polymer Degradation and Erosion 
 In the last phase of drug release, polymer degradation and erosion govern the rate of 
drug release. This phase is characterized by the onset of matrix erosion, and release rate is 
greater than the diffusion controlled release in Phase 2.  Polymer degradation refers to 
hydration and erosion of the polymer matrix. During degradation, physical changes occur such 
as softening, pore creation/closure, pH changes, and crystallization.(70)  Factors that influence 
polymer degradation include amount of water uptake, pH, polymer chemical bond type, and 
copolymer composition. Degradation of biodegradable polymers occurs as the polymer begins 
to swell by water uptake, which can be accelerated in the presence of osmotic solutes within 
the polymer matrix. When the water enters the PLGA matrix, chemical degradation occurs as 
the polymeric matrix hydrolytically cleaves into its monomers and oligomers.  Simultaneously, 
pores begin to form within the polymer matrix, through which the oligomers/monomers can 
escape and thereby reduce the mass of the particle.   It is known that the micro-environment of 




PLGA microspheres are acidic due to buildup of glycolic and lactic acid within the matrix 
during degradation. This low micro-environment pH can further lead to the autocatalysis of the 
PLGA/PLA matrices. The hydrolysis of PLGA and PLA can be acid or base catalyzed.(69) 
Addition of basic, pore forming salts (such as MgCO3 and Mg(OH)2) increase water uptake 
leading to increased polymer degradation, and consequently increases drug release.   These 
basic salts also aide in neutralization of PLGA’s low micro-environment pH and slow 
autocatalysis, whereas addition of carboxylic acid anhydrides showed the opposite trend (69, 
71). 
Polymer erosion is more complex than degradation because it depends upon other 
processes such as depredation, swelling, dissolution and diffusion of oligomer, and 
morphological changes, all leading to a decrease in molecular weight.(72)  For PLGA, the 
mass loss of the polymeric device occurs at a critical molecular weight of  ̴ 1 kDa irrespective 
of the lactic/glycolic acid ratio.  The erosion of biodegradable polymers can occur by two 
different mechanisms: surface erosion or bulk homogeneous erosion.  Surface erosion occurs 
faster than bulk homogeneous erosion due to intrusion of water into the polymer bulk, and 
erosion of the outer layer begins first (69).  Large polymer matrices have slower drug release 
kinetics due to slower release of formed oligomers. Higher molecular weight polymers are 
more subjected to heterogeneous erosion and autocatalysis.  Crystallization of insoluble salts 
can occur on the outer shell of polymer due to accumulation of PLGA degradation products 
contacting buffers or salts (70).  When bulk erosion occurs, the polymer degrades slower 
because water uptake is much faster than the degradation, and results in homogeneous 
degradation (69).  Polymers that are built from very reactive functional groups degrade by 
surface erosion, where as those made from less reactive functional groups such as PLA or 




PLGA degrade by bulk erosion mechanisms.  PLA's slower degradation rate can also be 
attributed to steric effects, due to the alkyl group that hinders the attack of water (72). 
1.10.   Scope of Research 
 The scope of this research is to develop long acting local 4HPR millicylindrical 
implants for secondary oral cancer chemoprevention (Fig. 1-5).  These 4HPR millicylinder 
formulations should be capable of delivering high levels of drug at the lesional target site, 
while eliminating 4HPR’s extensive first pass metabolic degradation and toxic side effects 
associated with high dose systemic delivery routes. Our aim is to utilize CR PLGA 
millicylinders to provide steady therapeutic drug levels over 1-2 months.  Equally as important 
as developing local 4HPR formulations, is evaluating 4HPR’s tissue disposition. To date, there 
are no data that depict 4HPR’s tissue binding affinity during local delivery.  Limited 
penetration distance is the most prevalent challenge encountered during local drug delivery, 
which is further exacerbated by the fat deposit’s barrier action due to 4HPR affinity for lipid 
rich regions.  To overcome 4HPR extreme aqueous insolubility, solubility enhancing strategies 
will need to be employed, while permeation enhancer may be necessary to overcome limited 
tissue dispersivity.  The following paragraphs outline the steps taken to achieve these 
objectives. 





Figure 1-5:  Millicylinders for local long-acting oral cancer chemoprevention. 
 
   In Chapter 2, 4HPR will be formulated into PLGA millicylinders for long-acting local 
delivery and evaluated in vitro and in vivo for their release, implant water uptake, and polymer 
erosion.  The challenges addressed include 4HPR limited aqueous solubility and incomplete 
drug release from the PLGA millicylinders. We have selecting a continuously eroding PLGA 
polymer that will target the 1-2 month delivery period, however the potential for the 
hydrophobic 4HPR to precipitate over time was quite apparent.  Initial formulation steps 
optimized 4HPR loading, addition of solubilizers, and pore forming agents to promote 4HPR 
release. The in vivo evaluation 4HPR PLGA millicylinders in rat SC tissues was compared to 
drug release from an immediate dissolving sugar matrix, to determine if the controlled release 
of 4HPR was dictated by PLGA or by dissolution of the hydrophobic drug. An initial efficacy 
study in mouse xenograph oral cancer model was performed.  The findings of these in vivo 
release studies will be the motivation for further elucidating of the unusually slow 4HPR 
release from PLGA into the aqueous tissue environment.  Results of that mechanistic 4HPR-
PLGA investigation can be found in Appendix 2. 




  In Chapter 3, the limitations of the initial PLGA-4HPR millicylinder formulations were 
realized, and therefore creation of amorphous drug systems for solubility enhancement was 
investigated.  A robust PVP-4HPR ASD showed incredible solubility enhancement over 1 
week, and was loaded into PLGA millicylinders, and release was evaluated in vitro and in vivo.  
The in vivo release of the amorphous drug far outperformed the crystalline drug release from 
our implants in proceeding experiments. 
  In Chapter 4, 4HPR tissue binding kinetics and partitioning into blood/plasma 
components was assessed ex vivo, and will be useful to determine factors that may influence 
4HPR’s tissue dispersion.  The effect of 4HPR uptake by addition of various solubilizing and 
permeation enhancing excipients will be evaluated.  A comparison of the 4HPR uptake in 
subcutaneous connective and buccal epithelia tissue types was also performed.  4HPR’s 
binding to cell membrane components was also evaluated, to determine factors responsible for 
4HPR’s high non-specific tissue binding.  
  In Chapter 5, 4HPR’s tissue penetration after release from long-acting millicylinders 
was evaluated in rabbit buccal epithelia. This is the first time that the spatial distribution of 
4HPR has been evaluated, and results from this study will have huge clinical impact on 
development of these local delivery systems for widespread treatment of pre-cancerous 
regions.  Quantitative Raman spectroscopic imaging methods were established using 
calibration standards that were prepared with excised buccal tissues incubated in drug 
solutions.  The 4HPR tissue levels was reported as a function of the diffusion distance, with the 
aim that these formulations prepared in Chapters 2 and 3 will enhance the penetration distance 
compared to the solid drug control in the immediately dissolving sugar matrix. 
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Chapter 2:  Formulate 4HPR into PLGA millicylinders for CR local delivery and 
evaluate release in vitro and in vivo 
2.1. Abstract 
Local, long-acting release fenretinide (4HPR) millicylindrical implants were prepared 
and evaluated for their release kinetics in vivo and their ability to suppress oral cancer tumor 
explant growth. Poly(lactic-co-glycolic acid)(PLGA) implants were prepared as a function of 
drug loading and the presence of various excipients (pore-formers, solubilizers, crystallization 
inhibitors) to enhance release of the insoluble 4HPR.  Release kinetics and bioerosion of PLGA 
were monitored both in vitro in a PBS/Tween 80 buffer and in vivo by recovery of the drug 
remaining at the injection site. 4HPR was released from PLGA implants much slower in vivo 
than in the drug solubilizing media in vitro, with a 3-week lag phase and continuous release of  
>2 months, but showed some release enhancement by addition of solubilizers. Water-soluble 
PVA/sucrose implants for release of 4HPR served to determine if drug dissolution provided 
suitable controlled release without the PLGA, and this formulation showed continuous drug 
release over 6 weeks in vivo. Placement of PLGA-4HPR implants adjacent to oral cancer tumor 
murine xenografts showed inhibition of tumor growth relative to sham implants, indicating the 
potential for the local 4HPR delivery approach to be useful for oral cancer chemoprevention. 
2.2. Introduction 
Oral squamous cell carcinoma (OSCC) is a worldwide health concern, and in 2016, 
~50,000 Americans were newly diagnosed with oral or pharyngeal cancer 




(http://oralcancerfoundation.org).  The vast majority of oral cancers arise from malignant 
transformation of preneoplastic surface epithelial lesions (1). Despite treatment advances that 
include intraoperative radiation, the 5-year survival rates of persons with OSCC is 
discouraging low (50%). Following initial therapy, HNSCC patients are managed by close 
clinical follow up often supplemented with imaging studies.  Despite vigilant monitoring and 
well-recognized risk factors for recurrence, over one third of patients develop life-threatening 
and often untreatable recurrent OSCCs (2).  Replacement of the current “watchful waiting” 
strategy with well-tolerated and effective secondary OSCC chemoprevention could make a 
significant clinical impact for these individuals. As OSCC management requires extensive, 
often disfiguring surgery, treated OSCC patients often experience depression and reduced 
motivation.  Development of an implantable delivery system to provide therapeutic drug levels 
without systemic effects and eliminate patient compliance issues could advance secondary 
OSCC chemoprevention.  Previous studies from our labs have demonstrated that fenretinide 
(4HPR) inhibits focal adhesion kinase- extracellular matrix (FAK-ECM) interactions and 
significantly reduces invasion, which is the ultimate step in OSCC development (3). To address 
OSCC’s redundant signaling cascades, secondary OSCC chemoprevention will ultimately 
require complementary agents (4).  Based on 4HPR’s multiple mechanisms of action including 
growth regulation and suppression of gratuitous signaling (5), it is our intention to include 
4HPR in the secondary chemopreventive formulation.        
Here, we chose to formulate 4HPR local controlled release (CR) implants using 
biodegradable poly(lactic-co-glycolic acid) (PLGA) to provide continuous release for >30 
days.  Local CR drug delivery systems are presumed advantageous over daily oral dosage 
forms in that the once monthly dosing could lead to better treatment outcomes, elimination of 




first-pass effect and patient compliance issues, lowered risk of systemic toxicity, and increased 
drug stability. PLGA is still the biodegradable controlled release polymer of choice in 
injectable depots owing to its safety, biodegradability, ease of processing, and tailorable release 
by adjusting its molecular weight, end-group capping, and ratio of lactide:glycolide 
monomers(6, 7,8). To date, the FDA has approved several PLGA CR drug products including 
both systemic delivery products such as the Lupron Depot (leuprolide acetate microspheres for 
prostate cancer) and local delivery formulations including Ozurdex® (dexamethasone 
intravitreal implant for macular edema), and Atridox (doxycycline in situ forming implants 
[ISFIs] for periodontitis)(9).  For our studies we chose to formulate 4HPR in millicylinders due 
to the ability to achieve high drug loading, and lower burst release compared to microspheres 
and ISFIs developed previously for systemic delivery(10,11).  Additionally, the millicylinder 
formulations are desirable for future evaluation of in vivo tissue penetration and efficacy 
studies, and will allow for precise drug-tissue distribution measurements from the point of 
origin, and are expected to remain in place for better targeting of the local pre-cancerous 
region. Due to the small size of millicylinders (~ 5 mg, 0.8 mm i.d. x 1 cm), they can be easily 
injected through a trocar syringe or surgically implanted.   
Previous work has been done by our lab in formulating local 4HPR drug delivery 
systems including PLGA microspheres, ISFIs, and buccal mucoadhesive patches as well as 
determining 4HPR solubility in various PLGA solubilizing solvents, release media 
compositions, and selected surfactants (10, 12).  In previous pharmacokinetic (PK) studies, we 
compared serum levels of 4HPR encapsulated in PLGA microspheres and ISFIs relative to a 
control drug suspension dosed subcutaneously (SC) in rats, and found that PLGA CR 
formulations were successful at strongly reducing the burst release compared to the control 




suspension (13). However, after 15 days, the amount of 4HPR released from the PLGA 
formulations coincided with those of the drug suspension and showed a steady decline for 
more than a month. Based on this data, after 2 weeks it was unclear whether the actual drug 
was exhibiting controlled release properties due to dissolution into surrounding interstitial 
fluid, or slow release from tissue lipid “reservoirs” where 4HPR could have accumulated after 
fast dissolution.  
These studies extended our previous work to include sustained duration (1-2 months) in 
vitro and in vivo of 4HPR encapsulated in PLGA CR millicylinders.  Local delivery of 
hydrophobic 4HPR presents a significant challenge owing to its extreme water insolubility, 
with a logP of 6.31.  We have selecting a continuously eroding PLGA polymer that will target 
the 1-2 month delivery period, although we considered the potential for the hydrophobic 4HPR 
to precipitate over time causing dissolution rate-controlled release instead of typical PLGA-
erosion control.  Initial parameters assessed included varying 4HPR loading (10, 20, 30%), 
along with selected solubilizers and penetration enhancers in vitro and in vivo.  We have 
previously shown that the addition of a basic salt, magnesium carbonate (MgCO3), to the 
millicylinder can lead to more favorable release kinetics due to its slow pore forming 
capabilities (14), similar to what was originally patented for release of proteins(15). To 
facilitate the release of the hydrophobic drug into aqueous interstitial fluid, we co-encapsulated 
4HPR with PLGA and solubility enhancing excipients including sodium deoxycholate (NaDC) 
via micelle formation and beta-cyclodextran (β-CD) via inclusion complexes. Other excipients 
were also investigated based on their ability to inhibit drug crystallization and aide in implant 
disintegration including polyvinylpyrollidone (PVP K30) (16, 17, 18), and hydroxypropyl 
methylcellulose (HPMC K4M) (19, 20).  HPMC has also been utilized to facilitate drug release 




due to its swelling behavior that promotes pore formation. All excipients studied have been 
categorized as generally regarded as safe (GRAS) by the US FDA, and many are currently 
used in FDA approved drug products (21). 
2.3. Materials and Methods 
2.3.1. Materials 
 50:50 acid end-capped PLGA 503H (24-38 kDa), was purchased from Evonik, 4HPR 
was generously supplied by Merck Co, and acitretin was used as an internal standard 
(analytical grade, Sigma-Aldrich). Excipients used were sodium deoxycholate, (NaDC, 99% 
pure, Acros), polyvinylpyrrolidone (PVP K30, 40 kDa, BASF), hydroxypropyl methylcellulose 
K4M (HPMC K4M, Dow Chemical, Midland, MI), and β-CD (Sigma-Aldrich). Water-soluble 
implants were composed of polyvinyl alcohol (PVA, 9-10 kDa, 80% hydrolyzed, Sigma-
Aldrich) and D-sucrose (Sigma-Aldrich).  All other materials were reagent grade or better 
including:  MgCO3, acetone, ethanol (EtOH), tetrahydrofuran (THF), and Tween 80.  Solvents 
for UPLC-UV and MS analysis were HPLC or MS grade including acetonitrile (ACN), 
methanol (MeOH), double distilled water (ddH2O), phosphoric acid (H3PO4), ammonium 
formate (NH4COO) and formic acid (HCOOH). Silicon tubing (0.8 mm i.d.,) was purchased 
from BioRad Laboratories.  Ethylenediaminetetraacetic acid (EDTA, analytical standard, 
LECO, St. Joseph, MI) and Bovine Serum Albumin (BSA, 99% pure, heat shock fraction, 
Sigma-Aldrich) were used as standards for nitrogen analysis.  
2.3.2. 4HPR Millicylinder Preparation  
To prepare PLGA millicylinders, 60% w/w 50:50 acid end-capped PLGA (24-38 kDa) 
was dissolved in acetone at room temperature by slowly vortexing in a capped 2 mL Eppendorf 
tube. 4HPR and excipients were added to the polymer mixture, and those excipients that were 




insoluble in acetone (including MgCO3 and NaDC) were cryomilled (Retsch swing mill 
cryomill, PN 20.749.001) and sieved to < 90 μm prior to their addition to the formulation.  The 
solids were incorporated into polymer solution by stirring with a spatula. Additional acetone 
was added and recorded to obtain a solution with an extrudable viscosity. Note, that solutions 
with low viscosity result in hollow implants, and therefore the highest extrudable viscosity was 
sought to obtain non-hollow and dense implants. Next, the resulting gel solution was loaded 
into a 3 mL syringe equipped with an 18 g blunt end needle attached to silicone rubber tubing 
(0.8 mm i.d.), and slowly extruded.  The implants were dried at room temperature for 2 days, 
and then transferred to vacuum oven and dried at 40 °C for an additional 2 days, after which 
the tubing was carefully removed and implants were cut to the desired length of 1 cm. Efforts 
were taken in all 4HPR experiments to minimize light exposure due to the drug’s known 
photo-instability. 
Formulation efforts were necessary to accelerate 4HPR release rates.  Initial studies 
optimized the 4HPR loading level (10, 20, 30% w/w).  To improve release kinetics additional 
excipients were added including 20% NaDC or CaDC, along with investigating the effects of 
varying the concentration of the pore former MgCO3 (3, 10, 15 % w/w).  Other excipients were 
added to accelerate release, aid in drug solubilization, and prevent drug crystallization and 
included β-CD, HPMC K4M, and PVP K30.  For the in vivo studies, a water soluble matrix 
4HPR millicylinder was prepared with a PVA/ D-sucrose (40%, 30% w/v respectively in 
ddH20) matrix with and without excipients, followed by extrusion and drying in the same 
fashion as PLGA implants. 




2.3.3. NaDC and CaDC PLGA Millicylinders  
Design of CR of solubilizer of deoxycholic acid was attempted via preparation of the 
less soluble calcium salt of deoxycholic acid and compared to NaDC.  To prepare the CaDC, 
10 mL of 2 mM CaCl2 · 2H2O in ddH2O (pH adjusted to 9 with 0.1 N sodium hydroxide) was 
added to 10 mL of 10 mM NaDC in ddH20 (pH 7.7), and stirred at room temperature for 3 h, 
during which the CaDC salt formed and precipitated.  The reaction mixture was centrifuged, 
and supernatant removed and discarded.  The CaDC salt was freeze dried, cryomilled and 
sieved to < 90 μM.  PLGA millicylinders were prepared using polymers 503 and 503H and 
loading with either 20% CaDC or 20% NaDC. In vitro releases performed by placing 1 implant 
in 1 mL PBST 0.02% Tween80 and assayed by LC-MS. 
2.3.4. 4HPR Solubility in the presence of Selected Excipients  
Solubility studies were performed with selected excipients including NaDC, HPMC, β-
CD, and PVP K30 at levels of 1, 2, 5, 10, 20% w/v in double distilled water (ddH2O).  For all 
studies, 2 mg of 4HPR was added to 1 mL of solution and incubated at 37° C while rotating, 
and protected from light with aluminum foil covered vials. The resulting suspension was 
centrifuged and the supernatant was analyzed by UPLC/UV and day 7 solubility was reported.  
Previous work by our lab has determined 4HPR solubility parameters in selected organic 
solvents used in our assays and in presence of other solubilizing excipients(10). In addition to 
these selected excipients, a comprehensive compilation of 4HPR solubility from previous 
solubility studies from our lab, literature sources, and my data, can be referenced in Appendix 
1. 




2.3.5. 4HPR Implant Loading 
To determine the amount to 4HPR loaded into the implant, one millicylinder was 
weighed into a 15 mL centrifuge tube, PLGA and 4HPR were co-dissolved by addition of 0.5 
mL THF, followed by precipitation of PLGA by addition of 9.5 mL EtOH. Next, the sample 
was centrifuged, and supernatant was assayed by UPLC/UV.  Encapsulation efficiency was 
invariable and ranged from 97-103%. 
2.3.6. 4HPR In vitro release 
 4HPR in vitro release from millicylinders was determined by placing one millicylinder 
(5-7 mg) in 5 mL eppindorf tube containing 4 mL PBS pH 7.4 + 2% Tween 80, necessary to 
maintain sink conditions, and incubating at 37 °C on a shaking platform (200 rpms). The 
solutions were sampled by complete media replacement, until nearly 100% release, after which 
a mass balance accounting was done by determining the amount of 4-HPR remaining in 
millicylinder using the loading assay described above. 
2.3.7. 4HPR In vivo release 
 To evaluate 4HPR release in vivo, millicylinders were weighed and implanted 
subcutaneously (SC) in the flanks of male Sprague Dawley rats using a 12 g trocar. Each rat 
could receive up to 6 implants. For each formulation, 3 implants were implanted in each rat, 
and 1 rat per time point (days 1, 7, 14, 28, 42, 60) was sacrificed. Millicylinders were carefully 
harvested to ensure complete removal and release from encompassing tissues.  The wet 
millicylinders were weighed, dried by vacuum for 2 days, and weighed again to determine the 
mass loss and water uptake, and SEM images acquired.  The amount of 4HPR released was 
determined by assaying the amount of 4HPR remaining in recovered millicylinder by loading 
assay 




2.3.8. 4HPR UPLC-UV Assay 
4-HPR levels in in vitro release media and millicylinders digests were determined by 
UPLC/UV. Because of 4HPR’s high extinction coefficient (47,900 M-1-cm-1 at 365 nm), 
excellent sensitivity was achieved via UPLC/UV with a LLOQ of 5 ng/mL. The reverse phase 
UPLC/UV analyses were carried out with a Waters Acquity UPLC system and Empower 
software under the following conditions: Acquity BEH C18 2.1x100 mm column, mobile 
phase 80:20 ACN: ddH2O + 0.1% H3PO4, isocratic flow rate 0.65 mL/min, UV detection at 
365 nm, and total analysis time of 2 min. 4HPR calibration standards were prepared in mobile 
phase (0.5-100 μg/mL) from a 0.5 mg/mL 4HPR stock solution in ACN, which reflects the 
large linear dynamic calibration range. 
2.3.9. CaDC/NaDC UPLC-MS Assay 
A UPLC-MS assay for NaDC and CaDC was developed using Waters Acquity UPLC-
MS (quadrupole mass analyzer, Acquity QDa) system and Empower software under the 
following conditions: Acquity BEH C18 2.1x100 mm column, mobile phase 37.5:37.5: 25 
MeOH: ACN: 0.02 M NH4COO pH adjusted to 4.3 with HCOOH, isocratic flow rate 0.4 
mL/min, and total analysis time of 3 min.  MS was operated in positive ion mode and the 
molecular ion m/z 392.5 (dexoxycholic acid) was monitored.  NaDC calibration standards were 
prepared by dissolving a stock solution 5 mg/mL NaDC in PBS, and working standards 
prepared in the range of 10-500 µg/mL.   
2.3.10. Millicylinder Morphology via Scanning Electron Microscopy 
The morphology of millicylinders was examined by scanning electron microscopy 
(SEM) using a Phillips XL FEG SEM.  The millicylinders were dried, sputter coated with gold 




for 90 sec, then imaged using 3 kV electric beam. Cross section and surfaces of millicylinders 
were imaged and inspected for 4HPR crystallization or solubilization in polymer matrix. 
2.3.11. Protein content in PLGA after in vivo Release by LECO Nitrogen Analysis  
The amount of protein infused into 4HPR PLGA millicylinders after in vivo release was 
determined by nitrogen analysis on LECO instrumentation (TruSpec CHN Micro, PN200-716, 
St. Joseph, MI). The LECO instrument was calibrated by weighing EDTA standards ranging 
from 0.2 -3 mg, and percent nitrogen content was determined upon incineration of sample. To 
prepare samples for the protein analysis, the PLGA millicylinders (20% 4HPR + 20% 
NaDC+15% MgCO3 + 1% PVP) were carefully removed from SC tissue after 28 and 42 days 
of in vivo release with minimal excess tissue encasing the implant. The drug was extracted 
from implant using the 4HPR loading assay (section 2.4), supernatant was removed, and 4HPR 
levels determined. The remaining precipitate (likely composed of PLGA and proteins, both of 
which are insoluble after the loading assay) was dried at 40 °C x 2 days in a vacuum oven, and 
dried mass was recorded. The percent nitrogen in the PLGA-protein pellet was measured, and 
percent protein was estimated by normalizing to the model protein BSA (16% w/w nitrogen), 
as albumin is the most abundant serum protein.  To summarize this mass balance quantitation, 
the total composition of the millicylinder was determined by: 1) percent 4HPR by loading 
assay, 2) percent protein by nitrogen analysis, and 3) PLGA calculated from total mass of dried 
implant - (4HPR + protein). 
2.3.12. Effects of 4HPR Implants on OSCC Tumor Nude Mice Xenografts 
The efficacy of 4HPR-PLGA millicylinders designed for 30-day controlled release 
dosing were tested by their effect on OSCC tumor xenografts. These studies were conducted at 
Ohio State University animal facility in accordance to ULAR regulations. For tumor induction, 




1x106 SCC2095sc human oral squamous cell carcinoma (OSCC) tumor cells were injected into 
right-back flank side athymic nude mice. OSCC tumor masses were developed for 7 days after 
OSCC cell injection. Mice were randomly assigned to two groups (n=4), including: 1) control 
sham- PLGA millicylinder and 2) two CR 4HPR-PLGA millicylinders implanted alongside of 
tumor, with treatment duration of 10 days. All mice were weighed and tumor volume was 
recorded each day. On day 10, mice were euthanized, 4HPR millicylinders were removed, wet 
mass recorded, then dried to obtain percent water uptake, then assayed for percent 4HPR 
release by loading assay. Statistical analysis was performed to analyze differences in the 
control sham-PLGA to the 4HPR-PLGA formulations on tumor growth inhibition using an 
unpaired t-test analysis. 
4HPR levels in tumors were quantified via tumor homogenization followed by drug 
extraction.  The wet mass of tumor was recorded, internal standard was spiked into tissue (50 
μL of 5 μg/mL acitretin), and 2 mL ice cold RIPA lysis buffer (to lyse contents of cells) was 
added to the tumor and homogenized using mechanical homogenizer (10,000 rpms x 1 min). 
Next, 3 mL ice cold ACN was added, homogenates sonicated on ice for 10 min, followed by 
centrifugation at 10,000 rpm x 10 min at 4 °C.  The supernatant was assayed by UPLC/UV and 
normalized by internal standard recovery. 4HPR levels in serum were determined by spiking 
10 μL 5 μg/mL acitretin into 50 μL serum, adding 140 μL ice cold ACN, sonicating on ice x 10 
min, followed by centrifugation, and assaying supernatant by UPLC.   
2.4. Results and Discussion 
2.4.1. Effect of 4HPR Loading on in vitro Release  
 To determine the maximum drug loading that would allow for the most continuous and 
complete release, we selected PLGA 503H for controlled release of 4HPR based on our 




previous work with formulating 4HPR into microspheres and ISFIs (10).  The free-acid low 
molecular weight PLGA continuously erodes at physiological conditions to allow continuous 
release (22). Also, we have found a positive effect upon addition of a poorly soluble basic salt 
(i.e. solubilizes upon pH lowering like antacids) on release of proteins and hydrophobic small 
molecules from PLGA millicylinders, which is attributed to pore formation and neutralization 
of PLGA monomers that have degraded within the bulk polymer (23).  Based on these 
considerations, 4HPR was encapsulated in PLGA 503H millicylinders containing 3% MgCO3.  
Loading levels of 4HPR were varied at 10, 20 and 30% and in vitro release was evaluated (as 
shown in Fig. 2-1).  In the higher 4HPR loading levels (20, 30%) a 2-week lag phase was 
present, whereas 10% 4HPR had a more continuous release and released the greatest 
percentage after day 28 (53%). Therefore the 10% 4HPR-loaded implant formulation 
containing 3% MgCO3 was selected for in vivo release and characterization as described 
below. 
 
Figure 2-1: Effect of 4-HPR loading on in vitro release.  The implants were composed of PLGA 503H + 3% 
MgCO3 + 10, 20 or 30% 4HPR. Values represent mean ± SE (n=3). 
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2.4.2. In vivo release of 4HPR-PLGA Millicylinders with Pore Forming Agent  
The optimal releasing implant from Fig. 2-1 containing a pore forming agent was 
evaluated after SC implantation in rats.  Kinetics of drug release, implant erosion, and water 
uptake were examined as shown in Fig. 2-2a.  Although the 10% 4HPR with 3% MgCO3 pore-
forming solubilizing base formulation performed well in vitro, very little if any controlled 
release was observed in vivo, with much less drug released by day 28 (18% in vivo vs. 53% in 
vitro). This in vivo/in vitro discrepancy may reflect the presence of high levels of Tween 80 
solubilizer present in the in vitro release media.  The PLGA in vivo erosion kinetics is shown in 
Fig. 2-2b for the 4HPR formulation and the no-drug sham control (i.e. PLGA + 3% MgCO3).  
Polymer erosion was nearly complete after day 28, however, 82% of drug remained.  
Moreover, most of 4HPR release occurred on the first day. The erosion rates of drug and sham 
formulations were similar, with slightly faster erosion in the sham, which indicates that 4HPR 
does not significantly alter the PLGA 503H millicylinder standard erosion profile.  As seen in 
the figure, there was a significant polymer mass loss that occurred between 14-28 days, which 
is consistent with expected PLGA 503H erosion kinetics from the dense implant.  SEM images 
showing the erosion over 28 days for both the drug and sham implants can be found in 
Supplemental Information Figure S2-1. The incomplete release from the implant along with the 
high PLGA erosion rate confirms our suspicion that the polymer has little effect on the late 
stage 4HPR release, and it is highly likely release is governed by the slow dissolution of the 
solid drug itself. 
 
 




Figure 2-2. In vivo performance of 4HPR PLGA 
millicylinder formulation without solublizers (10% 4HPR 
+ 3% MgCO3).  a) 4HPR release in vivo vs. in vitro (in a 
solubilizing media containing PBS+ 2%Tween), b) in vivo 
erosion of 4HPR PLGA implants compared to sham 
implants (PLGA + 3% MgCO3 only), and c) in vivo water 
uptake in 4HPR PLGA implants and sham PLGA 
implants. Values represent mean ± SE (n=3). 
 
The water uptake kinetics (Fig. 2-2c) of 
both the drug and sham implant were also 
similar, with 225% and 228% water uptake 
respectively. Water uptake is therefore not 






2.4.3. Solubility and Release Enhancing Excipients  
Previous studies from our group indicated that 4HPR’s poor aqueous solubility 
adversely affected a 4HPR controlled release during the 1 month study 13. To enhance 4HPR 
solubility and polymer drug release, we introduced several solubilizing excipients, 
crystallization inhibitors, and disintegrants for co-encapsulation with the drug and PLGA.  
NaDC selection was based on numerous studies on the solubilization and permeation 
enhancing behavior of bile salts(24,25, 26) inclusive of retinoid solubilization (27,28). The 
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aqueous solubility of 4HPR at 37 ˚C in the presence of excipients is shown in Fig. 2-3. NaDC 
provided the best solubilization with 20% NaDC providing 1030 μg/mL 4HPR solubility, i.e., a 
200:1 mass ratio of NaDC: 4HPR. β-CD resulted in a 40 μg/ml 4HPR solubility at 20% 
excipient level. The crystallization inhibitor/pore forming agent HPMC did not solubilize 
4HPR, while the disintegrant/crystallization inhibitor PVP K30 provided only minimal 
solubility enhancement of 0.66 μg/mL at 20% PVP compared to 0.2 µg/ml 4HPR aqueous 
solubility without excipients.  Despite little solubility enhancement achieved with HPMC and 
PVP, these agents were still pursued as they could improve release kinetics by alternative 
aforementioned mechanisms.   
We have proceeded to develop 4HPR-PLGA millicylinders that were capable of 
accelerating in vitro release (Supporting Information, Fig. S2-2) by 1) increasing 4HPR 
solubility by addition of 20% NaDC, and 2) increasing PLGA porosity to aid in drug diffusion 
by increasing (MgCO3).  The addition of the 20% NaDC allowed us to achieve a 20% drug 
loading, while decreasing the 3-week lag phase.  In this solubilized formulation (20% NaDC), 
increasing MgCO3 from 3% to 15% further enhanced the extent of 4HPR release after 28 days 
from 50% to 71%.  Next the effects of specialized excipients (β-CD, HPMC, and PVP) added 
to PLGA +20% 4HPR + 20% NaDC + 15% MgCO3 millicylinders were examined in vitro and 
in vivo as shown in the following section. 





Figure 2-3. Effect of excipient concentration on 4HPR solubility in deionized water at 37 °C. 
 
2.4.4. In vivo Release from 4HPR-PLGA millicylinders with Solubilizers and 
Crystallization Inhibitors 
The next set of PLGA millicylinders formulations aimed to increase 4HPR release in 
vivo by co-incorporating a high level of solubilizers, pore forming agents, and specialized 
excipients. The baseline formulation tested was 20% 4HPR + 20% NaDC + 15% MgCO3.  The 
specialized excipients included:  5% β-CD to enhance solubility by formation of an inclusion 
complex with 4HPR, 1% HPMC K4M to promote swelling, aide in pore formation, and inhibit 
crystallization, and 1% PVP K30 to enhance solubility, inhibit crystallization, and aid in 
disintegration. The in vivo/in vitro release with these specialized excipients is shown in Fig. 2-
4a.  Much slower release was observed in vivo for all compared to in vitro (day 28 release was 
~25% vs. ~80%), and release in vivo in these cases was only slightly improved compared to the 
initial formulation containing 10% 4HPR+ 3% MgCO3 (Fig. 2a) without solubilizers (25% vs 
18% by day 28).  Inclusion of the crystallization inhibitor PVP to the baseline formulation was 
effective at providing controlled release of 4HPR, whereas the other excipients additives had 
an initial burst release with no further drug release until after 4 weeks.   
































The PLGA erosion was evaluated, and all these formulations showed similar erosion 
profiles, which were unaffected by HPMC, β-CD, or PVP (Fig 4b). The erosion profiles were 
as follows: 0-15% of eroded on day 1, 15-25% eroded by day 7, and 20-30% eroded by day 28. 
Greater variability on day 28 likely reflects the extent of millicylinder-attached to surrounding 
connective tissue. Higher connective tissue levels could result in an overestimate of mass (and 
underestimate of PLGA erosion). On day 28, these implants containing high levels of MgCO3 
and NaDC had significantly less PLGA erosion compared to the non-solubilized implant (30% 
vs 60%), but nonetheless released more drug. These findings are consistent with the in vitro 
mechanistic data provided in the Supplemental Information (Fig. S2-3), which showed that 
NaDC and MgCO3 inhibit PLGA erosion, but also promote implant water uptake due to their 
osmotic properties. These results indicate that 4HPR release from PLGA implants in vivo is 
not an erosion-controlled process over the 28 day period. 
Implant water uptake was evaluated as shown in Figure 2-4c, and was similar for these 
4 formulations, where all excipients (B-CD, HPMC, and PVP) promoted same level of water 
uptake as the baseline formulation containing 20% NaDC and 15% MgCO3, yielding  ~ 75%, 
150%, 250% water uptake on days 1, 7, 28 respectively.  When compared to the initial 
formulation without solubilizers (Fig. 2-2c), we see that the presence of these osmotic agents 
only significantly increased water uptake on day 1, while after 7 and 28 days, they behaved 
similarly (25%, 155%, 225%), but was much less compared to in vitro (>500% after 28 days), 
indicating that the tissue environment decreases implant water uptake. This again confirms that 
that drug release in vivo from PLGA implants is not driven by implant water uptake.  
 





Figure 2-4. a) In vivo /in vitro release for PLGA 503H + 20% 4HPR + 15% MgCO3 + 20% NaDC (baseline) and 
specialized excipients including 5% B-CD, 1% HPMC K4M, and 1% PVP K30. b) Implant erosion, and c) 
implant water uptake in vivo.  (mean ± SE, n=3) 
Thus far we have shown that addition of solubilizing, pore forming agents and 
specialized excipients to the PLGA implants, while effective in vitro at accelerating 4HPR 
release, had little effect in vivo on accelerating 4HPR release after 4 weeks (~25% drug 
release).  Furthermore, we have concluded from these two in vivo experiments (with and 
without solubilizers) that neither PLGA erosion rate nor implant water uptake can explain the 
slow in vivo drug release.  Therefore, the likely cause is very slow dissolution of the drug. To 
test this, 4HPR in vivo release from PLGA implants with solubilizers was compared to a water-
soluble matrix implant (PVA/sucrose) over 2 months. In addition, a second PVA/sucrose 
formulation incorporated a solubilizer and crystallization inhibitor (NaDC, PVP). Two salt 
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the intent that the less water soluble CaDC would be released slower, and help facilitate 4HPR 
release out of implant at later time points.  A water-soluble matrix implant was prepared in a 
PVA/sucrose vehicle with and without solubilizers (20% 4HPR+ 20% NaDC + 1% PVP), and 
compared to PLGA formulation previously shown to have the most desirable release (Fig. 2-4, 
20% 4HPR + 15 % MgCO3 + 1% PVPK30+ 20% NaDC or CaDC). The in vivo evaluation 
(Fig. 2-5a) shows a controlled 4HPR release over 2 months for the PLGA formulations, and 
that the effect of bile salt type (sodium vs. less soluble calcium salt) had little effect on the rate 
of 4HPR release, which exhibited a 3-week lag period.  Notably, both bile salts showed nearly 
identical 4HPR release profiles, despite achieving a slower release of the deoxycholic acid 
(DC-) solubilizer over 14 days with the calcium salt, compared to an 80% burst release with 
NaDC (Fig. 2-5c). These results indicate that 4HPR release from PLGA millicylinders may not 
be controlled by solubilization, at least not by NaDC. 
When examining the drug release from the water soluble PVA/sucrose implants, we 
observed that 4HPR was released steadily during the first 3 weeks, then a large surge in drug 
release, followed by a controlled release pattern similar to the PLGA implants in weeks 4-6 
(Fig. 2-5a). The additional solubilizing excipients in this PVA/sucrose implant led to an 
accelerated 4HPR release after 28 days, where 78% was released vs. 59% for those without the 
extra excipients.  In the PLGA CR formulations, only 32% 4HPR was released after 1 month, 
and the presence of the 3-week lag phase is likely due to the rate of PLGA erosion, where we 
have previously shown (Fig. 2-4c) that PLGA did not exhibit appreciable erosion in vivo until 
after 2 weeks.  After 1 month, the water-soluble excipients would have dissipated from the 
implantation site, leading us to the logical conclusion that the controlled release is due to 
dissolution of the hydrophobic drug solid into the surrounding aqueous tissues. After 6 weeks, 




both water soluble PVA/sucrose implants formulations (with and without solubilizers) had 
performed similarly, and released ~90% 4HPR, whereas the PLGA only released ~50% 4HPR.  
Similarities in the release slopes of PLGA and PVA/sucrose implants between weeks 4-6 
suggests that late stage release of 4HPR from PLGA is controlled by dissolution of the drug.   
The images of the implants after a month in vivo release in rat SC tissue are shown in 
Figure 2-5b, and we see that the PLGA implants maintained their cylindrical shapes, with no 
apparent yellow 4HPR diffusion into the surrounding tissue. The PVA/sucrose implants were 
no longer in their millicylindrical form, and the addition of the NaDC and PVP solubilizers 
enabled greater 4HPR tissue dispersion.  We further note that the two implants (PVA/sucrose, 
PLGA) could potentially be used together for further extended release as the water soluble 
PVA/sucrose formulation can be used to overcome the initial lag phase, while PLGA can 
provide a 2+ month long acting release of 4HPR. 
 These data from 4HPR in vivo release from millicylinders align with results from our 
previous PK study, where a slow and continuous release of 4HPR from a SC injected drug 
suspension occurred after 2 weeks, following a large burst release, confirming that the 
controlled release properties are due to the dissolution of the hydrophobic drug.  The fact that 
4HPR release from PVA/sucrose water-soluble matrix formulation is faster than the PLGA and 
different from the solid control used in PK study, suggests that perhaps the PVA/sucrose 
formulation may release faster than pure 4HPR crystals.  We were unable to test 4HPR crystals 
here because we could not collect them to determine the fraction drug remaining, but future PK 
analyses could be used to determine this question. 





Figure 2-5 a) In vivo release of 4HPR from CR PLGA millicylinders vs. water soluble matrix PVA/sucrose 
implants with and without solubilizers. The PLGA implants contained 20% 4HPR + 15% MgCO3 + 1% PVP+ 
20% NaDC or CaDC, while the PVA/sucrose implants contained either 20% 4HPR or additional solubilizer and 
crystallization inhibitor (20% NaDC + 1% PVP). b) Implant images prior to harvesting from rat SC tissue on day 
28 (yellow represents 4HPR). C) In vivo release of sodium and calcium deoxycholic acid (DC-) from PLGA 
millicylinders. (mean ± SE, n=3) 
 
These PLGA-4HPR millicylinders were further examined to determine what other 
physiological factors besides polymer properties were hindering drug release and dispersion 
into tissue. These tests included SEM images of tissue-millicylinder interactions and nitrogen 
analysis to estimate protein levels within the millicylinders. The SEM images of a PLGA 
millicylinder (20% 4HPR + 15% MgCO3 + 1% PVP+ 20% NaDC) after 28 days in the SC 
environment are displayed in Figure 2-6.  In these micrographs, the tissue binding to the 




millicylinders is quite apparent, where the millicylinder has become completely encased within 
a fibrous tissue capsule.  The resistance exerted by this tissue encasing could be partially 
responsible for the inhibition of drug release from the millicylinders.  Upon harvesting of the 
millicylinder, the tissue encasement was removed and the extracted millicylinder (Fig. 2-6 c,d) 
was further examined. Observation of the implant cross sections shows mostly crystalline 
species, perhaps drug or protein, along with remnants of the porous PLGA matrix. The low 
local pH within the PLGA implant could be contributing to plasma protein precipitation. The 
composition of this drug-polymer-protein mass was investigated after removing from the tissue 
encasement and the amount of protein was estimated via LECO nitrogen analysis. After 28 
days, the extracted millicylinder contained 23 ± 1% w/w 4HPR of the extracted mass, similar 
to the initial drug loading of 20%.  From the LECO analysis, the estimated percent protein 
(normalized to BSA) bound in this extracted mass was 25 ± 4%, and PLGA was calculated to 
be 52 ±5%, which aligns well with the in vitro erosion data for this formulation of 60%.  After 
42 days, this extracted PLGA-4HPR-protein was composed of 16% 4HPR, ~55% protein, and 
~29% PLGA.  From this analysis, we observe high levels of protein within the PLGA-4HPR 
implant, which could play a role in the drug release. 





Figure 2-6. SEM images depicting 4HPR-PLGA millicylinders interactions with the tissue environment after 28 
days in vivo. PLGA millicylinder shown was composed of 20% 4HPR + 15% MgCO3 + 1% PVP+ 20% NaDC. a) 
Cross section of millicylinder encased with tissue, b) zo zoomed in to show tissue growth into millicylinder, c) 
4HPR-PLGA millicylinder removed from tissue encasing, and d) cross section (zoomed in to show precipitated 
4HPR, permeated tissue components, and remaining PLGA matrix). 
 
2.4.5. Evaluation of in vivo Efficacy 
The optimized and characterized formulation of 503H+ 20% 4HPR+ 20% NaDC + 
15% MgCO3 + 1% PVP was tested in vivo in tumor xenographed mice for the ability to 
decrease the rate of tumor growth compared to control blank PLGA millicylinders + PBS 
injections. Spatial dependency of the tumor growth suppression effects of polymer implants on 
tumor growth were assessed by daily caliper measurements.  As shown in Figure 2-7, the 
PLGA-4HPR millicylinders were effective at reducing the rate of tumor growth over 10 days 
(1.3 ± 0.3 fold increase in volume from initial, n =3) compared to the control Sham PLGA 




millicylinder (2.0 ± 0.3 fold increase, n=2) (Note: smaller sample sizes were used than desired 
due to lack of tumor xenograph uptake initially, and therefore statistical analysis could not be 
performed). The efficacy of 4HPR-PLGA millicylinder in these studies served as proof of 
concept for our full studies that were sufficiently statistically powered  and showed that 4HPR 
was effective in combination with other chemotherapeutic agents tocilizumab, and 2-
methoxyestradial at reducing rate of tumor growth (4).  Furthermore, H&E stained tissue 
sections demonstrated tumor necrosis in close proximity to the 4HPR implant, while tumor 
tissue proliferated a few millimeters from the implants (data not shown).  Therapeutic 
efficacious 4HPR levels (>10 μM)  of 90 ± 76 μM were achieved in tumor after CR delivery 
with 4HPR PLGA millicylinders, although levels were highly variable as reflected in the large 
standard error of the mean. 4HPR was not detected in serum, which is a favorable aspect that 
local drug delivery is capable of alleviating potentially toxic systemic side effects.   
The release performance of the PLGA-4HPR after implantation alongside the perimeter 
of the tumor is listed in Table 2-1.  The PLGA-4HPR millicylinders released 16.0 ± 2.0% of 
their load after 10 days equating to ~160 μg 4HPR (x 2 millicylinders = 320 μg dosed), which 
was approximately double of the released amount of the same formulation implanted in flanks 
of rats (7.5 ± 2.8% released on day 7). This difference could be due to the different properties 
of tissue environments, where the tissue surrounding the tumor may have greater blood flow 
and acidic pH compared to the SC tissue. The 4HPR-PLGA implants had greater water uptake 
compared to the sham PLGA implants (367% vs. 197%, Table 2-1), which aligns well with our 
mechanistic characterization studies.  
 
 




Table 2-1.  Tumor efficacy study with 4HPR-PLGA millicylinders. Mean ± SE, n=3 




4HPR level in tumor (μM) 
Sham PLGA 367 ± 21 % - - 
4HPR-PLGA 197 ± 22 % 16 ± 2% 90 ± 76 
 
 
Figure 2-7: Efficacy of 4HPR PLGA millicylinders (503H 
+ 20% 4HPR +20% NaDC+ 15% MgCO3 + 1% PVP) in 
reducing tumor mass of SCC2095sc human OSCC tumor 
cells xenographed in Athymic nude mice relative to sham 




Here we describe our approach to control the release of 4HPR in SC tissues and tumor 
environments.  We found that 4HPR releases from PLGA millicylinders much slower in vivo 
compared to in vitro, likely due to difference in solubilization in the in vitro release media 
compared to in vivo.  After exhibiting a significant lag phase in vivo, PLGA implants that 
included various excipients provide release to proceed continuously for at least 2 months.  The 
lag phase can be obviated by formulating a millicylinder without PLGA but with soluble 
components (PVA/sucrose/PVP/NaDC) to promote dissolution and crystallization inhibition. 
Indeed, the shorter and longer acting formulations could be useful in the future as a 
combination, as the overlapping release may be desired.  Initial evaluations of the efficacy of 
the PLGA implants demonstrate inhibition of OSCC tumor xenographs with local controlled 
release.  Therefore, these data motivate further development of the local controlled release 

































2.6. SUPPLEMENTAL INFORMATION 
2.6.1. Supplemental Methods 
Effects of Implant Erosion, Water Uptake, and Percent Solids on Release kinetics 
 A mechanistic study was carried out in vitro to determine the effects of formulation 
variables (4HPR loading, MgCO3 levels, presence of NaDC) had on drug release including 
polymer erosion and water uptake.  The in vitro release assay was utilized as previously 
described. Accurate PLGA mass loss was corrected for implant mass loss due to NaDC and 
4HPR released at given time points. The following equations were used: 
   =  
   
 
  100% 
  =
    
  
  100% 
 Additionally, the effect of percent solids (4HPR, MgCO3, NaDC) initially present in 
PLGA millicylinders was correlated with the drug burst release on day 1.  
CaDC synthesis and PLGA-CaDC and NaDC millicylinders 
The CaDC synthesis method was adapted from literature methods (24).  Briefly, to 10 
mL of 10 mM NaDC in ddH20 (pH 7.7), 10 mL of 2 mM CaCl2 · 2H2O in ddH2O (pH adjusted 
to 9 with 0.1 N sodium hydroxide) was added and stirred at room temperature for 3 h, during 
which the CaDC salt formed and precipitated.  The reaction mixture was centrifuged, and 
supernatant removed and discarded. The CaDC salt was freeze dried, cryomilled and sieved to 
< 90 μm. Validation of CaDC synthesis was done by inspecting crystal structure via SEM 
imaging, and comparing to literature CaDC crystal structures (24, 26), which depicts thin 
filament mesh-like structures identical to those in the literature. 




  CaDC and NaDC (20%) PLGA millicylinders were prepared in PLGA 503H and 503 
implants, and release evaluated in vitro by placing 1 implant into 1 mL PBST 0.02% Tween80.  
Release media sampled up to 1 month and assayed by LC-MS. 
2.6.2. Supplemental Results 
Morphology of PLGA-4HPR millicylinders with pore forming agents after in vivo release 
The morphology of the initial formulation of PLGA + 10% 4HPR + 3% MgCO3 after in 
vivo release was examined by SEM and compared to a no-drug sham PLGA control (+ 3% 
MgCO3) (Fig. S2-1), and shows the progression of pore formation and polymer erosion.  On 
day 1, both the no-drug sham and 4HPR implants were folded and had begun to curl. The sham 
was slightly more porous, but overall they had very smooth surfaces.  On day 7, both the sham 
and 4HPR implants look similar and show an increase in pore size. On day 14, the 4HPR 
implants have developed a larger pore network and crystals (likely 4HPR) on surface, while the 
sham-PLGA implants are folded and have a smoother surface. On day 28, both the 4HPR and 
sham-PLGA have broken apart, showing high polymer erosion, consistent with the erosion loss 

























Figure S2- 1. Implant morphology via SEM after in vivo release on days 1, 7, 14, and 28 of  PLGA 503H + 10% 
4HPR + 3% MgCO3 millicylinders compared to a no-drug sham PLGA + 3% MgCO3 implants. 
 
Optimizing 4HPR Release In vitro By Addition of Excipients 
The in vivo release profile of implants containing 10% 4HPR + 3% MgCO3 had 
incomplete drug release (< 20% 4HPR after 28 days) and lacked controlled release properties. 
Therefore, two approaches were taken to accelerate release and evaluated in vitro: 1) increase 
4HPR solubility by addition of solubilizers, and 2) increase diffusion pathways through 
polymer by increasing the level of pore forming agent (MgCO3).  Increasing 4HPR solubility 
could potentially allow for greater drug loading which would be useful at increasing drug 
levels at target site, so 10% and 20% 4HPR + 20% NaDC in PLGA + 3% MgCO3 were 
evaluated in vitro (Fig. S2-2a).  The 10% 4HPR implant performed the same with and without 




NaDC, however, substantial increase in percent release was observed with 20% 4HPR + 20% 
NaDC.  Although the addition of 20% NaDC improved release kinetics substantially by 
decreasing the 21 day lag phase, still only ~50% drug was released after 28 days, and therefore 
further release enhancement was necessary. The next release enhancement strategy increased 
the amount of pore-former MgCO3 (3, 10, 15%) to the solubilized formulation (PLGA + 20% 
4HPR + 20% NaDC). As shown in Fig. S2-2b, increasing MgCO3 from 3% to 10% is relatively 
ineffective, however, 15% MgCO3 substantially enhances drug released after 28 days from 
50% to 71% 4HPR for 10% and 15% MgCO3 respectively.  These formulation strategies 
proved successful in vitro and allowed for greater drug loading to be achieved, resulting in at 
75% drug release after 28 days.  The effect of these high levels of additives in PLGA 
millicylinders will be investigated in the following section. 
 
Figure S2- 2. Optimizing in vitro release of PLGA-4HPR millicylinders via solubilization and pore formation. a) 
Effect of addition of 20% NaDC to 10% and 20% 4HPR PLGA 503H implants.  b) Effect of amount of pore-
forming agent MgCO3 loading (3, 10, or 15%) in PLGA 503H+20% 4HPR + 20% NaDC millicylinders. Values 
represent mean ± SE (n=3). 
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 In vitro Mechanistic Evaluation of Parameters affecting 4HPR release: Polymer Erosion, 
Water Uptake, and Percent Solids 
 The purpose of these in vitro mechanistic evaluations was to elucidate the 
mechanism(s) of 4HPR release from PLGA millicylinders and delineate the effects of drug 
loading, MgCO3 level, NaDC, and total percent solids initially present in implant had on 
implant erosion, water uptake, and the extent of 4HPR release.  The formulations that were 
evaluated are listed in table S2-1. 
Table S2- 1. Representative formulations for in vitro characterization study 
Formulation # 4HPR (%) MgCO3 % NaDC% 
1  10 3  
2 20 3 - 
1 & 2 sham  - 3 - 
3 20 3 20 
3 sham - 3 20 
4 sham - 15 20 
5 sham - 15 - 
 
First, effect of 4HPR, NaDC, or MgCO3 on polymer erosion was evaluated (Fig S2-3a). 
No differences in PLGA erosion was observed at different 4HPR loading levels (10% [#1] and 
20% [#2], 54%, and 59% respectively), but was slightly greater than the corresponding no-drug 
formulation (47%). The addition of 20% NaDC (to the 3% MgCO3+ 20% 4HPR implant [#2]) 
resulted in significantly less erosion compared to its corresponding sham control #3 (27% vs 
58%).  The no-drug sham #3 with 20% NaDC+ 3% MgCO3 had similar erosion to implants 
containing 4HPR without NaDC (#1,2).  When MgCO3 is increased from 3% to 15% in 
implants containing 20% NaDC (#3 vs #4), the erosion significantly slows from 58% to 40%.  
When NaDC is removed from these implants (#5), the erosion is further decreased to only 
33%.  To summarize, increasing 4HPR loading slightly increased implant erosion, while NaDC 




slightly prolongs erosion, and increasing MgCO3 levels to 15% dramatically decreased the 
erosion rate.   
Another parameter that can affect the rate of drug release from implant is the extent of 
water uptake, which drives PLGA hydrolysis and erosion.  Because 4HPR is hydrophobic, 
increased water uptake may facilitate faster drug precipitation within the implant and hinder 
drug release.  As shown in Figure S3b, increasing the drug loading from 10% to 20% (#1 and 
#2) resulted in a substantial uptake in water after 28 days (505% vs. 159%), and both were 
greater than the corresponding sham formulation (119%).  We can conclude that 4HPR draws 
water into implant over time.  Both NaDC and MgCO3 substantial increased implant water 
uptake, as expected due to their osmotic properties. On day 7, the greatest water uptake 
occurred with the sham +15% MgCO3 (#5), which had 4x's more water uptake than the sham 
+3% MgCO3 (#1, 2), but only 2x’s greater water uptake than sham implants containing 20% 
NaDC + 15% MgCO3 (#4 sham).  It can be concluded that the extent of water uptake in PLGA 
implants is influenced by MgCO3 > NaDC > 4HPR. Although positive release effects via 
solubilizers and pore forming agents are observed in early stage release, erosion inhibition and 
excessive implant water uptake could negatively impact later stage drug release due to 
precipitation of 4HPR within the implant.     






Next, the effect of percent solids (4HPR, MgCO3, NaDC) initially present in PLGA 
millicylinders was correlated with the extent of drug burst release on day 1 (Fig. S2-3c), and 
show that greater percent solids lead to greater burst release (r2=0.91), likely due to formation 
of pores as the water soluble excipients escape the implant. Some formulations contained > 
60% solids, leaving less than 40% PLGA matrix to govern the controlled release.  
Figure S2- 3. Mechanistic in vitro evaluation of formulation variables (4HPR loading, MgCO3 levels, and 
NaDC) on: a) PLGA implant erosion, and b) water uptake. C) Effect of percent solids on amount of 4HPR 
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Astonishingly, although only 40% PLGA was present, only a small amount of 4HPR was 
released (<10%) after day 1, further validating that 4HPR release is a dissolution controlled 
mechanism, rather than controlled release from its PLGA matrix.      
CaDC Synthesis and In vitro Release from PLGA millicylinders 
We hypothesized that the solubilizer NaDC would be almost completely released from 
the implant within the first week due to its high aqueous solubility, and therefore drug release 
would halt once the solubilizer was gone. This was the case in both in vitro and in vivo release 
of NaDC (80% released after 1 day, Fig. 2-5c).  In attempt to provide slow the CR of this 
solubilizer, the calcium salt of deoxycholic acid (CaDC) was synthesized, due to its lower 
aqueous solubility.  Validation of CaDC salt was confirmed by SEM image in Fig. S2-4a, 
showing the filament mesh-like crystal structures similar to literature.  The results from the in 
vitro release from PLGA millicylinder (Fig. S2-4b) shows that CaDC releases much slower 
than NaDC in PLGA 503H, whereby 29% released by day 28 compared to 72% for NaDC.  
Also, slower CaDC release was observed in the 503H formulation compared to 503 (29% vs 
87% by day 28), indicating that the acid end-capped polymer will provide the most controlled 
release of this bile salt.   Contrary to our suspicions, CaDC from the ester capped PLGA 
released much faster than acid-capped PLGA, where we suspected that the calcium ions would 
bind strongly to carboxylic acid end-capped PLGA. 





Figure S2- 4.a) SEM image of CaDC crystals, and b) in vitro release of 20% NaDC and CaDC from PLGA 503 
and 503H millicylinders in PBST 0.02% pH 7.4 (mean ±SE, n=3). 
 
4HPR Tumor Levels after 4HPR-PLGA Millicylinder Dosing 
 A sample chromatogram trace of 4HPR extracted from the OSCC tumor after PLGA-
4HPR millicylinder delivery is shown Figure S2-5.  Acitretin, a synthetic retinoid, served as 
the internal standard and was added prior to tissue extraction.  Known peaks are labeled. 
 
Figure S2- 5. UPLC-UV Chromatogram of 4HPR dosed OSCC tumor extract, showing the 
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CHAPTER 3:  4HPR solubility enhancement by PVP-4HPR amorphous solid 
dispersions and release from PLGA millicylinders 
 
3.1. Abstract 
Purpose: The goal of this study was to develop long-acting 4HPR PLGA millicylinder implants 
for oral cancer chemoprevention.  Due to 4HPR’s extreme hydrophobicity, formation of 
4HPR- polyvinylpyrrolidone (PVP) amorphous solid dispersions (ASD) were investigated as a 
solubility enhancement technique.    
Methods: PVP-4HPR ASDs were prepared by co-dissolving in methanol to form a thin film, 
then cryomilled into particles.  Dissolutions tests determined solubility enhancement. The 
PVP-4HPR particles were loaded into PLGA millicylinders and drug release was evaluated in 
vitro and in vivo in s.c. tissues. 
Results: The optimal ratio was 9/1 w/w PVP-4HPR, which sustained a 50 to 1000-fold 
solubility enhancement in water over 1 week. Initial formulations of PLGA millicylinders 
loaded with PVP-4HPR showed rapid release of PVP, yet only 10% drug released in vitro after 
28 days. Addition of the plasticizer triethyl-o-acetyl-citrate (TEAC) into PVP-4HPR ASDs 
resulted in a 5.6-fold increase in 4HPR released in vitro from PLGA millicylinders, and 
showed a dramatic improvement of in vivo drug release from our previous PLGA-4HPR 
millicylinders, with nearly complete and continuous release over 1 month. 




Conclusions: Extreme 4HPR solubility enhancement was achieved with robust PVP-4HPR 
ASDs. The addition of TEAC to PVP-4HPR ASDs enabled complete and continuous release 
from PLGA millicylinders over 1 month in vivo. 
3.2. Introduction 
The synthetic analogue of all-trans retinoic acid (ATRA), fenretinide (4HPR), is a 
highly active and promising chemopreventive agent for oral cancer. Despite the known 
therapeutic effects of 4HPR, clinical trials using systemic delivery has shown poor efficacy due 
to significant drug inactivation by first pass metabolism and lack of drug accessibility to the 
target site1. Local delivery of 4HPR may therefore prove to be beneficial, and designing a 
long–acting release drug depot may be favorable for improved patient compliance in their 
lifelong chemoprevention therapy.  However formulation of 4HPR presents a significant 
challenge due to its extreme water insolubility, with a logP of 6.31.  Many techniques have 
been employed in attempt to increase aqueous solubility of a poorly soluble drug molecule, 
including 4HPR and other retinoid derivatives, including:  micellar solubilization(2, 3),  
reduction in particle size via milling, conjugation with amphiphilic moieties(4, 5),  
complexation to dextrans (6), PEGylation(2), encapsulation into PLGA microparticles (7-9), 
liposomes(10, 11), formation of drug-salt(5), formation of co-crystals(12), or preparation of 
amorphous solid dispersions (ASD’s) to name a few. Addition of solubilizers can enhance drug 
solubility by formation of micelles, however often times large amounts of solubilizers are 
necessary to achieve the desired drug loading, which may not be feasible to incorporate that 
amount into the delivery vehicle.  For example, we have found that the bile salt sodium 
deoxycholate (NaDC) greatly enhanced 4HPR solubility to 1 mg/mL however, it required 
200x’s more solubilizer than drug.  Our lab has also screened many 4HPR solubility and 




permeation enhancing excipients including: Tween, polyvinyl alcohol, Soluplus, ASD’s with 
PEG, and cosolvent systems to name a few (8,13,14). Although these were capable of 
solubilizing 4HPR, their high water solubility led to an immediate release, which is not 
amenable to the design of a long-acting release local delivery system.  This prompted us to 
explore other solubilization options for this poorly water-soluble crystalline drug. 
The 4HPR solubility in this enhancement technique investigated study was formation of 
an amorphous solid dispersion (ASD) with the polymer polyvinylpyrolidone (PVP). 
Amorphous solids are not crystalline because arrangement of molecules is disordered.  The 
ASD’s can greatly enhance drug solubility and bioavailability, and are prepared by dispersing 
drug molecules in a polymer such that the drug solubility in polymer is much greater than its 
crystalline solubility.  Upon contact with water, the amorphous drug dissolves much more 
quickly than the crystalline form due to absence of a crystalline lattice, and also due to the 
water solubility of the polymer (15).  With ASD’s, the drug is able to reach a super-saturated 
concentration, but the solubility decreases over time due to liquid-liquid phase separation and 
eventually drug precipitation.  Therefore, the ability to maintain the super-saturation over time 
is a measure of the ASD robustness, and can be addressed by optimizing the polymer type, 
polymer molecular weight and chain length, and mass ratio of polymer to drug. 
PVP has been widely used in pharmaceutical, cosmetic, food, and industrial 
applications since 1938 when first discovered, owing its usefulness to its ability to readily 
dissolve in a variety of solvents including water, alcohols, amides, chlorinated hydrocarbons. It 
is odorless, colorless, non-irritating to skin, non-ionic, absorbs large amounts of water, and has 
adhesive and thickening properties(16). Interestingly, PVP debuted as a blood plasma 
substitute that helped to save lives in World War Two. PVP’s chemical properties are exploited 




in the beer and wine industry for stabilization of polyphenols, where the interactions between 
PVP’s carbonyl groups and hydroxyl groups of polyphenols is well known and 
characterized(17,18). PVP could potentially exhibit the same interactions between 4HPR’s 
redox-reactive phenol group as well. PVP has been shown to adsorb onto the hydroxyl surface 
groups of oxides by acid-base interactions with the carbonyl bond in the PVP backbone(19), 
which acts as a Lewis base in aqueous solutions(20). One disadvantage is that the presence of 
large quantities of salt may lead to precipitation of PVP(19).  In the pharmaceutical industry, 
PVP is used to form films for tablet coatings, a disintegrate in tablets, and crystallization 
inhibitor by complexing with insoluble precipitates, and generally regarded as safe (GRAS) by 
the US FDA(21). In the FDA approved topical tretinoin (retinoic acid) gel formulations, 0.06% 
PVP is added as a crystallization inhibitor(22).  Recently, Laurent Pharmaceuticals developed 
PVP-4HPR solid dispersions for oral dosing and found that it enhanced 4HPR’s 
bioavailability(23). Another group prepared PVP-4HPR nanoparticles and found that the ratio 
of 4:1 PVP-4HPR provided greatest cell uptake in CaCO2 cells(24).  
The aim of this work was to (A) enhance 4HPR solubility by formation of PVP-4HPR 
ASD and (B) provide controlled release dosing over 1-2 mo. of this solubilized form of 4HPR 
from poly-(lactic-co glycolic acid) (PLGA) millicylinders for local delivery applications.  
Delivering solubilized 4HPR to the local tissue environment may help facilitate widespread 
tissue distribution, which is a hurdle in local delivery systems. Previously we have reported 
that in vivo release of 4HPR from PLGA millicylinders has similar release rates to the solid 
drug depot alone, due to slow dissolution of the precipitated drug even after 56 days. To 
accomplish these objectives, PVP-4HPR ASD particles were prepared at different drug loading 
levels by co-dissolving in methanol, forming a thin film, then cryomilling into particles < 90 




μm.  The solubility enhancement and robustness of these PVP-4HPR particles was evaluated in 
water and PBST buffer systems, and the optimum drug-polymer ratio was determined.  The 
PVP-4HPR ASD’s were characterized using differential scanning calorimetry (DSC), 
thermogravimetric analysis (TGA), isothermal titration calorimetry (ITC), and scanning 
electron microscopy (SEM).  Next, various PLGA millicylinder preparation methods were 
investigated to circumvent the issue of incomplete release of hydrophobic 4HPR into aqueous 
media, including: loading cryomilled PVP-4HPR particles into PLGA, co-dissolving the drug 
and polymers in DCM, coating PVP-4HPR core implants with PLGA, and investigating use of 
the plasticizer triethyl-o-acetyl-citrate (TEAC) to enhance release.  Our results show that PVP-
4HPR-TEAC 9/1/1 particles loaded into PLGA implants were able to achieve in a 5.6-fold 
increase (35%) in total 4HPR released after 28 days compared to a similar formulation without 
TEAC.  Furthermore, this optimized ASD formulation showed a dramatic improvement from 
our previous in vivo release from PLGA-4HPR millicylinders, with nearly complete and 
continuous release over 1 month.  These formulations will have future applicability for lifelong 
oral cancer chemoprevention measures.  
3.3. Materials and Methods 
3.3.1. Materials 
 
PLGAs (50:50) were purchased from Evonik, including 503H and 503 (24-38 kDa, acid 
and ester end-capped respectively), 4HPR was generously supplied by Merck Co.  Excipients 
utilized included: polyvinylpyrrolidone polymer (PVP K30, 40 kDa, BASF) and triethyl-o-
acetyl-citrate (TEAC, Sigma-Aldrich.).  See Figure 3-1 for chemical structures of these 
materials. All other materials were reagent grade or better including:  MgCO3, acetone, 
dichloromethane (DCM), ethanol (EtOH), tetrahydrofuran (THF), and Tween 80.  Solvents for 




UPLC-UV and LC-MS analysis were HPLC or MS grade including acetonitrile (ACN), 
methanol (MeOH), double distilled water (ddH20), phosphoric acid (H3PO4). Millicylinders 
were extruded through silicon tubing (0.8 mm i.d., BioRad Laboratories).  Additional media 
for the solubility study included fetal bovine serum (FBS, Life Technologies) and Dulbecco's 









Figure 3-1. Chemical structures of a) 4HPR, b) PVP, c) Triethyl-o-acetyl-citrate (TEAC), and d) PLGA. 
 
3.3.2. Solubilization and Crystallization Inhibition of 4HPR by PVP  
4HPR solubility in PVP aqueous solutions (1, 2, 5, 10, and 20% w/v in ddH20) was 
evaluated by adding 2 mg of 4HPR to 1 mL of PVP solution, incubating at 37° C on a rotator 
in the dark, and was sampled after 1 and 7 days.  Prior to sampling, the samples were 
centrifuged and 10 μL of supernatant was assayed by UPLC-UV, and re-dispersed for the day 7 
time point.  
PVP’s drug crystallization inhibition properties were evaluated by spiking a solubilized 
4HPR in acetone (0.5 ml of 10 mg/mL) into 2 mL of 1% or 10% w/v PVP in ddH20, or a 
ddH20 control in an open glass vial, and stirred at room temperature at 350 rpm for 24 h to 
allow for acetone evaporation.  The solutions were filtered, and 4HPR concentration assayed 
by UPLC. The solid 4HPR precipitate was examined for crystalline character by scanning 




electron microscopy (SEM) and compared to the crystal structures of 4HPR without any 
treatment and 4HPR recrystallized from acetone. 
3.3.3. Formation of PVP-4HPR Amorphous Solid Dispersions 
 PVP-4HPR ASD’s particles were prepared by co-dissolving 4HPR with PVP in MeOH.  
Briefly, PVP (50% w/w) was dissolved in MeOH, then 4HPR was added at mass ratios of 9/1, 
8/2, or 7/3 PVP-4HPR. Later studies incorporated TEAC into the films at a mass ratio of 9/1/1 
PVP-4HPR-TEAC. The solutions were vigorously mixed, shaken for 2 h to maximize 
polymer-drug interactions, poured into a Teflon-lined petri dish to form a thin film, slowly 
dried at RT for 2 days, then further dried in vacuum oven at 40° C for 2 days. The film was 
cryomilled (Retsch swing mill cryomill, PN 20.749.001) at a frequency of 1/30 sec for 30 min, 
and particles were sieved to < 90 μm. The film morphology was inspected for drug 
crystallization via light microscopy prior to cryomilling, and the cryomilled particles were 
imaged via SEM. The 4HPR loading in cryomilled films was determined by dissolving 2 mg 
PVP-4HPR cryomilled particles in 1 mL MeOH, diluting into mobile phase, centrifuging, and 
4HPR assayed by UPLC-UV.  
3.3.4. 4HPR-PVP Dissolution Studies to determine Solubilization Enhancement 
 Dissolution studies were conducted with PVP-4HPR particles (9/1, 8/2, 7/3, all <90 
μm) compared to control 4HPR by adding 5 mg of solids to 1 mL of dissolution media (ddH20, 
PBST 0.02%, or PBST 2% pH 7.4) and incubating on a shaking platform at 37 °C in the dark.  
Media were sampled after 1, 6, and 12 h, then daily up to 7 days by removing 10 μL aliquots, 
diluting in mobile phase, and assaying for 4HPR by UPLC-UV.  The solubility enhancement 
was calculated by dividing the concentration of 4HPR from PVP-4HPR complex (Cs, PVP-4HPR) 




by 4HPR’s intrinsic solubility (Cs, 4HPR).  Additionally, the solubility of 9/1 PVP-4HPR 
particles was determined in cell based media (5% FBS/DMEM) after 24 h. 
Solubilty Enhancement =  
C ,
 C ,  
 
3.3.5. Formulation of Controlled Release PLGA PVP-4HPR ASD Millicylinder Implants 
The goal of these PLGA millicylinder formulations was to provide a controlled release 
of the solublized 4HPR prepared in the PVP-4HPR ASD.  Because hydrophilic PVP and 
hydrophobic PLGA are not soluble in similar organic solvents, unique approaches were taken 
to load PVP-4HPR ASDs into PLGA millicylinders. All implants contained 5% 4HPR 
theoretical loading, and the formulation strategies are outlined in Table 3-1.  Care was take in 
all experiments to minimize light exposure to the drug by covering with foil. 
Table 3-1. Formulation Strategies for Controlled Release PLGA 4HPR-PVP ASD Millicylinders 
Batch# Preparation Methods Rationale 
1-5 Load varying ratios of PVP-4HPR particles into PLGA 
dissolved in acetone 
Maximize 4HPR loading 
Determine optimum PLGA type 
6 Co-dissolve PVP, 4HPR, PLGA in DCM 
Coat with PLGAs 
DCM solubilizes all 
components, CR of PVP 
7,8 Coat PVP-4HPR and PVP-4HPR-TEAC core implants with 
PLGAs 
Reservoir of solubilized drug  
9-11 PVP-4HPR-TEAC (9/1/1) particles loaded into PLGA 
Compare to control PLGA-TEAC-4HPR 
TEAC keeps PVP-4HPR ASD 
intact 
 
The initial formulations (#1-5) investigated the ratio of PVP-4HPR particles (9/1, 8/2 or 
7/3) and polymer type (acid or ester end-capped). Briefly, 60% PLGA 503H or 503 was 
dissolved in acetone, and required amount of PVP-4HPR particles to obtain 5% 4HPR loading 
was added to the PLGA solution and vigorously stirred. Note, different PVP-4HPR ratios 
resulted in different levels of PLGA and PVP in the implants.  The resulting solution was 




loaded into a 3 mL syringe equipped with an 18 g blunt end needle attached to silicon tubing 
(0.8 mm i.d.) and slowly extruded. The implants were dried at room temperature for 2 days, 
and then transferred to vacuum oven and dried at 40 °C for an additional 2 days, after which 
the tubing was carefully removed and implants were cut to the desired size of 1 cm.  
The next formulation (#6) attempted to provide controlled release of PVP from PLGA 
implant by co-dissolving all compounds in DCM with same composition as #1 
(PLGA/PVP/4HPR 45/50/5).  PLGA 503H was dissolved in DCM (60%), PVP and 4HPR 
were added and vigorously stirred,  shaken at RT for 2 h in a capped tube to allow for complete 
mixing, then extruded and dried as previously described.  Some implants were coated with 
PLGA to further slow the release of PVP, and left inside the silicon tubing for the coatings. 
Three different PLGA coatings were tested:  PLGA 503H, PLGA 503H + 3% MgCO3 (a basic 
pore forming salt), and PLGA 503 + 3% MgCO3.  Briefly, PLGA coatings were prepared by 
dissolving 50% PLGA in acetone and adding MgCO3, then extruded into the tubing containing 
the dried implants, and allowed to dry for 2 days at 40 °C in a vacuum oven.  The final 
implants removed from tubing, cut to 1 cm. 
The next set of formulations (#7, 8), PVP-4HPR (9/1) or PVP-4HPR-TEAC (9/1/1) 
core implants were coated with PLGAs.  To prepare PVP-4HPR millicylinders, PVP was 
dissolved at 60% w/v in MeOH, then 4HPR and TEAC was added and vigorously stirred.  The 
implants were extruded as previously described, dried for 2 days at RT, coated 2 times with 
PLGA’s as described for formulation #6, and dried for 2 days at 40 °C. 
The final set of formulations (#9-11) incorporated PVP-4HPR-TEAC particles into 
PLGA and compared to control PLGA-4HPR-TEAC implants. PVP-4HPR-TEAC 9/1/1 
particles were added to PLGA 503H dissolved in acetone with a total implant composition of 




PLGA/PVP/4HPR/TEAC 40/50/5/5.  A control formulation (#10) was prepared by adding 
7.5% TEAC and 5% 4HPR to PLGA 503H + 4HPR, which is representative of the PLGA-
TEAC ratio (11:1) in formulation #9. In attempt to further accelerate release, additional 4% 
TEAC (#11) was added to the PLGA solution prior to adding the PVP-4HPR-TEAC 9/1/1 
particles.  
3.3.6. 4HPR Loading Assays in PLGA Millicylinders  
To determine the amount to 4HPR loaded into the implant, one millicylinder was 
weighed into a 15 mL centrifuge tube, PLGA and 4HPR were co-dissolved by addition of 0.5 
mL THF, followed by precipitation of PLGA by addition of 9.5 mL EtOH. Next, the sample 
was centrifuged, and supernatant was assayed by UPLC/UV.  Encapsulation efficiency was 
invariable and ranged from 97-103%. 
3.3.7. In vitro Release of 4HPR and PVP from PLGA-PVP Millicylinders 
4HPR and PVP in vitro release from millicylinders was performed by incubating 1 
millicylinder (5-7 mg) in a non-solubilizing buffer of 4 mL PBS pH 7.4 + 0.02% Tween80 at 
37 °C on a shaking platform (200 rpm) while covering vials with aluminum foil to protect from 
light.  The solutions were sampled by complete media replacement up to 6 weeks. 
3.3.8. In vivo Release of 4HPR from PLGA-PVP Millicylinders 
To evaluate 4HPR release in vivo, millicylinders were weighed and implanted 
subcutaneously (s.c.) in the dorsal region of male Sprague Dawley rats using a 12 g trocar. 
Each rat could receive up to 6 implants. For each formulation, 3 implants were implanted in 
each rat, and 1 rat per time point (days 1, 14, 28) was sacrificed. Millicylinders were carefully 
harvested to ensure complete removal and release from encompassing tissues.  The amount of 




4HPR released was determined by assaying the amount of 4HPR remaining in recovered 
millicylinder by loading assay. 
3.3.9.  4HPR UPLC-UV Assay 
4HPR levels in PVP-4HPR particles, millicylinder loading, and in vitro release media 
was determined by UPLC/UV.  The reverse phase UPLC/UV analysis utilized a Waters 
Acquity UPLC system and Empower software under the following conditions:  Acquity BEH 
C18 2.1x100 mm column, mobile phase 80:20 ACN: ddH2O + 0.1% H3PO4, isocratic flow rate 
0.65 mL/min, UV detection at 365 nm, and total analysis time of 2 min.  4HPR calibration 
standards were prepared in mobile phase (0.5-100 μg/mL) from a 0.5 mg/mL 4HPR stock 
solution in ACN, and reflects the large linear dynamic calibration range. 
3.3.10. PVP UPLC-UV SEC Assay 
PVP levels in in vitro release media was determined by UPLC/UV size exclusion 
chromatography (SEC).  The PVP assay was adopted from Johnson &Johnson25 and utilized a 
Waters Acquity UPLC system and Empower software under the following conditions:  Acquity 
BEH H125 1.7 μm 4.6x150 mm column, mobile phase 80:20 0.1 M sodium acetate buffer in 
ddH20: MeOH, isocratic flow rate 0.7 mL/min, UV detection at 220 nm, and total analysis time 
of 4 min. 
3.3.11. Particle and Millicylinder Morphology via Scanning Electron Microscopy (SEM) 
 The morphology of 4HPR, 4HPR-PVP cryomilled film particles, and millicylinder 
cross sections were examined by scanning electron microscopy (SEM) using a Phillips XL 
FEG SEM.  All samples were completely dried, sputter coated with gold for 90 sec, then 
imaged using 3 kV electric beam.  




3.3.12. Differential Scanning Calorimetry (DSC) and Thermogravimetric Analysis (TGA) 
Glass transition temperature’s (Tg) of the PVP-4HPR particles and millicylinders were 
determined via DSC (Discovery, TA instruments).  Briefly, 2-3 mg of the PVP-4HPR particles 
or millicylinders were added to a hermetic pan, and samples were heated with a modulating 
temperature program from -10 °C to 180 °C.   The amount of residual solvent trapped in the 
cryomilled films and millicylinders after drying was determined by Thermogravimetric 
Analysis (TGA, Discovery, TA instruments).  The following temperature ramping profile was 
used:  10 °C/min until 300° C, then 20 °C/min till 600° C.  
3.3.13. Isothermal Titration Calorimetry (ITC) for PVP-4HPR Affinity Stoichiometry  
  ITC was used to measure the stoichiometry of interactions between 4HPR and PVP, 
using a nano-ITC (TA instruments), equipped with a low volume gold sample cell.  300 μL of 
0.2% 4HPR (in MeOH) was loaded into sample cell, stirred at 250 rpms at 25 ˚C,  and 20 x 2.5 
μL aliquots of 10% PVP (in MeOH) were titrated into the 4HPR solution.  The reference cell 
was filled with 100% MeOH, and a blank isotherm for MeOH injections into MeOH was 
subtracted from the sample measurements.  
3.4. Results 
3.4.1. 4HPR Solubility in PVP Solutions and Crystallization Inhibition 
The results from the 4HPR solubility in PVP solutions is shown in Fig. 3-2a. The initial 
solubility studies show that PVP aqueous solutions were not capable of significantly increasing 
4HPR solubility, where even at 20% PVP, only 0.7 μg/mL 4HPR was solubilized. The PVP 
crystallization inhibition study showed that PVP was slightly effective at preventing 4HPR 
precipitation upon addition of 4HPR/acetone solution to PVP solutions, and both the 1% and 
10% PVP solutions resulted in cloudy solutions, while the control ddH20 solution showed 




aggregation of hydrophobic drug that adhered to the walls of the glass vessel. Based on these 
observations, PVP appeared to be functioning as a surfactant or wetting agent.  The solubility 
of 4HPR/acetone in PVP solutions increased 10-fold compared to PVP solutions without 
acetone, likely due to the solubility enhancement from acetone, which may have not 
completely evaporated. The stability of these solutions after 4 mo. of light exposure at RT 
shows that PVP prevents photo-degradation as evident by the yellow color of 4HPR solids 
compared to the orange solids in ddH2O (Fig. 3-2b).  The morphology of 4HPR crystals (no 
treatment), 4HPR recrystallized in acetone, and 4HPR precipitated in 10% PVP and ddH2O are 
displayed in (Fig. 3-2c-f), and show that 4HPR recrystallization in acetone(Fig. 2d) lead to a 
more disordered crystal structure from the original cuboidal shaped 4HPR crystals (Fig. 3-2c). 
When 4HPR had precipitated from the PVP solutions (Fig. 3-2e), it appears that 4HPR has 
adhered to PVP surface, and looks very different from 4HPR precipitation in ddH20 (Fig. 3-2f). 
 





Figure 3-2. 4HPR solubility, stability, and morphology in solid state and PVP and PVP-acetone solutions. A) 
4HPR solubility in 1-20% PVP after 7 days at 37 °C compared to 4HPR dissolved in acetone (0.5 mL of 10 
mg/mL) added to PVP solutions and stirred uncapped at RT x 1 d,  b) Photo-stability enhancement by PVP from 
crystallization inhibition experiment (4HPR in acetone) after 4 mo. light exposure at RT. C-E) are SEM images of 
c) 4HPR solid, d) 4HPR recrystallized in acetone, e) 4HPR dissolved in acetone then precipitated in 10% PVP 
aqueous solution, f) 4HPR dissolved in acetone, then precipitated in ddH2O. 
 
3.4.2. Formation of PVP-4HPR ASDs 
 Although the results from the PVP solubility and crystallization inhibition study did not 
show PVP’s effectiveness of increasing 4HPR solubility, the literature shows the utility of PVP 
in increasing hydrophobic drug solubility by formation of ASDs.  Ledet and coworkers 
increased 4HPR solubility by formulating PVP-4HPR (16-20% 4HPR) nanoparticles by 
preparing films that were homogenized and then lyophilized, and resulted in an increased 
uptake in CaCO2 cells24. Laurent Pharmaceuticals prepared PVP-4HPR (20-60% 4HPR) ASDs 
for oral dosage which increased bioavailability of 4HPR compared to a corn oil formulation23. 
Because PVP is a hydrophilic polymer, it will dissolve quickly in aqueous solutions, resulting 
in a large burst release of the excipient, which may contribute to dissociation of the drug-PVP 




ASD.  A literature search revealed that PVP melting could be delayed by addition of dibutyl 
phthalate (DBP) to beeswax/ PVP implants for veterinary therapies(26). Due to the known 
health risks of phthalates, TEAC has been listed as suitable substitute for DBP in a wide range 
of applications(27), and was added to the PVP-4HPR ASD’s.  
In our studies, a film was prepared by co-dissolving 4HPR at different loading levels in 
PVP and MeOH. In Figure 3-3(a-b), the light microscopy shows the translucentness of the 
PVP-4HPR system after drying, indicating that 4HPR was solubilized in PVP. The cracks in 
the film are apparent and are due to the brittle character of PVP. The SEM images (Fig. 3-3c-f) 
of the cryomilled PVP-4HPR particles shows the interaction between PVP and 4HPR, where 
4HPR’s regular cuboidal crystal structure (Fig. 3-2c) is no longer present.  No noticeable 
difference in morphology of 9/1 and 8/2 PVP-4HPR particles, but slightly less adherence of 
4HPR to PVP surface in the 7/3 PVP-4HPR particles was observed.  The 9/1/1 PVP-4HPR-
TEAC particles were noticeably different from the 9/1 PVP-4HPR particles.  The 4HPR 
loadings in the PVP-4HPR particles are listed in Table 3-2.  
Table 3-2. 4HPR loading in PVP-4HPR particles.  Mean ± SE, n=3. 
Film Composition % 4HPR 
9/1 PVP-4HPR 9.7 ± 0.0 
8/2 PVP-4HPR 18.3 ± 0.3 
7/3 PVP-4HPR 26.1 ± 0.4 
9/1/1 PVP-4HPR-TEAC 9.2 ± 0.2 





Figure 3-3. Morphology via light microscopy of films (a,b) and SEM images of PVP-4HPR 
cryomilled film particles (<90 µm) (c-f) with varying ratios of PVP-4HPR as noted on figure. 
 
3.4.3. 4HPR Dissolution and Solubility Enhancement with PVP-4HPR particles 
 The solubility enhancement of the different ratios of PVP-4HPR particles (<90 μm) 
were evaluated in water and PBST’s (Fig. 3-4). It should be noted that the net PVP 
concentration in all studies was < 0.5% w/v upon dissolving the complex, and based on the 
previous PVP solubility study, it should have negligible effect on solubility when in aqueous 
phase, and therefore the solubility enhancement is an indication of the robustness of the ASD 
system.  By far the greatest solubility was achieved with 9/1 PVP-4HPR, where >300 μg/mL 
4HPR was maintained in ddH2O for 7 days, equating to a 50 to 1000-fold solubility 
enhancement. In the higher drug loaded ASD’s (8/2 and 7/3 PVP-4HPR), little solubility 
enhancement (2.4, 1.3-fold increase respectively) was observed after 7 days in ddH2O. The 
solubility enhancement of 4HPR with PVP-4HPR ASDs was significantly less in PBS buffer 




with 0.02% or 2% Tween, likely due to disruption of polymer-drug interactions by salts, as this 
is a known phenomenon with PVP ASD’s.  In 0.02% PBST, the 8/2 and 9/1 PVP-4HPR 
performed the similar and had sustained a 170 to 50-fold solubility enhancement over 7 days, 
but much less enhancement with 7/3 PVP-4HPR ASDs.  In 2% PBST, all compositions have 
limited solubility advantage (1 to 6-fold) due to the extensive solubilization by Tween.  Here, 
4HPR solubility trend is reversed in 2% PBST:  7/3 > 8/2 > 9/1 PVP-4HPR up to 24 h, which 
suggests a competition between micellar solubilization by Tween and PVP-4HPR ASD. After 
24 h in PBST 2%, the solubility steeply declines until day 4, where equilibrium had been reach 
and all have equivalent solubility to the drug alone. In respect to dissolution time to reach max 
solubility: in ddH20 PVP-4HPR 9/1 took 6 h, 8/2 and 7/3 took 48 h, and in PBST’s all took 6 h.  
For translation into in vivo applications, it is expected that there will be plasma 
proteins, fats, sugars, and other surfactants present that may affect the solubility of the PVP-
4HPR ASD, and could either aid in solubilization of 4HPR, or interruption of the drug-polymer 
interactions. To test this, 5 mg of 9/1 PVP-4HPR was dissolved in 1 mL of a cell based media 
of  5% FBS in DMEM (containing plasma proteins and glucose) and solubility after 24 h was 
337 ± 11 ug/mL 4HPR equating to 87 ± 3% solubilized (data not shown).  The sustained 
solubility enhancement (>7 days) will be useful for our local controlled release drug delivery 
applications, and possibly enhance 4HPR tissue dispersion. 





Figure 3-4. Dissolution and solubility enhancement of 4HPR from PVP-4HPR ASDs at various drug loading 
levels evaluated in different levels of micellar solubilizing and non-solubilizing media over 1 week. A-C) 
Show4HPR concentrations and D-F) shows the calculated solubility enhancement compared to control 4HPR. 
(Media are denoted on figure, 5 mg particles added to 1 mL media, data represents mean ±SE, n=3). 
 

























































































































































































3.4.4. Characterization of PVP-4HPR ASDs by Microcalorimetry: DSC, TGA, ITC 
The extent of drug solubility in the polymer is an important aspect of ASD’s, and the 
level of solubility can be measured by measuring the Tg of the system via DSC, and drug 
activity can be obtained and used calculate the Flory-Huggins interaction parameter (Х)(28). 
While this data is useful for selection of the optimum polymer for ASD’s, it is not within the 










where Tg,mix is the glass transition temperature of the mixture (in Kelvin), and w is the weight 
fraction of each component. A limitation of the Fox equation is that it can only be applied to 
blends with weak intermolecular interactions. Factors affecting the Tg include molecular size 
and shape, and extent and strength of hydrogen bonding, all of which can affect the packing or 
free volume. It is likely that PVP and 4HPR exhibit strong hydrogen bonding, and therefore 
this equation may not lead to accurate predictions.  It is important to note that any residual 
water present can act as a plasticizer (Tg = -138 ˚C) and leads to a decrease in Tg.  For 
example, if 5% water (Tg = -138 ˚C) is present in 100% PVP (Tg=164 ˚C), the Tg of the 
hydrated excipient will decrease to 120 ˚C.  Because the Tm of 4HPR and Tg of PVP are so 
similar, 164 °C and 174 °C respectively, the heat flow peaks cannot be resolved, and DSC 
cannot be used for calculation of ratios.  
  The results from the Tg measurements of 4HPR, PVP, and the PVP-4HPR particles 
are shown in Fig. 3-5a, where presence of only one Tg would be indicative of formation of an 
ASD.  When comparing the Tg’s of the different ratios of PVP-4HPR particles the 9/1 ratio has 
the greatest Tg (155 °C) vs. the 8/2 and 7/3 films (131, 133 °C respectively), which are both 




lower than the Tm of 4HPR (174 °C) and Tg of PVP (164 °C).  These lower Tg’s would likely 
be due to less crystalline solids, while the 9/1 PVP-4HPR particles have an excess of 
crystalline PVP.  Nonetheless, only one Tg is present with all PVP-4HPR ASD’s, which 
suggests an amorphous system. When the plasticizer TEAC is included PVP-4HPR particles 
(PVP-4HPR-TEAC 9/1/1), the Tg dramatically decreases to 91 °C, as expected. The TGA 
analysis showed that all of these PVP-4HPR particles had been sufficiently dried with residual 
solvent levels of 1-6% based on mass loss reading at 100 °C (representative TGA spectra in 
Supplemental Information, Fig. S3-1). The results of the ITC binding experiment shows an 
inflection point of the heat flow versus PVP injections into 4HPR solution after 10 injections, 
equating to an interaction stoichiometry of PVP:4HPR of 4.58:1, or ~9/2 or 18% 4HPR (Fig. 4-
5b).   
DSC data comparing Tg’s of 9/1 PVP-4HPR particles loading into PLGA 
millicylinders can be referenced in Supplemental Information Fig. S3-2, and discusses how the 
Tg may indicate PLGA and PVP-4HPR phase miscibility.   





Figure 3-5. a) Effect of 4HPR loading and TEAC plasticizer in PVP ASD’s on Tg compared to 4HPR and PVP 
alone.  b) PVP-4HPR interaction stoichiometry by ITC reveals optimum ratio of 4.58:1 PVP-4HPR or 18% 4HPR, 
as indicated by the inflection point in heat flow after 10 injections of PVP into 4HPR solution (300 μL 0.2% 
4HPR titrated with 2.5 μL injections of 10% PVP in MeOH.  10 aliquots of PVP=2.5mg PVP into 0.6 mg 4HPR). 
3.4.5. In vitro and In vivo Evaluation of PVP-4HPR PLGA Millicylinders 
3.4.5.1. Effect of Polymer Type and PVP/4HPR Ratios 
The first set of formulations (#1-5,) investigated the different ratios of PVP-4HPR 
particles loaded into either PLGA 503H or 503, with goal of using the lower ratio of PVP-
4HPR (i.e. 8/2 or 7/3) to achieve a greater drug loading in PLGA implant. As shown in Fig 3-6, 
the 9/1 PVP-4HPR PLGA implants (#1) outperformed the others with a 10-fold increase in 
amount of 4HPR released after 28 days (7.7% vs. 0.7-4.2%), results that correlate with the 
dissolution studies, yet this is still not at the desired release level. This formulation also had a 
large PVP burst release (>80% after 3 days), likely due to greater percent solids or less PLGA 
in implant compared to the other ratios. The ester-capped PLGA 503 (#4,5) released more 
4HPR than the 503H with similar PVP-4HPR composition.  The overall trend was that greater 
PVP level had a more favorable 4HPR release, but a higher PVP burst. These opposition of 
trends for desired 4HPR and PVP release profiles make it challenging to co-formulate into one 
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system, and will require more creative strategies.  See Table 4-3 for a summary of results of all 
PLGA-PVP-4HPR millicylinder performances, which includes the composition, 4HPR loading 
and day 28 release, and time to 80% PVP release. 
 
Figure 3-6. Effects of  PVP-4HPR ratio and polymer type on in vitro release of a) 4HPR and b) PVP from PLGA 
implants (mean ±SE, n=3). PLGA implants were prepared by loading either PLGA 503 or 503H with PVP-4HPR 
(9/1, 8/2, 7/3) ASD particles to yield implants containing 5% 4HPR. 
The morphology of formulations #1-5 was examined by SEM prior to and after 28 days 
of in vitro release (Fig. 3-7).  From these images, we can observe the initial crystallinity and 
miscibility of 4HPR or PVP in PLGA, and also the extent of implant erosion after 28 days. The 
greatest implant homogeneity is observed in #1 (PLGA 503H+ 9/1 PVP-4HPR), but as the 
PVP/4HPR ratio decreases (requiring a lesser amount of the ASD to be loaded into implant to 
achieve 5% 4HPR loading in #2 and 3), more crystals (likely 4HPR precipitation) are present.  
In #4 and #5, more crystallinity is observed in PLGA 503 ester end-capped, which is a 




reflection of insolubility of both PVP and 4HPR in PLGA 503, and correlates with the faster 
4HPR and PVP release.  On day 28, it appears that the PLGA 503H implant erosion rate 
increases as the PVP level decreases. This trend is opposite of expected, where the in vitro 
release shows PVP released more slowly in the 7/3 and 8/2 PVP-4HPR compared to the 9/1 
complex. Upon visual inspection, the lower PVP-4HPR ratio loaded implants had greater 
swelling (for 503H formulations), slower erosion, and released PVP and 4HPR slower.  Also 
on day 28, the PLGA 503 implants (#4, 5) did not show any erosion, but the formation of a 
pore network was present. 
 
Figure 3-7. SEM images of cross sections of PLGA millicylinder implants (#1-5) loaded with PVP-4HPR 
particles with varying ratios prior to and after 28 days in in vitro release media.  Numbers correspond to 
formulations#1-3 prepared with PLGA 503H, and #4, 5 with PLGA 503. #1: PVP/4HPR 9/1 particles, #2, 4: 
PVP/4HPR 8/2 particles, #3, 5: PVP/4HPR 7/3 particles. 
 
3.4.5.2. PLGA-PVP-4HPR millicylinders co-dissolved in DCM +PLGA Coatings 
In the previous experiment, nearly complete PVP release was observed after the first 
few days, which left the insolubilized drug in the implant.  In the next set of formulations (#6a-
d), we hypothesized that co-dissolving PVP, 4HPR, and PLGA in DCM would slow the release 
of PVP due to physical entanglement of PVP’s and PLGA’s polymer chains, and thus provide 
controlled release of the PVP-4HPR ASD. Additionally, these millicylinders were coated with 




different PLGA’s, including acid and ester end-capped, with and without pore forming agent 
(503H, 503H+3% MgCO3, or 503+ 3%MgCO3) to provide an additional diffusion barrier to 
slow PVP release. The results of in vitro releases of (Fig. 3-8) shows that the uncoated implant 
(#6d) released 4HPR the fastest and had the best PVP release profile, yet still the desired 4HPR 
release kinetics were still not achieved, with only 10% released after 42 days. This could be 
attributed to the inability of PVP to interact with 4HPR in presence in PLGA, and therefore no 
4HPR solubility enhancement occurred.  However, the hypothesis was true that PVP release 
can be controlled by physical entanglement of the polymer chains using DCM solvent. The 
coatings did slow 4HPR and PVP release as expected, with the slowest release with coating 
503H and 503 +3% MgCO3.  The slowest PVP release occurred in uncoated implants, while 
the fastest was with 503H + 3% MgCO3 coating, results that suggest that PLGA repels PVP 
from implant. 





Figure 3-8. 4HPR (a) and PVP (b) in vitro release from PLGA coated millicylinder #6 (PLGA 503H/PVP/4HPR 
45/50/5, all commixed in DCM) (mean ±SE, n=3). C) SEM’s show cross-sectional morphology of #6 PLGA 
coated implants, including a close up of the coating-core edge for each implant. 
3.4.5.3. PLGA coated PVP-4HPR and PVP-4HPR-TEAC core implants 
In the next set of millicylinder formulations, we sought to create a reservoir of the 
soluble drug by preparing core implants with PVP-4HPR (#7) and PVP-4HPR-TEAC (#8), and 
coating with PLGAs to slowly release the solubilized drug. These millicylinders had open 
ends, providing a port for drug release.  It was postulated that the addition of TEAC to the PVP 
implant (#8), would aid in keeping the PVP-4HPR ASD intact, facilitate slower release of 
PVP, leading to controlled release of a soluble form of 4HPR. TEAC is not soluble in PVP, but 
soluble in PLGA. The in vitro releases of these PLGA coated PVP-4HPR and PVP-4HPR-
TEAC implants (Fig 9a-d), shows similar release rates with 10% 4HPR release after 28 days, 




however, slightly slower 4HPR release was observed when TEAC added to implant.  We 
observed that the PVP-4HPR core implant melts immediately, resulting in rapid PVP release, 
leaving behind crystallized 4HPR in PLGA coatings. The effect of the PLGA coatings on 
4HPR release was: 503 + 3% MgCO3 > 503H > 503H + 3% MgCO3. 
The effect of the PLGA coatings on PVP release shows the slowest releases when 
coated with PLGA 503H (3 days for 80% release), and addition of the basic pore forming salt 
MgCO3 accelerated PVP release. This effect of MgCO3 accelerating PVP release was also 
observed in #6 PLGA coated formulations. This could be attributed to MgCO3’s neutralization 
of PLGA’s acidic end groups, which may play a role in hydrogen bonding of PVP and 
adhering the coating to the implant. The least favorable coating for delaying PVP release was 
PLGA 503, and nearly 100% PVP was released after first day, likely due to similar 
phenomenon, where ester end-capped PLGA had less hydrogen bonding with PVP, and 
exhibited a greater repulsion for each other. In the SEM images (Fig. 4-8c),the PLGA coatings 
containing 3% MgCO3 do not adhere as tightly to the PVP-4HPR-TEAC implant compared to 
the PVP-4HPR implant, suggesting that TEAC may play a role in repulsion of PVP to PLGA 
or of 4HPR to PLGA.  Although these formulations (#7, 8) did not perform well in vitro, 
insight was gained into how PLGAs and TEAC affect the release rate of the PVP-4HPR 
complex. 







Figure 3-9.  In vitro release of 4HPR (a,c) and PVP (b,d) from PVP-4HPR-TEAC 9/1/1 (a,b) or PVP-4HPR 9/1 
(c,d) core implants coated with PLGA (503H, 503H + 3% MgCO3 or 503+ 3% MgCO3) (mean± SE, n=3). E) 
SEM’s show cross-sectional morphology of #7 and #8 PLGA coated implant, including a close up of the coating-
core edge for each implant. 




3.4.5.4. PLGA millicylinders loaded with PVP-4HPR-TEAC ASDs enhance 4HPR release 
 The aim of the next formulations (#9-11) was to utilize TEAC to keep the ASD intact. 
In the previous PLGA coated PVP-4HPR-TEAC cores, the TEAC was only slightly effective 
at slowing the release of PVP. Also, it was suspected that the PVP-4HPR ASD was 
dissociating in the presence of PLGA due to chemical interactions, and it was postulated that 
addition of TEAC would inhibit this interaction due to masking PLGA’s carboxylic acid end 
groups (See chemical structures in Fig. 3-1). As shown in Fig. 3-10, the PLGA millicylinder 
loaded with TEAC-PVP-4HPR particles 9/1/1 (#9), and resulted in a 5.6-fold increase in 4HPR 
release after 28 days (34% vs 6% 4HPR respectively) compared to formulation #1 without 
TEAC. To determine if TEAC’s plasticizing effects on PLGA was responsible for the 
favorable 4HPR release from #9, a control implant without PVP was evaluated (#10: PLGA 
503H+4% TEAC+ 5% 4HPR), and did not perform well with only 0.5% released after 28 days.  
Furthermore, in the last formulation #11, TEAC was added to PLGA prior to addition of the 
PVP-4HPR-TEAC ASD to further enhance 4HPR release, if in fact the favorable drug release 
was due to PLGA plasticization.  This formulation released slightly less than #9, (23% after 
day 28), so it could be established that the TEAC is likely exerting its effects by allowing the 
PVP-4HPR complex to remain intact, rather than due to the PLGA plasticization.  The 
solubility of each of these components in PLGA can be seen in SEM cross-sectional images 
(Fig. 4-10c).  The PVP-4HPR-TEAC ASD is not soluble in the PLGA (#9), TEAC is soluble in 
PLGA (#10), and the additional TEAC in PLGA prior to addition of the PVP-4HPR-TEAC 
ASD (#11) resulted in poor implant formation with holes present. 
 Next, this optimized formulation (#9) or PLGA+ PVP-4HPR-TEAC, was evaluated in 
vivo after SC implantation and compared to an immediately dissolving PVP-4HPR (9/1) 




implant.  The in vivo release shows slow and continuous release over 30 days (Fig. 3-10d), and 
the controlled release PLGA formulation out-performed the completely amorphous ASD.  This 
is a significant improvement from our previous PLGA-4HPR millicylinder implants, where we 
found that only 25% drug could be release after 30 days in vivo.  
 
Figure 3-10. Effects addition of TEAC to PVP-4HPR particles loaded into PLGA implants on in vitro and in vivo 
releases.  A) SEM images PVP-4HPR-TEAC particles and implant cross section show PVP-4HPR-TEAC 
particles are more intact in PLGA than PVP-4HPR particles, and TEAC is insoluble in PLGA. b) in vitro release 
of 4HPR accelerated by TEAC, c) in vitro release of PVP not affected by TEAC (#10), and d) Desirable 4HPR 
release kinetics achieved in vivo in SC region of rats with PLGA+ 4HPR-PVP-TEAC, which outperformed the 





Table 3-3.  PVP-4HPR-PLGA millicylinder implant compositions and in vitro performances 
Batch Preparation Method PLGA type 









% 4HPR % 
PLGA 
coating 







1 PLGA +9/1 PVP-4HPR particles 503H 50 5 45 -- 4.1 ± 0.5 -- 7.7 ± 0.2 3 
2 PLGA +8/2  PVP-4HPR particles 503H 75 5 20 -- 3.5 ± 0 -- 0.7 ± 0.3 >35 
3 PLGA +7/3  PVP-4HPR particles 503H 83 5 12 -- 3.1 ± 0.3 -- 1.0 ± 0.8 >35 
4 PLGA +8/2  PVP-4HPR particles 503 75 5 20 -- 2.3 ± 0.6 -- 4.1 ± 0.2 28 
5 PLGA +7/3  PVP-4HPR particles 503 83 5 12 -- 3.1 ± 0.1 -- 4.2 ± 0.2 7 
6a 
Co-dissolve PLGA (503H), PVP, 
4HPR in DCM  
*coated with PLGAs 
Coat 503H  
45 5 50 -- 
3.4 <0.1 4.2 ± 0.5 >42 
b 
Coat 503H+ 




3%MgCO3 3.1 0.1 3.1 ± 0.4 
>42 
d 503H, no coat 3.2 -- 9.5 ± 0.7 35 
7a 
PVP-4HPR-TEAC (9/1/1) 
*core coated with PLGAs 
Coat 503H  
-- 9 82 9 
5.9 1.7 9.4 ± 1.6 7 
b 
Coat 503H+ 




3%MgCO3 5.8 1.9 9.5 ± 0.0 
1 
d -- 7.6 -- -- -- 
8a 
PVP-4HPR (9/1) 
*core coated with PLGAs 
Coat 503H  
-- 10 90 -- 
7.0 -- 10.9 ± 0.2 28 
b 
Coat 503H+ 




3%MgCO3 7.1 2.0 7.2 ± 0.2 
3 
d -- 9.1 2.1 -- -- 
9 PLGA+ PVP-4HPR-TEAC (9/1/1) 503H -- 5 45 5 5.5 -- 33.5 ± 1.3 3 
10 PLGA+ TEAC (11/1) + 4HPR   503H 87.5 5 -- 7.5 5.9 ± 0.4% -- 0.7 ± 0.2 -- 
11 
PLGA+ TEAC (11/1)  + 
PVP-4HPR-TEAC(9/1/1) particles 
503H 41 5 45 9 
2.7 ± 0% -- 22.8 ± 0 7 
 All percentages are expressed as w/w. 
 Note: in #6-8, only 1 millicylinder was used for 4HPR loading determination due to the limited supply.





The initial solubilization studies showed that PVP aqueous solutions are not effective at 
solubilizing 4HPR. When 4HPR is first dissolved in acetone prior to adding to the PVP solution 
however, its solubility is enhanced.  PVP acted as a wetting agent and formed a cloudy colloidal 
drug suspension, and also reduced 4HPR’s photo-sensitivity by maintaining 4HPR’s yellow 
color. Next, amorphous PVP-4HPR complexes were prepared, and the 9/1 PVP-4HPR complex 
resulted in a 50-fold solubility enhancement of 4HPR was achieved (in ddH20) and sustained 
over 7 days.   
One of the advantages of amorphous molecules is faster dissolution and greater apparent 
solubility for extended periods of time. One of the disadvantages of amorphous molecules is that 
they can have decreased physical stability, and can form different crystal structures after 
recrystallization. This was evident in our 4HPR acetone recrystallization studies where different 
crystal structures were observed, and confirms the presence of multiple polymorphic states, as 
described in literature where two polymorphs of 4HPR are known, with Tm’s of 173-175 °C and 
178-180 °C (9).  Stability of co-amorphous drug systems is influenced by their Tg and 
intermolecular interactions (26, 27). PVP’s high Tg (174 °C) gives rise to better stability of the 
PVP-4HPR amorphous solid dispersion due to hindered drug diffusion and inhibition of drug 
precipitation in the glassy matrix.  A nearly completely amorphous and highly homogeneous 
dispersed drug can be validated by having a single glass transition temperature, indicating a high 
degree of homogeneity (23).  Based on the long duration of sustained solubility from the 9/1 
PVP-4HPR complex shown in the dissolution study, which was tested months later, we see that 
this is a very stable system.   




Further investigation into the PVP-4HPR interactions by ITC revealed that the optimum mass 
ratios of ~9/2 PVP-4HPR (or 18% 4HPR), which requires half the amount of PVP we found 
necessary for superior 4HPR solubility enhancement.  These results agree with the optimal PVP-
4HPR ratios found by Ledet and coworkers (20% 4HPR)(24) and Laurent Pharmaceuticals (20% 
4HPR)(23).  It is suspected that out 9/1 PVP-4HPR ratio performed the best by providing excess 
PVP to prevent PVP-4HPR dissociation or to increase hydrogen bonding.  This is also consistent 
with the study of molecular mobility of PVP-nifedipine glassy dispersions that found that PVP 
mobility was delayed by increasing strength of hydrogen bonding along with increasing PVP 
concentration which contributed to the stability of the complex (28).  The most likely mechanism 
of PVP-4HPR ASD stability is due to hydrogen bonding between PVP’s carbonyl and 4HPR’s 
hydroxyl group.   
 Next, PLGA millicylinders were prepared using different methods for loading of PVP-
4HPR ASDs into the implant.  Solubility considerations of the components in various solvents 
and PLGA matrix were important for delivery of the intact PVP-4HPR complex.  The challenge 
here was to design a system that accounted for the different chemical properties of hydrophobic 
4HPR and hydrophilic PVP which had differing affinities for hydrophobic PLGA matrix.  This 
inherently led to rapid release of PVP, leaving behind precipitated 4HPR shielded from aqueous 
environment in PLGA. PLGA is soluble in the organic solvents DCM and acetone (typically 
used in preparations because of their high volatility needed for drying of implants), PVP is 
insoluble in acetone, but soluble in DCM and MeOH, and 4HPR solubility in these solvents is as 
follows:  acetone > MeOH > DCM(8).  For our in vitro release studies, a non-solublilizing buffer 
system was used (PBS 0.02% pH 7.4), and therefore any appreciable amount of 4HPR released 
will be indicative of release of the solubilizing 4HPR-PVP complex. 




Our first experiments (#1-5) loaded different ratios of PVP-4HPR particles into PLGA dissolved 
in acetone, and yielded poor 4HPR release kinetics, (<10% after 28 days), due to rapid and 
nearly complete release of PVP after 3 days.  This confirms the challenge of co-delivery of drugs 
and excipients with different chemical properties. The next set of formulations (#6) used DCM 
as a co-solvent, where all three components were solubilized, and successfully provided PVP 
controlled release by entanglement of PVP and PLGA polymer chains, however it impaired 
PVP-4HPR interactions and resulted in incomplete 4HPR release (10% after 6 weeks).  
Additionally, #6 was coated with PLGA’s, but did not have a significant positive affect on 4HPR 
release kinetics, but did slow PVP release as expected.   
 Because PVP is a hydrophilic polymer, it will dissolve quickly in aqueous solutions, 
resulting in a large burst release of the excipient, which may contribute to dissociation of the 
drug-PVP ASD.  A literature search revealed that PVP melting could be delayed by addition of 
dibutyl phthalate (DBP) to beeswax/ PVP implants for veterinary therapies (29). Due to the 
known health risks of phthalates, TEAC has been listed as suitable substitute for DBP in a wide 
range of applications (30), and was added to the PVP-4HPR ASD’s.  Next an attempt was made 
to create millicylinder systems that contained core PVP-4HPR or PVP-4HPR-TEAC complexes 
coated with PLGAs to provide controlled release of the ASD.  The results of these in vitro 
release studies were disappointing, where nearly all of the core had dissolved after the first few 
days, and >90% of the precipitated drug was left behind in the PLGA coatings.  However, we did 
learn a few things: PLGA coatings containing 3% MgCO3 do not adhere as tightly to the PVP-
4HPR-TEAC implant compared to the PVP-4HPR implant, suggesting that TEAC may play a 
role in repulsion of PVP to PLGA or of 4HPR to PLGA.  An important question is what is the 




preference of 4HPR in PLGA vs. PVP? By decreasing the amount of PLGA, we may be able to 
limit 4HPR partition into PLGA, and remain in the PVP-4HPR solubilizing complex.  
 The final formulation utilize PVP-4HPR-TEAC particles and was suspected that TEAC was 
enhancing drug release by insulating PVP-4HPR ASD and inhibit its dissociation by PLGA. This 
was the most favorable release, with 35% released after 28 days, equating to a 5.6-fold increase 
in release compared to the formulation without TEAC. Furthermore, this optimized ASD 
formulation showed a dramatic improvement from our previous in vivo release from PLGA-
4HPR millicylinders, with nearly complete and continuous release over 1 month. 
3.6. Conclusions 
 Here we show that 4HPR solubility can be significantly enhanced by formation of PVP-
4HPR ASDs at the optimum ratio of 9/1.  We have formulated this solubilized form of 4HPR-
PVP ASD into long-acting release PLGA millicylinders for local delivery. By incorporating the 
plasticizer TEAC into the PVP-4HPR particles, a 5.6-fold increase on 4HPR in vitro release was 
observed compared to those implants without TEAC. The in vivo release of 4HPR from the 
PLGA PVP-4HPR-TEAC implants have shown remarkable controlled release properties over 1 
month.  These results shows the utility of PVP-4HPR ASD into controlled release local drug 
delivery and will be beneficial for life-long oral cancer chemoprevention applications. 
  




3.7. Supplemental Information 
3.7.1. Tg’s of PVP-4HPR particles and PLGA-PVP-4HPR +TEAC Millicylinders 
The glass transition temperature (Tg) of the PVP-4HPR particles was measured to 
determine if a complex had formed, which would could be confirmed by verification of one Tg.  
The Tg of the dried PLGA-PVP-4HPR millicylinders was also measured to determine if PVP or 
4HPR affected the Tg of PLGA implying miscibility of the components.  
 Tg 1 is a reflection of PLGA and excipient miscibility. 
 Tg 2 is a reflection of the percent amorphous PVP-4HPR in system, likely the Tg from 
PVP (163 °C) or Tm of 4HPR (174 °C), due to dilution by amorphous PVP-4HPR.  
Figure S1 shows Tg’s of representative PLGA-PVP-4HPR millicylinder formulation with 
and without TEAC, compared to the PVP-4HPR particles all having complex ratios of 9/1.  The 
Tg’s of #8A and 8C (PVP-4HPR coated with 503H or 503+3%MgCO3) are similar, 126 and 121 
°C respectively, but an additional Tg is present with #8A at 34 ˚C, representing PLGA 503H.  
These PVP-4HPR 9/1 cores have a much lower Tg than the corresponding particles (155 °C), 
possibly due to residual solvent or water present. The PVP-4HPR-TEAC core coated with PLGA 
503H (#7a), has Tg’s at 30 °C and 97 °C, while the corresponding particles has a Tg of 87 °C, 
and the 10 °C difference could be due to precipitation of the PVP in presence of the PLGA 
coating and TEAC.  And finally formulation #7 contained the PVP-4HPR-TEAC 9/1/1 particles 
loaded into PLGA 503H, and has Tg’s at 37 °C and 140 °C.  The later Tg is much greater than 
the corresponding particles (87 °C) and the core implant coated with PLGA 503H (97 °C).   
These elevated Tgs in formulations #9 and the 9/1 PVP-4HPR particles (compared to the 8/2 and 
7/3 ratios) may play a role in the favorable release and solubility enhancement. 





Figure S3- 1.  Overlay of Tg’s by DSC of PLGA-PVP millicylinder formulations (#7A, #8A,C, #9) and compared 
them to the Tg’s of the PVP-4HPR 9/1 or PVP-4HPR-TEAC 9/1/1 particles. 
3.7.2. TGA Analysis 
The TGA analysis shows <5% residual solvent present after drying implant after ready mass loss 
at 100 °C. 
 
 






Figure S3- 2. TGA spectra of (a) #7d PVP-4HPR 9/1 core (uncoated) vs (b) #7a  coated with PLGA 503H.
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Chapter 4: 4HPR’s Binding Kinetics to Tissue and Cell Membrane Components 
 
4.1. Abstract 
Fenretinide (4HPR) tissue binding kinetics were characterized using varied ex vivo tissues 
(intact, thinly sliced, homogenates), in vivo sites [buccal epithelia and subcutaneous (s.c.) tissue] 
with concurrent assessment of varied solubilizer and permeation enhancer levels. Effects of 
tissue-composition i.e. lipid on 4HPR interactions were also assessed.  4HPR tissue uptake was 
evaluated as a function of free-drug level and drug-tissue aqueous partitioning coefficients (Kpu) 
were calculated.  These results show that time of exposure, but not solubilizer or permeation 
enhancers, affected tissue uptake. Furthermore, 4HPR exhibited a fifteen-fold greater binding 
affinity to buccal epithelia relative to s.c. connective tissues. Obtaining 4HPR solubility in 
aqueous solutions was the limiting factor for tissue uptake. While the majority of non-specific 
tissue binding likely reflects lipid interactions, it is well known that 4HPR also demonstrates 
high affinity protein binding. To conclude, this study found that 4HPR-tissue binding revealed an 
apparent lack of saturation, as tissue uptake rates remained comparable even at highest 4HPR 
levels. 4HPR’s tissue binding propensity introduces the prospect of 4HPR-mediated tumor-
stromal chemoprevention.   
4.2. Introduction 
The lipophilic vitamin A derivative, 4-hydroxy(phenyl)retinamide [fenretinide (4HPR)] 
was developed in the 1970’s to elicit  retinoid chemopreventive effects in cells devoid of the 
retinoic acid receptor (1).  In vitro, 4HPR demonstrated extensive cancer-preventive potential via 
its induction of terminal differentiation and/or apoptosis in a variety of premalignant and 




malignant cells (2). As a result of 4HPR’s poor bioavailability, however, in vitro efficacy did not 
translate to clinical efficacy (3). Another complication is 4HPR’s extensive first pass metabolic 
inactivation during systemic delivery. In contrast, local delivery can delivery therapeutic 4HPR 
doses to target tissue without adverse effects e.g. nyctalopia (4).  4HPR binds with high affinity 
to several proteins including kinases associated with gratuitous signaling e.g. focal adhesion 
kinase (5) and STAT3 (6). Such 4HPR-protein interaction extend 4HPR’s tumor suppressive 
effects beyond lesional to stromal and inflammatory cells (7). Pharmacokinetic (PK) data from 
previous 4-HPR clinical trials  (100-200 qd oral) demonstrated 4HPR’s tissue retention (20%), 
rapid equilibrium in plasma (<24 h) (8), greater preference for tissue than plasma, max plasma 
levels achieved after 4 h (Tmax) (3), half live (t1/2) is 12-24 h (3,4,9), and bioaccumulates in 
blood (detected 6 mo, post-treatment )(4). 
While 4-HPR’s dispersion through lesional tissue is essential for chemoprevention, 
4HPR’s tissue binding affinity during local delivery has not been evaluated. Notably, limited 
penetration distance is the   most prevalent challenge encountered during local drug delivery 
(10).  A variety of factors govern tissue-drug distribution including diffusion rates, convection, 
elimination, protein binding, cellular uptake, capillary permeation, degradation and entrance into 
cell and subcellular components and intracellular metabolism and efflux (11). Following 
subcutaneous delivery (s.c.), diffusion and convection enable a drug’s entrance to the 
extracellular space, while elimination can occur via local metabolism or clearance. Locally 
delivered drugs can enter systemic circulation via capillary flow or lymphatic uptake.  Due to 
their enhanced permeability, lipophilic drugs like 4HPR are cleared from the local site within the 
first 30 min.  Due to the ease of drug-capillary diffusion, the rate-limiting step in systemic 
distribution is blood flow.  Also, the microvasculature patterns vary, and are most abundant 0.1 




mm below skin. Barriers to interstitial space diffusion include presence of lipids, proteins, or 
blood vessels, in contrast to molecular diffusion in a boundary free medium which depends only 
on molecular size, the temperature, and medium viscosity, and results from random or Brownian 
motion of particles (12). Additionally, drug binding to tissue components such as lipids or 
proteins, can prevent drug clearance and keep more drug at the target site.  While it is widely 
held that only unbound drug is active, stromal protein bound 4HPR can serve as a tissue 
reservoir and also elicit chemopreventive effects.  Provided these extensive parameters, there is 
likely an optimal chemoprevention “sweet spot” between binding and clearance.  A final local 
delivery consideration is that that retinoids, including 4HPR, exhibit high binding affinities to 
lipid rich cell membranes and plasma proteins(13) that can limit its ability to permeate 
throughout the treatment site.  
These studies characterized 4HPR tissue binding kinetics using a variety of ex vivo 
tissues, delivery sites [buccal vs. s.c.], tissue preparations (intact, homogenate, or thinly sliced), 
with inclusion of solubilizers and permeation enhancers in medias. Buccal mucosa is known to 
have greater permeation than s.c. (4-4,000 fold), contingent upon the molecule, lipid profiles and 
local blood flow (14). Thinly sectioned tissues and tissue homogenates could augment greater 
binding due to increased binding site exposure. Comparative competitive binding experiments 
with another retinoid molecule, acitretin, whose tissue and plasma protein interactions have been 
well characterized (15) were performed.  4HPR solutions were incubated with isolated cell 
membrane fractions to assess 4HPR’s lipid binding affinity.  Aqueous drug- tissue partition 
coefficients (Kp) were calculated for each tissue type and solubilizing media.  Our results show 
4HPR exhibits very high non-specific tissue binding. Further, comparable rates of drug-tissue 




uptake occurred even at the highest 4HPR levels, which imply that 4HPR solubility as opposed 
to tissue saturation limits 4HPR-tissue uptake.  
4.3. Materials 
4HPR was generously supplied by Merck Co. Acitretin was purchased from Sigma-
Aldrich.  Polyvinylpyrrolidone polymer (PVP K30, 40 kDa) was purchased from BASF. All 
other materials were reagent grade or better including ethanol (EtOH), dimethylsulfoxide 
(DMSO) and Tween 80. Solvents for UPLC/UV analysis were HPLC grade including 
acetonitrile (ACN), double distilled water (ddH20), and phosphoric acid (H3PO4). Tissues were 
sectioned using optimum cutting temperature compound (OCT, Tissue Tek), and adhered to 
poly-lysine coated glass slides. Phosphate buffer saline (PBS) for tissue incubation media and 
radioimmunoprecipitation assay buffer (RIPA) to lyse cells and tissues, were prepared in house 
according to standard recipes. Naïve rat SC tissue, and porcine buccal tissues were used.  
4.4. Methods 
An overview of the 4HPR binding studies and purposes are listed in Table 4-1, followed 










Table 4-1. Overview of 4HPR Binding Studies 
Purpose Parameter(s) Rationale 
Binding to 
tissues 
Binding (μg 4HPR/ g tissue) vs. 
free drug concentration: 
Examine effects of each listed parameter on drug-tissue 
uptake: 
Effects of Tween and other 
solubilizers 
 Evaluate extent of solubilization on uptake 
 Addition of tween and/or other solubilizers to media is 
necessary for 4HPR solubility during in vitro studies  
 Effects of penetration enhancers  
 Permeation enhancers should allow drug to access more 
binding sites  
 Buccal epithelia vs. s.c. tissue 
 Buccal epithelia  4-4000x’s greater permeability due to 
buccal fat pad which alters lipid profile 
 Does tissue site affect 4HPR binding affinities?  
 Intact tissue, tissue homogenates, 
and thinly sectioned tissue 
 Thinly sectioned and homogenized tissues will have 
greater exposure of binding sites, and potentially greater 
uptake 
 Comparing each of these will address drug-tissue 
penetration depth and tissue saturation 
 Competitive binding with another 
synthetic retinoid (acitretin) and 
4HPR 
 Competition with another retinoid may decrease 4HPR 
binding, due to occupying binding sites 
 Time & concentration 
dependence 
 
 Equilibrium binding time determined 
 Determine if tissue saturation is achieved, and if uptake 
linear  
 Aqueous phase-Tissue 
partitioning (Kpu) 
 Compare effects of tissue types, incubation media, and 




Binding (μg 4HPR/ g cell 
membrane components) vs. free 
drug concentration 
 Effects of 4HPR’s established high affinity lipid binding 
on bioaccumulation 
 
4.4.1. Tissue Binding  
4.4.1.1. 4HPR Uptake in Buccal Epithelial (Intact and Homogenates) as a Function of 
Solubilization by Tween  
 Porcine buccal tissue was freed from connective tissue (70-100 mg wet mass) and 
incubated at 37 °C in 0.5 mL of 40 μg/mL(~100 μM) 4HPR prepared in PBS pH 7.4 + 0.02, 0.5, 
1, or 2% Tween 80 (n=5 each).  Epithelial tissues were homogenized (75-100 mg in 0.5 mL of 
0.5% PBST, n=5) at 10,000 rpm x 2 min.  Media were sampled (20 μL) at 0, 6, and 24 h and the 




percent 4HPR uptake was determined by disappearance of 4HPR compared to starting 
concentration using the UPLC assay listed below. The amount of 4HPR (μg) uptake per g of wet 
tissue mass was reported after 6 h and 24 h, along with percent bound. 
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−
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4.4.1.2. 4HPR uptake in Intact s.c. Tissue with Solubilizers, Permeation Enhancers, and 
Competitive Ligands 
 Intact rat s.c. tissue was cut (1x1 cm2), weighed, and incubated with 10 mL of 4HPR 
solutions containing solubilizers and permeations enhancers. In the first experiment, tissues were 
incubated in PBS + 2% Tween + 0.1% DMSO (0, 2.5, 5, 12.5, 25, 50 μg/mL 4HPR) for 24 h at 
37 °C on a shaking platform. In one sample, tissue was co-incubated with competitive ligand 
acitretin (5 μg/mL) and 5 μg/mL 4HPR solution. The percent uptake was determined by 
sampling incubation media before and after incubation, assaying 4HPR by UPLC.  Drug-tissue 
extractions on thinly sliced incubated tissues were performed to obtain concentration penetration 
depth profiles.  After 24 h, the intact tissues were removed from media, rinsed 2x’s in 0.02% 
PBST, snap frozen, and cryosectioned (Leica 3050S cryostat) into 60 μm sections (n=6).  Blank 
tissue was also collected for analyte extraction recovery controls (see tissue extraction methods). 
4HPR was extracted from tissues using the extraction method listed below, and 4HPR tissue 
uptake was expressed as μg 4HPR/mg tissue and plotted against free drug concentration.  For the 
competitive binding between acitretin and 4HPR, the relative percent uptake of each was 
compared.  
The second experiment evaluated the effect of the solubilizing complex of PVP-4HPR on 
tissue uptake.  PVP-4HPR amorphous complex (9/1 w/w) was prepared by solvent casting in 




MeOH, followed by cryomilling (Retsch swing mill cryomill, PN 20.749.001) and sieving 
particles < 90 μm.  Rat SC intact tissue sections (1x1 cm2) were incubated with 10 mL of PVP-
4HPR solutions (5-150 μg/mL [12-380 μM] 4HPR) for 24 h and solutions assayed for 4HPR 
level before and after incubations. A mass balance to account for drug precipitation was 
performed by quantifying 4HPR tissue levels after extraction.  
4.4.1.3. 4HPR uptake in s.c. Thin Tissue Sections:  Time and Concentration Dependence 
 Rat SC tissues were snap frozen, a 1x1 cm2 tissue block was cryosectioned into 20 μm 
sections and thaw mounted on poly-lysine coated glass slides. A representative tissue mass was 
recorded by averaging 3 tissue section masses collected intermittently throughout the relatively 
homogeneous tissue block. The tissues sections were pretreated by incubating in PBS + 0.5% 
Tween for 30 min.  To determine equilibrium binding time, tissues were incubated in 4 or 40 
μg/mL (10 or 100 μM) 4HPR in PBST 0.5% for 1, 2, 4, 6, 12, and 24 h (n=2 each time point). At 
each time point, tissues were washed in PBS x 2 then ddH20, 4HPR was extracted from tissue, 
and uptake reported as a function of incubation time.  The equilibrium binding time was chosen 
based on the greatest tissue uptake. For the concentration dependent binding, tissues sections 
were pretreated in PBST 0.5% and incubated at the equilibrium time in 4HPR PBST 0.5% 
solutions ranging from 1 to 250 μM (0.2 to 170 μg/mL). Tissue uptake was plotted as a function 
of free drug concentration.  
4.4.2. Subcellular Component Binding 
The binding of 4HPR to lipid cell membranes method was adopted from NIMH-PDSP 
assay protocol book.16  Cell membrane fractions were isolated from fresh porcine buccal 
epithelium (~ 70 mg, n=5), 1 mL of ice cold RIPA lysis buffer added, and tissues were 
homogenized at 10,000 rcf for 2 min.  The tissue homogenates were centrifuged at 1000 rcf x 10 




min, and the supernatant containing the whole cell lysate was transferred to a new tube. The cell 
membrane fraction was isolated from the whole cell lysate by centrifuging the supernatant at 
21,000 rcf x 20 min, yielding a pellet. The cell membrane pellet was washed 2x’s with 1 mL of 
ice cold RIPA buffer, and centrifuged at 21,0000 rcf x 20 min, supernatant was discarded, 
yielding a purified pellet of cell membrane components. The mass of the purified cell membrane 
pellet was recorded, then incubated with varying volumes (500, 1000, or 250 μL) of 100 μM 
4HPR in PBST 1% for 24 h at 37 °C on a shaking platform. The fraction of unbound (fu) 4HPR 
after incubation with cell membrane fractions was determined by assaying the amount of 4HPR 
in incubation media by UPLC prior to and after 24 h. 4HPR uptake was reported as μg 4HPR per 
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4.4.3. 4HPR Aqueous Phase- Tissue Partitioning (Kpu)  
From the in vitro tissue binding experiments, 4HPR aqueous phase-tissue partition 
coefficients (Kpu) were calculated, which refer to the ratio between drug concentration in tissue 








Because 4HPR is a weak acid with pKa=9.76, ionization contributions at pH 7.4 are negligible.  
For physiological relevant calculations, the unbound fraction of drug in plasma (fup) is needed to 
extrapolate drug levels in media to plasma (17).   
= ∙   
4.4.4. Tissue and Plasma Extraction Assays 
4HPR was extracted from tissue and tissue homogenates. The wet masses of tissues were 
recorded, internal standard (5 μL of 0.5 mg/mL acitretin) was spiked into tissue samples, 200 μL 
of ice cold ACN added, sonicated on ice for 10 min, then clarified by centrifuging at 12,000 rcf 
for 5 min, and the amount of 4HPR in supernatant was determined by UPLC assay.   
4.4.5. Statistical Analysis 
Due to the relatively small sample sizes which prohibited determination of normality, 
nonparametric analyses were used. The Kruskal Wallis analysis of variance, followed by the 
Dunns multiple comparison test was used to assess the effects of time, and tissue status on 4HPR 
uptake (Fig. 5-1) and competitive binding with acitretin (Fig. 5-2). The Pearson correlation was 
used to evaluate the effects of 4HPR levels on tissue uptake (Fig. 5-5) and impact of solubilizing 









4.5.  Results 
4.5.1. Tissue Binding 
Binding time, but not levels of solubilizing agent or tissue state, affects 4-HPR uptake.  
4.5.1.1. 4HPR Uptake in Buccal Tissue (Bulk and Homogenates) as a Function of 
Solubilization by Tween  
The results of the 4HPR uptake in intact porcine buccal epithelia are shown in Figure 4-1. 
These data show a time dependent drug uptake i.e. increased 4-HPR binding at 24h relative to 6 
h (~180 vs. 80 μg 4HPR/g tissue respectively), with significant differences at these time points 
(p<0.05). In contrast, 4HPR uptake was independent of Tween levels as comparable micellar 
solubilization was obtained with 0.5, 1 or 2% Tween. Also, the tissue homogenate (0.5% Tween) 
and the intact tissue uptakes were comparable.  After 24 h, ~75% 4HPR was bound to both tissue 
and homogenates (See Fig. 4-1b.) Although 100 μM 4HPR was insoluble in PBS + 0.02% 
Tween80, tissue components (lipids, proteins) actually increased 4HPR solubility in PBS 0.02% 
Tween80 incubation media from 0.33 μg/mL initially, to 1.83 ±1.38 μg/mL after 24 h. The 
results from Figure 1 show: 
a) Time significantly affects drug uptake, even when PBST concentrations are the same. 
b) These time differences are seen within the same PBST groups. 
c) No real appreciable differences among PBST levels and homogenates.  
d) Perhaps most importantly of all, the tissue doesn't appear to get "saturated" with 
4HPR, uptake keeps increasing with time. 





Figure 4-1. 4HPR uptake in porcine buccal intact tissue and tissue homogenates after incubation with 100 μM 
4HPR in PBS + Tween80 (0.5, 1, 2%) after 6 and 24 h as represented by a) μg 4HPR/g tissue and b) Percent 4HPR 
bound to tissue (n=5, mean ± SE, *indicates p<0.05).  Only time, but not Tween level in PBST or homogenization 
affected 4HPR uptake.   
 
4.5.2. 4HPR uptake in Intact s.c. Tissue with Solubilizers, Permeation Enhancers, and 
Competitive Ligands 
Effect of PBST 2% + 0.1% DMSO on Uptake, and Competition with Acitretin  
Results of the 4HPR SC tissue binding in PBST 2% + 0.1% DMSO incubation media 
(Fig. 4-2) show a linear increase in uptake as the free drug concentration increases (r2=0.9875), 
while tissue saturation was not reached at 38 μg/mL 4HPR. Each data point is average of 6x60 
μm sections, equating to a penetration depth profile of 360 μm, with no significant difference at 
each concentration, indicating homogeneous permeation.  Each retinoid-distinguish e.g. 4HPR 
and acitretin exhibited 44% and 46% binding respectively. When 4HPR was coincubated with 
the same concentration of acitretin, binding of both retinoids decreased to 38% and 21%, 
respectively (but total retenoid uptake equated to 59%) (indicating that acitretin significantly 
(p<0.05) inhibits 4HPR binding when both drugs added concurrently.  These data imply a 1.8 

















































Effect of PVP-4HPR Solubilization on s.c. tissue uptake 
  Intact SC tissue 4-HPR uptake in super-saturated PVP-4HPR 9/1 solutions (Fig. 4-3a) 
showed similar drug uptake to tissues incubated with PBST 2% + 0.1% DMSO (Fig. 4-2). Both 
solutions provided comparable tissue uptake (10 μg 4HPR/g of tissue) when incubated in 10 
μg/mL 4HPR solutions, equating to a ~1:1 4HPR/tissue mass ratio (a full Kp comparison 
proceeds this section).  There is a linear increase in tissue uptake as free drug concentration 
increases, with a lag phase existing up to 7 μg/mL free 4HPR, yet tissue is still not saturated after 
10 μg/g tissue. Appreciable 4-HPR precipitation from the supersaturated PVP-4HPR solution 
was observed after the incubation, where the initial 4HPR concentrations of 5-150 μg/mL had 
only yielded free drug levels 0.2-10 μg/mL after. This is shown in the mass balance in Figure 4-
3b, where the amount 4HPR recovered in tissue + media is much lower than the amount dosed, 
suggesting that PVP-4HPR is not a stable complex in the presence of tissue components (likely 
salt).  



























Figure 4-2. 4HPR binding to rat SC tissue after 24 h incubation in a solubilizing media of PBS+ 2% Tween80+ 0.1% 
DMSO. Each data point is average of 6x60 μm sections, equating to a penetration depth profile of 360 μm. 





Figure 4-3. A) 4HPR binding to rat s.c. tissue after 24 h incubation in PVP-4HPR 9/1 solutions. B) Mass balance of 
4HPR from the PVP-4HPR tissue incubations shows that the amount 4HPR recovered in tissue + media is much 
lower than the amount dosed, indicating the extent of 4HPR precipitation from the supersaturated solutions.  
 
4HPR uptake in s.c. Thin Tissue Sections:  Time and Concentration Dependence  
 The results of tissue uptake to determine equilibrium binding time after incubating thin 
s.c. tissue sections (20 μm) in PBST 0.5% drug solutions is shown in Fig. 4-4a. The equilibrium 
binding time was determined to be 4 h, due to greatest tissue uptake in the 100 μM 4HPR 
solution, while at low 4HPR level of 10 μM, equilibrium binding time was 2-6 h. At the later 
times points, the tissue was more apt to detach from the glass slide in the incubation media, 
which occurred in the 10 μM 4HPR level at 24 h. The results from the concentration dependent 
uptake of 4HPR is shown in Fig. 4-4b show linear (r2=0.9761), unsaturated, uptake at 170 
ug/mL 4HPR which had bound 144 μg 4HPR/g tissue.  This lack of tissue uptake saturation at 
this high drug levels is a rather unique finding.    





Figure 4-4. 4HPR binding kinetics with thinly sliced (20 μm) rat s.c. tissue in PBST 0.5%.  A) Determination of 
equilibrium binding time by at two concentrations of 4HPR.  B) Concentration dependent uptake of 4HPR after 4h 
incubation time. 
 
4.5.3. Cell Membrane Lipid Components Binding 
 The subcellular membrane component faction isolated from porcine buccal epithelial 
yielded 1-7% of the initial mass (< 5mg from 70 mg respectively). The results of 4HPR binding 
to subcellular cell membrane components are shown in Fig. 4-5.  When the amount of 4HPR 
dosed is normalized to the mass of the cell membrane component (Fig 4-5a), we see a linear 
uptake, with no saturation of binding occurring at the free drug level of 34-38 μg/mL (~100 μM, 
Fig 4-5b). Statistics revealed a strong positive correlation between 4HPR levels and uptake.  
When top data point was removed (highest 4HPR level), the linearity decreased, implying that 
the highest 4HPR level was still linear, and the tissue not yet saturated. Table 4-3 summarizes 
these data, and shows 5-12% 4HPR in solution had bound to the isolated cell membrane fraction. 
To determine if buccal tissue binding was due to lipid interactions, we compared uptake in intact 
buccal to that of the cell membrane fraction. As shown in Table 4-4, the uptake in buccal cell 
membrane fraction was 500-2200 μg 4HPR/g cell membrane fraction, and could be back 
extrapolated to uptake per total tissue (based on 1-7 % w/w cell membrane fraction in tissue) to 




5-155 μg 4HPR/g tissue.  Comparing this value to the intact buccal uptake in of 144 μg 4HPR/g 
tissue (in PBST 1%), we can see that the cell membrane components (lipids) are largely 
responsible for the binding of 4HPR. 
Table 4-2. 4HPR binding to cell membrane components in porcine buccal tissue homogenates 










pellet % Bound 
20 75.3 1.57 13 1.42 11% 
20 71.6 4.61 4 0.53 12% 
20 71.3 0.87 23 1.53 7% 
40 72.5 0.79 50 2.35 5% 
10 73.0 1.06 9 0.70 7% 
 
Figure 4-5. 4HPR binding to porcine buccal epithelia cell membrane components after 24 h: a) Normalized to mass 
of cell membrane, and b) as a function of free 4HPR in media after equilibrium.  Varying volumes (250, 500, 1000 
uL) of 10 μM 4HPR in PBS + 1% Tween 80 were spiked into the cell membrane pellet. 
   
Table 4-3. 4HPR Uptake in Buccal tissues vs. Cell Membrane fraction 
Tissue type Uptake (μg 4HPR/g tissue) 
Intact buccal 141 ± 4 
Buccal cell membrane fraction 500-2200 
Extrapolated buccal 
 (based on 1-7% w/w cell membrane in tissue) 5-155 
              *100 uM 4HPR in PBST 1%, 24h 
 
 
4.5.4. Effects of Tissue Type on 4HPR Aqueous-Tissue Partitioning (Kp) 
Comparison of 4HPR uptake in different tissues and media is shown in Fig. 4-6 and Kp  
values in Table 4-6. Interestingly, all s.c. tissues had similar uptake despite type of preparation 




(intact, thinly sectioned), or presence of solubilizing and permeation enhancing medias (Tween, 
PVP-4HPR, DMSO). Statistics reveal a positive correlation between 4HPR levels and uptake, 
with the exception of the intact s.c. tissue incubations with PVP, where a less linear relationship 
correlation of r2=0.7393 was found.  This lack of linearity may be due to the precipitation of 
4HPR in the super-saturation solution, as indicated in Fig. 4-3.  At lower free drug levels (<10 
μM 4HPR) the s.c tissues exhibited Kp’s of ~0.35-0.55, while 4HPR levels of 10-350 μM, Kp’s 
were near 1. The most significant difference was tissue type, where uptake buccal epithelia had 
nearly 15-fold greater uptake than s.c. connective at free drug levels of 30 μM 4HPR.  
 
Figure 4-6. 4HPR tissue uptake comparison of buccal vs. s.c. in various media, intact and thinly sectioned tissues; a) 


















Intact PBST 0.5% 22 16.8 ± 2.5 
PBST 1% 29 12.4 ± 0.4 
PBST 2% 33 14.2 ± 1.0 
Homogenate PBST 0.5% 25 15.2 ± 1.8 
s.c. Intact PBST 2% + 1% DMSO 2-5  0.35 ± 0.21 
10-100 0.97 ± 0.16 
PVP-4HPR  10-25 0.56  ± 0.30 
Thin sections  PBST 0.5% 
 
0.4-5 0.52 ± 0.07 
10-350 0.96 ± 0.14 
 Kp was calculated based on free drug concentration after tissue uptake at equilibrium. 
 
4.6. Discussion 
4HPR plasma levels, as opposed to assessment of drug target tissue and plasma 
interactions, were the pharmacokinetic aspects evaluated in previous 4HPR human clinical trials 
(19). While local drug delivery has numerous pharmacologic benefits, locally-delivered drugs 
are hampered by limited tissue penetration distance (10,11,20).  In an effort to enhance drug 
solubility and diffusion and diminish 4HPR’s tissue penetration-limiting lipid and plasma-protein 
binding, this study introduced solubilizers and permeation enhancers.  Optimally, these studies 
would identify a binding ‘sweet spot’ which would prevent rapid drug clearance yet allow the 
active unbound drug to exert its pharmacological effects.  Several studies have demonstrated 
4HPR’s chemopreventive efficacy levels range between 2-5 uM, while cell toxicity observed at 
10 μM 4HPR (21). These binding experiments were therefore conducted within this 
chemopreventive therapeutic range.  
Tween has Limited Effect on 4HPR Uptake in Buccal Epithelia 
Our data revealed that 4HPR buccal epithelial uptake was comparable regardless of 
incubation media Tween levels (0.5, 1, or 2%).  Although homogenization can expose additional 
binding sites as a result of protein disruption and binding site unmasking, this technique can also 
create artifacts (22). Nonetheless, similar binding was observed in our buccal epithelia regardless 




of tissue state (intact or homogenates). Collectively, these data show buccal epithelia possesses a 
high 4HPR binding capacity with saturation not yet reached and/or incomplete tissue penetration.  
The observed high level 4HPR-epithelia binding likely reflects, at least partially, keratinocytes’ 
active role in lipid synthesis (23).  Furthermore, previous studies have shown retinoid challenge 
increased oral keratinocyte lipid production (24).  
Solubilizing and Permeation Enhancers do not Significantly Affect 4HPR Uptake in s.c. Tissue  
 Previously we have shown that 4HPR solubility can be enhanced by addition of 2% 
Tween, while DMSO augments both solubility and tissue penetration. Formation of a 9/1 (w/w) 
PVP-4HPR amorphous solid dispersion resulted in a 50-fold 4HPR solubility increase (data not 
shown).  Notably, 4HPR solubility in PBST + 0.5% is comparable to serum, while PBST + 2% 
resulted in 4HPR solubilization up to 500 μg/ml (25).  The high level of Tween (2%) was shown 
in the buccal binding experiment to have little effect on extent of binding, and was necessary to 
enhance 4HPR levels in tissue incubation media during attempted tissue binding saturation 
studies. No significant 4HPR tissue uptake differences were detected in intact s.c. tissue 
incubation during comparison of a combination of a DMSO penetration enhancer + 2% Tween 
solubilizing solution relative to the PVP-4HPR amorphous dispersion, nor the s.c. sections 
incubated in PBST 0.5%. Results show that drug-tissue saturation was not achieved in these 
solutions at free drug levels near 170 μg/ml 4HPR, and thus the limiting factor in tissue 
disposition is the ability to solubilize the drug.  Tissue sectioning results revealed a uniform 
penetration depth profile of 360 μm; findings consistent with inter-sample homogeneity.    
While a Competitive Ligand Decreases 4HPR Tissue Binding at Low Concentrations, 4HPR 
Demonstrates a Higher Binding Affinity  




 Tissue co-incubation studies with the same level of 4HPR and another synthetic retinoid, 
acitretin, showed 14% reduction in 4HPR binding while also demonstrating a 1.8 fold greater 
4HPR binding affinity. 4HPR’s higher binding affinity may reflect 4HPR’s greater lipophilicity 
(log P=6.31) relative to acitretin’s (logP=5.59), whose negative ionic charge reduces its 
lipophilicity.  Chemical structural differences may also be involved i.e. while acitretin retains the 
polyene chain, it lacks an amide linkage, a redox active phenol group, and replaces the 
trimethylcyclohexenyl group.  Previous work has shown that 4HPR induces protein 
conformational changes (6) upon binding, which may positively influence additional 4HPR 
binding. Results from the thinly sectioned s.c. tissues studies, which failed to show saturation 
even at high 4HPR levels, support this premise.   
4HPR has greater Partitioning in Buccal Epithelia relative to s.c. Tissue  
When comparing tissue type, we observe that 4HPR uptake is 15-fold greater in buccal 
epithelia compared to s.c. tissue, largely due to the extent of keratinization by ceramides acting 
as a penetration barrier, which are increased in buccal epithelium. Additional factors affecting 
tissue partitioning (Kp) in vivo include: 1) non-specific lipid plasma and tissue binding, 2) 
binding to proteins or lipoproteins in plasma and tissue interstitial space, 3) contributions of 
solubility and pH gradient between intra- and extracellular aqueous phases, 4) rapid equilibrium 
between plasma and tissue (i.e. permeability), 5) uniformity in distribution, 6) no transporter 
effect, and 7) tissue saturation (17).  Further, as only the aqueous phase free drug can bind to 
tissues and permeate cell membranes, determination of percent plasma binding is essential.  
Several attempts were made to measure plasma protein binding using spin filtration and dialysis 
methods, however, unsatisfactory results were due to 4HPR’s high affinity for the cellulosic 
membranes in these devices.  The pH gradient of blood (pH=7.4) and tissue (pH=7.0) can also 




affect drug partitioning (26). Because 4HPR is a weak acid (pKa=9.75), the ratio of fraction 
unionized in blood/tissue is 0.997, which renders the ionization contribution negligible. Our data 
show that the Kp in s.c. tissue is ~0.5 when free 4HPR > 10 μM and ~0.3 when free 4HPR < 10 
μM while buccal epithelia exhibit Kp’s near 15 for free drug levels > 10 μM. The implications of 
this stoichiometry are quite significant, as treated tissues would bind high levels of 4HPR with 
drug solubility as the limiting factor.  As efficacious 4HPR chemopreventive levels are ~2-5 μM 
4HPR, the extent of solubilization may not be a crucial local drug delivery design element.   
4HPR Exhibits High Binding Affinity for Cell-Membrane Lipids 
 To delineate the contributing factor(s) to the high levels of tissue binding, cell membrane 
component binding was measured.  It is known that retinoids, including 4HPR exhibit extensive 
plasma protein binding (27). The majority of these interactions are likely non-specific and reflect 
4HPR adherance to proteins or phospholipids protruding from cell membranes. Our results show 
4HPR binding to cell membrane components is comparable to the extrapolated binding to intact 
buccal epithelia. These data support the premise that 4HPR binds via phospholipid cell 
membrane interactions, which is probable given 4HPR’s high lipophilicity. Due to the high 
retention at local tissue site due to non-specific tissue binding (protein and lipids), the markedly 
reduced amount of drug necessary to deliver, and our previous studies(6) we anticipate negligible 
blood-plasma 4HPR levels.  
4.7. Conclusion 
 
In these experiments, we evaluated 4HPR binding kinetics in vitro in tissues, cell 
membrane components. For tissue uptake studies, both buccal and s.c. tissues were studied, 
along with effect of solubilizing and penetration enhancing media. The type of 4HPR 




solubilizing media and type of tissue preparation (intact, sectioned, homogenized) had little 
effect on tissue uptake, but rather the ability to solubilize 4HPR levels was the limiting factor in 
tissue disposition. Buccal tissue was shown to have ~15-fold greater 4HPR uptake than SC 
connective tissue, possibly due to differences in lipid profiles. We also show that the extent of 
4HPR non-specific tissue binding is predominately due to interactions with phospholipids in cell 
membranes. More importantly, these studies will aide in design and evaluation of local 4HPR 
delivery systems, which will aim to enhance drug-tissue penetration distance.    
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CHAPTER 5: Controlled release local fenretinide delivery systems enhance buccal 
drug distribution 
5.1. Abstract  
The work presented herein is the first time, to our knowledge that the 4HPR’s tissue 
distribution has been analyzed. We have chosen to deliver 4HPR locally from long-acting release 
polymeric implants, and the release kinetics along with the drug-tissue distribution were 
evaluated. Three different millicylindrical implant formulations were evaluated including a 
water-soluble matrix implant that provided continuous release based on the dissolution of the 
hydrophobic drug entity, PLGA implants capable of providing very long-acting continuous 
release (1-2 months) and PLGA implants loaded with a solubilized, amorphous drug 
(polyvinylpyrrolidone [PVP] -4HPR).  These implants were injected into rabbit buccal epithelia, 
and release and drug diffusion monitored after 1 and 14 days.  Quantitative Raman spectroscopic 
imaging was utilized to measure drug-tissue concentration gradients in excised tissue sections.  
Our results showed that the implants released much faster in the mouth compared to our previous 
studies in s.c. tissue, and that the drug distribution in the buccal tissues was on the order of 0.5- 8 
mm for all formulations.  The solubilized drug diffused the furthest through the tissue, and this 
movement was the greatest through the same tissue plane, versus traveling through tissue planes 
toward mucosa or deep epithelium.  This data will be useful for development of long-acting 
chemopreventive therapies for oral cancer. 






Fenretinide (4HPR) has demonstrated significant chemopreventive promise, however the 
inability to effectively deliver it has been its mainstay dilemma.  Limited efficacy in clinical 
trials with oral dosing was observed in part due to dose limiting toxicity. Unfortunately, 
researchers in the study did not identify the drug’s disposition at the site of action.  To overcome 
this limited efficacy with oral dosing route, local drug delivery route can be employed, which is 
capable of delivering a large amount of drug at target site while alleviating the undesirable side 
effects associated with oral dosing. However, the inability to achieve widespread drug-tissue 
distribution is the most prevalent challenge to overcome during local drug delivery [1, 2].  Not 
surprisingly, there are many factors that govern drug distribution in tissues including: rates of 
diffusion, convection, elimination, protein binding, cellular uptake, capillary permeation, 
degradation and permeability into cell and subcellular components (which may lead to 
bioaccumulation), and finally intracellular metabolism and efflux [3].  To maximize tissue 




distribution, often penetration enhancers are added to the formulation such as solubilizing agents, 
bile salts, chelators, anionic or cationic polymers[4]. 
As part of our previous efforts in developing local long-acting chemoprevention 
strategies for oral cancer, we have designed millicylindrical implants loaded with fenretinide 
(4HPR), a drug shown to have chemopreventive properties [5-8].  Local delivery of hydrophobic 
4HPR presents a significant challenge owing to its extreme water insolubility, with a logP of 
6.31.  Previous studies in our lab evaluated 4HPR plasma levels after subcutaneous (s.c.) 
injections from a controlled release poly (lactic-co-glycolic acid) (PLGA) vehicle, and found that 
after 2 weeks it was unclear whether the actual drug was exhibiting controlled release properties 
due to dissolution into surrounding interstitial fluid, or slow release from tissue lipid “reservoirs” 
where 4HPR could have accumulated after fast dissolution [10]. We have also shown that 4HPR 
has a high propensity for non-specific tissue binding, and that the ability to solubilize the drug 
was the limiting factor in tissue uptake, likely due to affinity for phospholipids and secondarily 
from protein interactions. We have shown that 4HPR can be released slowly over 6 weeks from 
water soluble matrix (poly-vinyl alcohol [PVA)/sucrose) millicylindrical implants in vivo in s.c. 
tissue, while the PLGA implants containing pore forming agents provide very long release 
profiles of > 2 mo. We have also found that 1000-fold 4HPR solubility enhancement by 
preparing PVP-4HPR (9/1 w/w) amorphous dispersion implants, which was sustainable for more 
than 1 week in water.  These formulations were chosen to evaluate in vivo for their potential to 
improve 4HPR tissue penetration distance.  For clinical translation of oral cancer 
chemoprevention, rabbit buccal epithelia was chosen to evaluate these implants, due to similarity 
in tissue permeability, thickness and degree of keratinization or oral epithelia to humans.   




 Several approaches can be taken to quantitate drug-tissue distribution depending upon the 
molecule’s properties or duration of drug exposure.  A fluorescent molecule can be easily 
imaged, however, conjugating a fluorescent moiety onto a drug can alter its tissue diffusion 
properties.  One could also radio-label the drug and use PET imaging, however it is not suitable 
for long-term studies due to stability of the radio-isotope. For molecules not fitting these criteria, 
the gold standard for drug-distribution studies is tissue sectioning, which could mean hundreds of 
tissue sections per distributive analysis, followed by drug extraction from tissues, HPLC 
analysis, and data processing.  Because this approach is quite laborious, and handling of large 
volumes of samples has the potential to introduce errors, we sought a different approach to 
measure drug distribution.    
Herein, we propose novel analytical methodology for quantitative Raman imaging 
techniques to characterize 4HPR distribution in buccal tissue. Since Raman micro-spectroscopy 
can be used to analyze almost any organic compound and requires no artificial chemical labels, 
our methodology could feasibly be utilized to characterize the natural distribution patterns for a 
multitude of colorless small molecules in a variety of tissue types.  The data presented in this 
paper discusses the interplay of controlled release local drug delivery of 4HPR, and how 
correlates the level of drug solubilizes, rate of release, physiology of local tissue environment on 
the extent of drug diffusion or dispersion into the tissue surrounding the implant. This is the first 
time that 4HPR’s tissue penetration has been evaluated, and will be useful for development of 
successful oral cancer chemopreventive delivery systems, in particular long-acting 4HPR-PLGA 
millicylinder implants.  
 




5.3. Materials and Methods 
5.3.1. Materials 
4HPR was generously supplied by Merck Co. Excipients and polymers used for 
millicylinders formulations included: PLGA (50:50, 24-38kDa, acid end-capped, Evonik), 
polyvinyl alcohol, (PVA, 9-10 kDa, 80% hydrolyzed, Sigma Aldrich), D-sucrose (Sigma-
Aldrich), polyvinylpyrrolidone (PVP K30, 40 kDa, BASF), triethyl-acetyl-citrate (TEAC), and 
magnesium carbonate (MgCO3). Silicon tubing (0.8 mm i.d., BioRad Laboratories) was used for 
implant extrusion. All other materials were reagent grade or better including ethanol (EtOH), and 
Tween 80. Solvents for UPLC/UV analysis were HPLC grade including acetonitrile (ACN), 
double distilled water (ddH20), and phosphoric acid (H3PO4). Tissues were sectioned using 
optimum cutting temperature compound (OCT, Tissue Tek), and adhered to poly-lysine coated 
glass slides prior to incubation. Phosphate buffer saline (PBS) was used for tissue incubation 
media. Oil-red-O and Harris hematoxylin stains were utilized in tissue histological examinations.   
5.3.2. 4HPR Tissue Calibration Standards for Raman Imaging 
 Rabbit buccal epithelia was excised from female New Zealand Rabbits and frozen on dry 
ice.  The tissue was cryosectioned (Leica 3050S crysotat) 20 µm in z-plane direction so that each 
section contained all layers of epithelia (mucosa, lamina propia, and epithelium), and was thaw 
mounted on poly-lysine coated glass slides. A representative tissue mass was recorded by 
averaging 3 tissue section masses collected intermittently throughout the relatively homogeneous 
tissue block. The tissues sections were pre-treated by incubating in PBS + 0.5% Tween for 30 
min, then incubated in 4HPR/PBST 0.5% calibration solutions (n=4)  ranging from 1-500 μg/mL 
for 4 h, followed by tissue wash PBS and ddH20.  At each concentration level, 3 tissues were 
extracted and assayed for 4HPR uptake by UPLC, and 1 was reserved for Raman imaging 
analysis, such that Raman imaging calibration curve could be constructed from UPLC 4HPR-




tissue uptake results.  Additionally, 4HPR tissue partitioning coefficient (Kp) was calculated 
from the concentration of free drug in incubation media (Cfree) and the tissue uptake (Ctissue). 
=  
5.3.3. Raman measurements 
All Raman images were acquired by a WiTec alpha300R confocal Raman microscope 
equipped with the 532nm solid-state sapphire excitation laser (tuned to ~35mW intensity) and a 
10x air objective (Zeiss Epiplan-NEOFLUAR, NA (numerical aperature) = 0.25) coupled to a 
CCD detector via a multi-mode fiber of 100m diameter, serving as the confocal pinhole. 
Calibration standard spectra were acquired by raster scanning over three separate 2000 x 200 
micron regions of each drug-incubated buccal tissue; relatively high spatial resolution was 
attained with a step-size of 20 microns and pre-bleaching of biological autofluorescence was 
accomplished by programming laser focus to pause for 0.5 seconds at each point before 
acquiring spectra over integration time of 0.5 seconds. In order to achieve reasonable acquisition 
times over the test sample regions of interest, large area raster scans were performed with a step-
size of 50 microns, pausing for 0.4 seconds at each point before acquiring spectra over 
integration time of 0.2 seconds. Depending on the spatial dimensions of tissue region scanned, 
total acquisition times ranged from six to fourteen hours per test sample.  
5.3.4. Raman data processing 
Using WiTec Project FOUR Software, all Raman spectra were first cleared of cosmic 
rays (filter size: 4, dynamic factor: 2) and noise was reduced via a moving average smoothing 
matrix; baseline subtraction was performed by fitting a 9th order polynomial to spectral data 
points in the following wavenumber ranges: 205-515, 840-900, 1345-1405, 1495-1530, 1770-




2690, and 3120-3750. To generate Raman images, data was exported to MATLAB and an in-
house algorithm was developed to ultimately identify and integrate 4HPR’s characteristic Raman 
peak at 1582 cm-1 at every pixel of the scanned tissue section. The glass background was first 
subtracted and a decision tree was employed to distinguish and remove spectral contributions 
from the naturally occurring biomolecule heme (which yields a strong interfering Raman signal 
at ~1588 cm-1) from that of 4HPR. A signal-to-noise ratio of  ≥3 was installed as the detection 
limit for a peak. Spectra were normalized to account for variation in tissue thickness, the 4HPR 
Raman peak at 1582cm-1 was integrated, and the drug/tissue mass ratio was calculated from the 
calibration curve. To optimize and verify algorithm parameters, test samples were generated and 
analyzed as per acquisition methodology, processed through the algorithm, and used to 
determine the rates of false positive and false negative 4HPR detection in different biochemical 
tissue environments. For all final in vivo 4HPR dosed tissue Raman images, algorithm result 
outputs were manually compared with unprocessed spectral images and regions where sample 
burning occurred were cropped out so as not to artificially influence drug distribution analysis. 
5.3.5. 4HPR Millicylinder Formulations  
Three 4HPR millicylinder formulations were evaluated for drug-tissue penetration 
enhancement including: 
1. PVA/Sucrose +10% 4HPR  (crystalline drug in a water-soluble matrix) 
2. PLGA+ PVP/4HPR/TEAC (controlled release of an amorphous solid dispersion) 
3. PLGA+ 10% 4HPR +3% MgCO3 (porous, very-long acting release) 
 Millicylinder preparation processes have been described in detail in Chapter 2.  Briefly, 
PVA/ D-sucrose (40%, 30% w/v respectively in ddH20) millicylinders were loaded with 10% 
4HPR, extruded into silicone rubber tubing, dried in vacuum oven at room temperature for 2 




days, then at 40 ˚C for 2 days, and cut from tubing into 1 cm lengths with an inner diameter of 
0.8 mm. PLGA+ PVP-4HPR-TEAC implants were prepared as described previously in Chapter 
3 by first preparing the amorphous solid dispersion of PVP-4HPR-TEAC  (9/1/1 mass ratio) by 
dissolving in MeOH, pouring into a thin film, drying, then cryomilling particles (Retsch swing 
mill cryomill, PN 20.749.001) and sieving particles <90 μm.  These particles were then loaded 
into PLGA (dissolved in acetone) at a ratio of 50/50 (PLGA to PVP-4HPR-TEAC particles), 
mixed, then extruded, dried and cut to size as described above.  The third formulation, PLGA+ 
10% 4HPR+3% MgCO3 was prepared as previously described in Chapter 2. 4HPR loading levels 
were verified using the millicylinder extraction assays as described in following sections. 
5.3.6. Implantation of 4HPR Millicylinders in Rabbit Buccal Epithelium 
 4HPR millicylinders were evaluated in rabbit buccal epithelia for their ability to enhance 
drug-tissue distribution and also their release rate.  Female New Zealand rabbits 3 months of age 
were purchased from Charles River Laboratories.  All experiments were conducted in 
accordance to University of Michigan’s Institutional Animal Care and Use Committee.  Prior to 
implantation, rabbits were anesthetized with 5% isoflurane inhalation via calibrated vaporizer, 
and pre-weighed implants were inserted into the buccal region via an 18G trocar. Each rabbit 
received 2 implants (1 per cheek), with 1 cheek utilized for Raman imaging analysis for drug 
distribution, and the other for determining the amount of drug released (n=3 per formulation per 
time point).  Serum samples were collected prior to implantation and at the endpoints.  On 
endpoint days 1 and 14 and rabbits were isoflurane anesthetized and then euthanized via 
intravenous injection of saturated potassium chloride solution.  The buccal tissues were 
harvested and kept on dry ice until tissue sectioning. For the tissue distribution analysis, a ~15 
mm length of buccal tissue containing a cross-section of the millicylinder was frozen onto a 




cutting chuck with OCT, and a 20 μm section near the middle of the implant was placed on glass 
slide, and imaged via Raman spectroscopy. For drug release from the implants, the implants 
were carefully removed, and drug was extracted via the loading assay.  The release data from the 
implants in rabbit buccal was compared to those administered in rats s.c. as described in Chapter 
2. 
5.3.7. Drug- Tissue Penetration by Raman Imaging 
 To prepare these 4HPR-tissue penetration curves, a 1 mm wide region containing the 
center of the implant was selected in both the y-plane (i.e. same tissue layer) and the z-plane 
(through different tissue layers).  The z-layer penetration was expressed as the movement 
towards the epithelium and also towards the mucosa.  The penetration distance was reported at 
the location where drug concentration decreased to 10% of its initial value (C10). 
5.3.8. 4HPR Millicylinder Loading and Release Digestion Assay  
4HPR loading and release was determined via implant digestion assay. For the PLGA 
implants, one millicylinder was weighed, and PLGA and 4HPR were co-dissolved by addition of 
0.5 mL THF, followed by precipitation of PLGA with addition of 9.5 mL EtOH. The samples 
were centrifuged, and supernatant was assayed by UPLC/UV.  For the PVA/sucrose implants, 
the implant was dissolved in 10 mL of EtOH.   
5.3.9   4HPR Serum Levels 
4HPR sera levels were determined in rabbits.  A 100 uL aliquot of serum was spiked with 
internal standard (5 μL of 0.5 mg/mL acitretin), extracted with 300 uL ACN by sonication on ice 
for 10 min, clarified by centrifuging at 12,000 rcf for 10 min, and the amount of 4HPR in 
supernatant was determined by UPLC assay, and extraction recovery normalized by the internal 
standard. 




5.3.10 4HPR UPLV-UV Assay 
4HPR levels in millicylinder digests, serum were measured by UPLC/UV.  The reverse 
phase UPLC/UV analysis was carried out with a Waters Acquity UPLC system and Empower 
software under the following conditions:  Acquity BEH C18 2.1x100 mm column, mobile phase 
80:20 ACN: ddH20 + 0.1% phosphoric acid (H3PO4), isocratic flow rate of 0.65 mL/min, UV 
detection at 365 nm, and total analysis time of 2 min.  4HPR LLOQ is 0.05 μg/mL. 
5.4. Results and Discussions 
5.4.1 Raman 4HPR Tissue Calibration Standards 
The first step in developing our quantitative Raman imaging method was to prepare a 
calibration curve with buccal tissue sections incubated in 4HPR dissolved in PBST 0.5% 
solutions (4 h previously determined to be the equilibrium binding time).  As shown in Figure 1a, 
there was a linear increase in 4HPR tissue uptake as the concentration of 4HPR in incubation 
media increases, with correlation coefficient of r2= 0.997.  We calculated 4HPR partition 
coefficient from the PBST 0.5% media into buccal epithelium sections, and found consistent 
partitioning (Kp) that ranged from 1.9-2.2 over a wide concentration range of 3-91 ug/mL free 
4HPR in media (Fig. 5-1b).  
Calibration sections were analyzed as per acquisition methodology and 3000 Raman 
spectra were collected across all regions of each tissue section and individually processed using 
algorithm to determine the integrated intensity of the 4HPR peak at 1582 cm-1. The average 
spectra for each calibration standard are reported in Figure 1c and the average (+/- SE) integrated 
intensity yielded a linear relationship with the actual drug/tissue mass ratio as determined by 
HPLC (r2=0.985). The linear range was determined to cover 6.5 – 200.7 ug 4HPR/g tissue, and 




tissue regions exceeding this range were considered to be saturated and colored white in the 
resulting Raman concentration images.  
5.4.2 Raman Hyperspectral Image Processing Algorithm 
To analyze 4HPR distribution throughout a single buccal tissue sample, at least 30,000 
Raman spectra were required. Acquired in a raster pattern across the tissue section under 
investigation, each spectrum must be individually processed and interpreted to extract relevant 
chemical information, thus creating a necessity for automated algorithms that perform processing 
functions in a time-efficient manner. Developed in-house, our MALTAB algorithm wascapable 
of processing tens-of-thousands of spectra per minute with outstanding reliability. One major 
advantage of Raman is the non-destructive nature of the analyses; tissue sections undergo 
minimal preparation ensuring the natural distribution patterns of 4HPR are unadulterated and 
enabling quantitative characterization as such. Tissue sections are typically prepared on glass 
slides and, as was in our case, contained residual blood. The oxygen-carrying heme protein in 
blood gives rise to an enhanced resonance Raman signal at 1588cm-1 that partially overlaps the 
characteristic peak of 4HPR, making algorithmic distinction between the two difficult. 
Exploiting heme’s unique Raman peak at 750cm-1, a decision tree was employed to identify 
spectral contributions from heme and using a scaled reference spectra obtained from pure blood, 
subtract the interference, leaving only spectral contributions from 4HPR and other tissue 
components to be quantified. No other chemical components present in our system, including 
millicylinder excipients, interfered with the 4HPR Raman peak at 1582cm-1 (see supplemental 
figure S1). To confirm the validity of algorithm functionality, Raman test datasets were acquired 
from dispersions of pure biochemical components or unadulterated buccal tissue on glass slides. 




Since the intended Raman results for the test samples were known, they were used to 
experimentally determine the reliability of the algorithm. 
 
Figure 5-1. Excised buccal tissues (sectioned 20 μm thick) incubated in known concentrations of 4HPR (in PBST 
0.5%) were assayed via HPLC, and served as calibration standards for quantitative interpretation of Raman spectra.  
A) 4HPR tissue uptake as a function of incubation media concentration b) 4HPR partitioning (Kp) from aqueous 
media to tissue, c) 4HPR Raman spectra showing limit of detection at 6.5 ug 4HPR/g tissue, and d) Raman 4HPR-
tissue calibration curve shows Raman signal intensity as a function of tissue concentration by HPLC. (n=3, mean ± 
SE). 
5.4.1 Evaluation of 4HPR Release and Distribution from Millicylinder Implants 
Effect of Tissue Type on Release rates (Buccal vs. s.c.) 
 The three millicylinder formulations prepared with different polymer systems and drug-
solubility enhancement were evaluated in vivo for their release rate as well as their drug-tissue 
distribution after 1 and 14 days.  The effects of implantation sites on drug release rate was 
evaluated by comparing release into buccal epithelia vs s.c, which was previously evaluated in 




our rat in vivo studies in Chapters 2 and 3. The immediately dissolving, water soluble matrix 
PVA/sucrose implant served as a benchmark for the dissolution controlled release of a 
hydrophobic solid drug depot.  The PLGA + 10% 4HPR + 3%MgCO3 formulation was shown to 
have very long-acting release in s.c. tissues (> 2 months release).  The PLGA+ PVP-4HPR-
TEAC formulation provided superior solubility enhancement due to formation of amorphous 
solid dispersion between PVP, 4HPR and TEAC, and served to test the premise that the ability to 
solubilize the hydrophobic drug is the limiting factor in tissue penetration.   
 The results for drug release from these implants are shown in Figure 5-2, and actual 
4HPR implant loading is noted in the figure. All of the implants released faster in buccal 
compared to s.c., likely due to greater blood flow in the mouth compared to skin.  In the 
PVA/sucrose formulation, the day 1 burst in buccal was almost double of the s.c. release. The 
PLGA-PVP-TEAC amorphous drug system also had a high burst release on day 1 in buccal 
(62%), while in s.c only 26% released, yet after 2 weeks, both released similar levels (69% and 
77% respectively).   This fast release is likely due to only 50% PLGA in the initial implant 
composition. The very long-acting release PLGA formulation with pore-forming agent MgCO3, 
released 4HPR twice as fast in buccal (29% vs 15%) after 14 days, and therefore was most 
capable of these formulations of providing long duration of release in the mouth, due PLGA’s 
well characterized slow release properties. 





Figure 5-2 4HPR in vivo release from three millicylinder formulations after 1 and 14 days in rabbit buccal epithelia 
compared to rat s.c. tissue types (mean ± SE, n=3).  The PVA/sucrose implant is an immediately dissolving, water 
soluble matrix, the PLGA+PVP-4HPR-TEAC implant provides controlled release of a solubilized form of 4HPR, 
while the PLGA+ 3% MgCO3 provided very long-acting drug release. 
 
4HPR Tissue Distribution 
 The drug-tissue concentration gradients were generated based on the Raman imaging 
methods and calibration curve shown in Figure 5-1.  In Figure 5-3, a representative Raman 
image is shown for 4HPR dispersion in buccal epithelia after 14 days of release from the PLGA-
PVP-4HPR-TEAC implant.  The preparation of the tissue-penetration curves is clearly marked 
around the implant hot spot, and shows selected regions of z-plane diffusion, (through different 
tissue layers), and y-plane diffusion (along same tissue layer). For example, the y-diffusion 
distance (Fig. 5-4b), is measured at the edge of the saturation zone (200 μg 4HPR/g tissue at 
6000 μm) to the C10 (20 μg 4HPR/g tissue at 200 um), and therefore equals 5.8 mm.  A complete 



























4HPR Actual Loading: 12.0 ± 0.5% 8.4 ± 0.1% 9.8 ± 0.1%




penetration curves, can be referenced in Supplemental Information Figure S5-3.
  
Figure 5-3 4HPR distribution in buccal epithelia after release from millicylinder implants. A) Representative Raman 
image of tissue dosed with PLGA+ PVP-4HPR-TEAC implants after 14 days detailing the process for generating 
drug-tissue penetration curves in both the b) y-plane (same tissue layer) and c) z-plane (towards epithelium or 
mucosa). Each data point represents a 50x50 μm pixel from the corresponding boxed region in (a), and the location 
of millicylinder is noted on plots with a yellow circle.  Full data set for each sample replicate and times points can be 
referenced in Supplemental Information Fig. S3. 
 
 4HPR’s tissue penetration from these implants is portrayed by distance by which 4HPR’s 
concentration decreased to 10% of initial (C10).  These distances were extracted from Raman 
images in Supplemental Figures S5-3, and is shown in Figure 5-4 for both the z-plane 
penetration towards the mucosa and towards the epithelium in addition to the y-plane 
penetration.  Most notably, the y-plane penetration along same tissue plane is much greater than 
penetration through different tissue layers. Statistical analysis was performed within groups, 
different directions within groups day 1 to day 14, and among the groups, different 
directions.  We used a nonparametric test due to the small n numbers, specifically the Kruskal 
Wallis Analysis of Variance followed by a Dunn’s Multiple Comparison post hoc test.  It is 




difficult to disseminate if there was preferential movements towards the epithelia or mucosa, as 
no trends could be determined with this sample size (n=3).  All formulations and time points had 
an average z-plane diffusion distance of 0.3 to 2.0 mm. Pre-cancerous cells will proliferate from 
the basal cell membrane, a region close to the where the implants were dosed, and therefore these 
implantation depths and drug diffusion distances in z-plane should be satisfactory for oral cancer 
chemoprevention.   
A better indication of the formulation’s drug penetration enhancing performance, can be 
observed along the y-plane.  The PVA/sucrose implants had an average penetration of 1.7 ± 0.6 
mm after day 1, while that value decreased to 1.1 ± 0.6 mm after 14 days.  This could be 
attributed to clearance of the drug from the active site where after 1 day they released 47% 
4HPR, and 68% after 14 days.  Perhaps the large burst release of crystalline drug was itself a 
barrier to drug movement.  Next, we see that the very slow releasing PLGA+ MgCO3 
formulation enabled greater drug penetration than the solid depot, whereby 4HPR moved on 
average 1.7 ± 0.6 mm and 2.8 ± 1.0 mm from implant after 1 and 14 days respectively.  Finally, 
the PLGA + amorphous, solubilized drug (PVP-4HPR-TEAC), had far surpassed the other 
formulations in tissue penetration enhancement, such that 4HPR penetrated on average of 2.6 ± 
1.0 mm and 5.8 ± 1.7 mm after 1 and 14 days respectively.  As hypothesized, the ability to 
deliver a solubilized form of the drug into the aqueous tissue environment was the limiting factor 
in the ability to achieve widespread tissue distribution. As the oral cavity is a curved surface with 
interruption of the mucosa surface by the rabbit’s lip pomenture, some of the diffusion variability 
could be attributed to differences in implantation angles or depths, and therefore cross-sections 
may have captured slightly different diffusion planes.  For all formulations, there was no 
detectable 4HPR in serum, which is a favorable aspect with local delivery systems, such that the 




undesired side effects associated with systemic drug delivery could be alleviated with these 
implants. 
 
Figure 5-4 4HPR penetration distances in buccal epithelia from millicylinder formulations after day 1 and 14 
determined by concentration gradients in tissue sections measured by semi-quantitative Raman spectroscopy.  
Penetration distance represents distance by which drug concentration decreased to 10% of starting value, which was 
20 μg 4HPR/g tissue, given that Raman signal intensity was saturated at perimeter of implant, giving initial 
concentration at edge of implant of 200 μg 4HPR/g tissue.  (Mean ± SE, n=3). 
 
Effect of Tissue Environment (Tissue layer, lipid profiles) on 4HPR dispersion 
 Our results shown in Figure 5-4 are evidence that successful formulations can enhance 
4HPR tissue distribution by solubilization of the drug.  However, other physiological factors may 
be either enhancing distribution or acting as a diffusion barrier, such as local blood flow, degree 
of keratinization of tissue, and local protein/lipid levels to name a few. To further examine this, a 
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which included staining with oil-red-o for lipids + Harrison hematoxylin stain, and evaluation of 
tissue bio-composition by Raman mapping of proteins and lipids in epithelium, submucosa, and 
mucosa.  In Figure 5-5a, we see that the red lipid-specific stain has the greatest uptake in the 
submucosa region, ie, the implantation site.  An attempt was made to correlate the amount of 
lipid and y-plane diffusion distance (along same tissue layer), for each of the 3 formulations 
(time points were combined). As shown in Figure 5-5b, the level of lipids does not appear to 
affect the diffusion distance for the PVA/sucrose and PLGA+MgCO3 formulations, however we 
see a positive effect of diffusion distance increase as local lipid levels increase for the solubilized 
PLGA+PVP formulation.  In Figure 5-5c, we see that Raman mapping shows the highest levels 
of protein and lipid in the sub-mucosa region, ie, implantation region, and is consistent with the 
oil-red-o staining (Fig. 5-5a). Further tissue pathological investigations may prove insightful for 
enhancing drug penetration distance for local delivery systems. 
 
Figure 5-5 Correlation of tissue composition with 4HPR penetration distance in buccal tissue.  A) Representative 
oil-red-o stained tissue (specific for lipids), b) 4HPR diffusion distance as a function of lipid level for each 
formulation, and c) Raman mapping of 4HPR,  lipid, and protein in a tissue section incubated in 4HPR/PBST 
solution, and co-localization of the biocomponents in the different tissue sections (epithelium, submucosa, mucosa). 





 Here, we have published for the first time, the tissue penetration behavior of 4HPR after 
local delivery in buccal epithelia from long-acting release implants.  We have developed 
quantitative Raman imaging and spectral processing methods to obtain high resolution of drug 
distribution in tissue sections.  We have shown that 4HPR diffusion distance can be enhanced 4-
fold by delivering an amorphous form of 4HPR from PLGA implants, compared to the solid 
dispersion control prepared in a PVA/sucrose matrix.  Therefore the ability to solubilize this 
hydrophobic drug is likely a limiting factor in its tissue distribution.  Furthermore, we have 
shown that the tissue type, ie buccal vs. s.c has a significant impact on the rate of drug release 
from these implants, such that nearly 2-fold increase in amount of drug released occurred in the 
buccal epithelia, likely due to greater blood flow.  There are other physiological factors that may 
contribute to the 4HPR diffusion, including lipid and protein level, or depth of implantation, and 
deserve further examination for future evaluation of the drug system’s performance. We have 
shown that these implants are capable of delivering 4HPR to the basal cell membrane tissue 
regions to target the pre-cancerous cells that may arise, and may be a beneficial strategy for 
secondary oral cancer chemoprevention. 
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5.6. Supplemental Information 
A. The following figures support the quantitative Raman imaging method development and 
validation.   
B. Additional figures show all of the raw Raman imaging data from the each formulation and 
time point, along with the corresponding concentration-diffusion gradient curves.  
Preparation of pure component algorithm test samples 
 To assess automated algorithm reliability and probability of false negative and positive 
interpretations, the most abundant chemical components in the system were identified and 
utilized to create test sample sets. The components of interest were 4HPR, protein, lipid, residual 
blood, and glass. For representative protein and lipid materials, albumin (MP Biomedicals; cat. 
#810033) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids, Inc.; cat. 
#850375P) were used. Each component was dissolved in an appropriate solvent (4HPR/lipid in 
methanol and protein/blood in water), transferred to glass slide, and allowed to evaporate dry as 
pure component dispersions. Additionally, an untreated tissue section containing residual blood 
and an untreated tissue section washed free of blood (with PBS) were analyzed on glass to 
determine reliability of algorithm’s scaled glass and blood subtraction. Large area Raman scans 
were acquired from the resulting test samples using the Raman acquisition methodology. These 
test datasets were processed through the algorithm and the error frequency was determined based 








Table S1. Algorithmic error probability testing determined from test datasets. 
 
 
Figure S5- 1 Millicylinder excipients and biocomponent Raman reference spectra show no interference with 
4HPR’s peak at 1582 cm-1 except from blood. Spectral contributions from glass are apparent in unprocessed tissue 
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Figure S5- 2 Raman hyperspectral image processing algorithm overview. Data acquisition and initial pre-processing 
performed using WiTec ProjectFOUR software (shown on top in yellow); automated MATLAB algorithm 
processing steps (shown on bottom in blue). 
 
The following pages contain Supplemental Figure S5-3: 
Figure S5- 3  Shown below are Raman images of 4HPR distribution in buccal epithelium section after 
release from long-acting implants after days 1 and 14, n=3.  Shown for each formulation and time point is 
the Raman heat map of 4HPR concentration in tissue section, oil-red-o (lipid specific) and hematoxylin 
stain to visual pathological features, and concentration –distance profiles in both the z-plane (through 
different tissue layers) and y-plane (through same tissue section).  
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Chapter 6:  Conclusions, Significance, and Future Work 
 The work presented in this thesis details successful 4HPR millicylinder implant 
formulations capable of providing 1 mo, 2mo, or > 2mo. release in vivo depending upon choice 
of polymer and excipients, including solubilizers. This represents and important step towards 
translation into clinical applications for oral cancer chemoprevention, by improving patient 
compliance and survival with less frequent dosing, and greater therapeutic efficacy due to wide 
spread tissue penetration. The challenges associated with local delivery of 4HPR, an extremely 
aqueous insoluble drug, included incomplete release from the implant, high non-specific tissue 
binding, and limited tissue dispersion, were addressed and overcome.   
In Chapter 2, local, long-acting release 4HPR millicylindrical implants were prepared 
from both PLGA and water soluble matrices with and without solubilizers and crystallization 
inhibitors. The implants were evaluated in vitro and in vivo over 1-2 mo.  Addition of the high 
levels of pore forming agent (MgCO3) and bile salt were added to improve the release, leaving 
only 40% PLGA in the implant system to govern the release.  The 4HPR in vivo release from 
PLGA only marginally improved by addition of solubilizers, where extremely long release 
duration (less than 50% 4HPR released after 2 mo.) was observed, which indicated a lack of 
PLGA erosion controlled release. These PLGA implants exhibited a burst release, followed by a 
3 week lag period, and increased drug release rate from day 21-56, likely due to PLGA erosion. 
It was suspected that 4HPR release at the later stages was governed by the slow dissolution of 
the hydrophobic drug, and therefore the in vivo release was compared to an immediate 




dissolving, water soluble matrix implant. The water soluble implants were capable of providing 
controlled release up to 6 weeks.  These studies led us to conclude that 4HPR release was 
governed by dissolution of the hydrophobic drug. These results are consistent with previous PK 
studies that compared s.c. dosing of 4HPR microspheres to a drug suspension, which showed 
similar controlled release of drug into plasma after 2 weeks. We suggest possibly combining the 
PLGA and water soluble implants to provide continuous dosing over 2+ mo.  In our initial tumor 
efficacy studies in oral cancer xenograph mice, we found our 4HPR-PLGA millicylinders were 
effective at reducing rate of tumor growth relative to no-drug controls. 
  The limitations of the initial PLGA-4HPR millicylinder formulations were realized in 
Chapter 2, and therefore creation of amorphous drug systems for solubility enhancement was 
investigated in Chapter 3.  A robust PVP-4HPR ASD showed incredible 50 to 1000-fold 
solubility enhancement over 1 week, and was loaded into PLGA millicylinders, and release was 
evaluated in vitro and in vivo. One of the drawbacks of using this solubility enhancing ASD 
system, is the large quantity of excipient necessary relative to the drug, and thereby decreases the 
drug dose that can be delivered.  The optimal PVP-4HPR ratio was determined to be 9/1, and 
therefore if loaded 50/50 into PLGA, the total 4HPR loading is only 5%.  The in vitro release 
with the 9/1 PVP-4HPR was not satisfactory, and after careful literature review, addition of the 
plasticizer TEAC to the PVP-4HPR ASD substantially improved release nearly 6-fold.  The in 
vivo release study with the solubilized amorphous PVP-4HPR immediate dissolving and PLGA 
+ PVP-4HPR-TEAC implants showed large release enhancement compared to our previous 
PLGA and PVA/sucrose crystalline drug formulations where slow, continuous, and nearly 
complete release was achieved over 30 days. These results are useful for tailoring formulations 




to target a wide range of release durations based on selection of polymer matrix and level of 
solubility enhancement. 
In Chapter 4, we evaluated 4HPR’s tissue binding and lipid cell membrane binding to 
predict the factors responsible for 4HPR tissue dispersion. These results show that time of 
exposure, but not solubilizer or permeation enhancers, affected tissue uptake. Furthermore, 
4HPR exhibited a fifteen-fold greater binding affinity to buccal epithelia relative to SC 
connective tissues. Most notably, obtaining 4HPR solubility in aqueous solutions was the 
limiting factor for tissue uptake. While the majority of non-specific tissue binding likely reflects 
lipid interactions, it is well known that 4HPR also demonstrates high affinity protein binding. 
Therefore, future 4HPR injectable formulations should aim to maximize drug solubility to 
achieve widespread distribution at the local lesioned site. 
 In Chapter 5, we have made significant headway in developing quantitative Raman 
imaging methods to determine 4HPR spatial distribution after dosed into rabbit buccal epithelia.  
This is the first time the 4HPR’s tissue distribution has been mapped, and the imaging methods 
are hugely advantageous over the traditional tissue sectioning and extraction methods.  With it, 
we can see the drug’s partitioning into the various layers of tissue, such as the mucosa 
epithelium, sub-mucosa, or deep muscle layers. In tandem, lipid staining allowed us to visualize 
the drug’s affinity for lipid rich regions, where we had hypothesized 4HPR’s high lipid affinity 
limits its penetration.  The millicylinders were implanted in rabbit buccal epithelia and drug 
release and distribution were evaluated over 14 day, including the formulations: crystalline drug 
control in an immediate dissolving sugar matrix, 4HPR-PLGA, and the extremely solubilized 
PVP-4HPR-TEAC ASD in PLGA implants. The results from the tissue distribution revealed that 
the amorphous drug had the greatest tissue penetration, results which are consistent with the 




conclusions from the ex-vivo tissue uptake study that found drug solubility was the limiting 
factor in uptake.  Without the solubility enhancement, there is no driving force to move 
hydrophobic 4HPR from the depot into the surrounding aqueous tissue environment. 
  To conclude, we have shown that formulation challenges of local delivery of this 
hydrophobic, high protein and lipid binding drug 4HPR, can be overcome.  For the first time, 
4HPR’s local tissue interactions and distributions were evaluated.  Also novel is the quantitative 
Raman imaging method.  These formulations will be of great value and importance for those 
patients who have suffered the debilitating effects of oral cancer, and will serve to provide them 
with effective and worry free cancer prevention therapies, which will be necessary for the 
remainder of their lives.  These formulation strategies can also be applied for local delivery of 
other hydrophobic drug molecules as well.  
   Future studies should investigate the use of other penetration enhancing excipients to 
further move the drug into surround tissue to treat a larger lesional area, for example, propylene 
glycol, tweens, menthol, chitosan polymers, bile salts, and hyaluronidase enzyme for tissue 
spreading. Alternatively, other depot forms such as in situ forming implants, hydrogels, or 
microparticles could be investigated.  The toxicity of these excipients should be evaluated locally 
and systemically, with inflammation at the implantation site being the most likely pitfall. 
Additionally, the translational aspect could evaluate the effects of radiation therapy on the 
stability or release of 4HPR from the implants, as patients maybe be concurrently preventing 
cancer regrowth while removing new lesions.  Future studies could also investigate the drug 
release and distribution at different implantation sites in mouth, including tongue, or floor of 
mouth, which have different levels of keratinization and tissue thickness.  
  






Appendix 1:  Excipients and solvents used for solubilization of 4HPR  
Compilation of experimental data and literature reviews  
Solvent Solvent/Solubilizer classification Solubility (mg/mL) 
Literature Data From our Lab 
Dichloromethane (DCM) Organic solvent (Hansen’s solubility calc.) 2.5 
Ethyl acetate (EtOAc) Organic solvent 21 
Chloroform  Organic solvent 7 
Methanol (MeOH) Organic solvent 36 
Ethanol (EtOH) Organic solvent 47 
1-Propanol Organic solvent 36 
2-Propanol Organic solvent 37 
Acetone Organic solvent 100 
Acetonitrile (CAN) Organic solvent 3.8 
THF Organic solvent >200 
Dimethylformamide (DMF) Organic solvent >99 
Dimethylsulfoxide (DMSO) Organic solvent >95 
N-Methylpyrrolidone (NMP) Organic solvent 150 
Phosphate buffer solution (PBS) Aqueous solvent 0.000023 
PVA (5% in water) Aqueous solvent, water 0.0008 
Tween 80 (1% & 3% in PBS) Aqueous solvent, PBS 0.2, 0.6 
Sodium deoxycholate (NaDC) 5% Bile Salt   (In Simulated Saliva Solution, pH 
6.8)-Buccal Mucosa patch study 
0.403 
Sodium cholate (NaC) 5% Bile Salt   (In Simulated Saliva Solution, pH 6.8) 0.264 
Sodium taurocholate(NaTC) 5% Bile Salt   (In Simulated Saliva Solution, pH 6.8) 0.203 
Sodium glycholate (NaGC) 5% Bile Salt   (In Simulated Saliva Solution, pH 6.8) 0.166 
Tween 20 (5%) Non-ionic Surfactant    
(In Simulated Saliva Solution, pH 6.8) 
0.404 
Tween 80 (5%) Non-ionic Surfactant  
 (In Simulated Saliva Solution, pH 6.8) 
0.457 
Brij 35 (5%) Non-ionic Surfactant  
 (In Simulated Saliva Solution, pH 6.8) 
0.150 
Brij 98 (5%) Non-ionic Surfactant  0.505 




(In Simulated Saliva Solution, pH 6.8) 
Soluplus (5%) Polymer   (In Simulated Saliva Solution, pH 6.8) 0.200 
Lecithin (5%) Lipid   (In Simulated Saliva Solution, pH 6.8) 0.098 
  µg/mL 
Brij 98 (0.1, 0.5, 1 %w/w) PBS ( From Merck Report) 15, 60, 130  
Brij 35(0.1, 0.5, 1 %w/w) PBS ( From Merck Report) 15, 40, 70 
Tween 80(0.1, 0.5, 1 %w/w) PBS ( From Merck Report) 15, 85, 170 
PluronicF127(0.1, 0.5, 1 %w/w) PBS ( From Merck Report),  15, 60, 70 
DI DI  (hydrophobic fenret Inj), 3 days 0.023 
Tween 80 (0.02, 0.1, 0.5, 1, 2%) PBS, (hydrophobic fenret. Inj), 3 days 6, 22, 100, 200, 625 
Experimental Data  µg/mL 
Water Water 0.2 
Tween 80 (2%) PBS  day 1, 7 Day 1: 300 
 Day 7: 499 
PEG400 Potential osmotic pump solution 941 
NMP (12.5%) in PBS ISFI solvent 0.25 
NMP (12.5%) in PBS 2% Tween  ISFI solvent/in vitro release media 624 
5% PG + 2.5% Menthol in PEG 
400 
Potential Osmotic pump solution  896 
5% NaDC in 2% Tween 80 PBS PBS 638 
NaDC (1, 2, 5, 10, 20 %) Water, Day1, 7 sampled Day 1: 
22,142,396,617  
Day 7: 32, 56, 157, 
567, 1038  
B-CD (1, 2, 5, 10, 20 %) Water, Day1,7 sampled, similar data 7, 13, 23, 34, 40 
HP-B-CD (1, 2, 5, 10, 20 %) Water, Day1, 7 sampled, similar data 0.06,0.09, 1.6, 7, 32 
TA-B-CD (1, 2, 5, 10, 20 %) Water Insol. 
PVP (1, 2, 5, 10, 20 %) Water, Day1, 7 sampled, similar data 0.04, 0.04, 0.36, 0.66 
HPMC (1, 2, 5, 10, 20 %) Water Insol. 
PEG4600 (1%) Nonionic surfactant.  In DI.  N.d. at 2,5,10, 20% 0.25 
PEG800 (1, 2, 5%) Nonionic surfactant.  In DI.  N.d. at  10, 20% 0.25 in all 
Pluronic F127 Prill (1,2,5,10%) Non-ionic surfactant, PEG-PG-PEG Mn=5800,  
water 
2, 8, 45, 115  
Phosphatidyl Choline (1, 5%) Lipid, in water, day 1,7 314,  946 
Serum day 1, 7 57, 67  




Na 4HPR salt in DI day 1, 7—(Prepared by kneeding in EtOH, or 
acetone rxn solvent) 
EtOH- 19, 104 
Acetone- 32, 112 
Na 4HPR salt PBST 0.02%, day 1, 7 56, 103 
Na 4HPR salt PBST 0.5%, day 1, 7 264, 295 
Na 4HPR salt PBST 2%, day 1, 7 632, 79 
Na 4HPR salt in serum  day 1, 7 (prepared from kneeding in acetone) 228, 126 











Appendix 2: Elucidation of Physicochemical interactions of Fenretinide with Poly(lactic-co-
gylcolic acid) in Long-acting release implants 
 
A2.1 Abstract 
Poly(lactic-co-glycolic acid) (PLGA) is an FDA approved bio-erodible polymer used for 
long-acting release drug delivery, whose chemical properties can easily by tailored to the 
intended target dosing frequency.  Fenretinide (4HPR), a synthetic retinoid molecule, has been 
exploited for its chemopreventive properties, in particular, oral cancer.  In our recent studies, we 
had developed 4HPR-PLGA delivery systems, however, we found extremely slow and 
incomplete drug release from our polymer matrix both in vitro and in vivo.  We had suspected 
that 4HPR was interacting with PLGA in such a way that prevented its release or facilitated 
degradation once released. 4HPR is a hydrophobic molecule, and also known to be subject to 
photo-and oxidative degradation due to its high degree of conjugation. Our studies found that 
4HPR was stable within the PLGA matrix after months of incubation in vitro, however, once 
released into aqueous media, had shown both photo-and oxidative degradation.  Mechanisms of 
PLGA-4HPR interactions were investigated including release in solubilizing/non-solubilizing 
media, LC-MS of degradation products in release media, polymer glass transition temperature, 
effects of residual carrier solvent, FTIR for carbonyl chemistry interactions, and Raman 
spectroscopy for π- electron interactions.  These data suggest that PLGA carboxylate groups are 
interacting with 4HPR’s amide bond, and prompting 4HPR hydrolysis into its parent retinoic 
acid structure, similar to known acylation reactions with PLGA and peptides. Also, the acetone 
carrier solvent appears to have an effect on the adhesion of 4HPR to the PLGA, and remains 




traps within the millicylinders prior to release.  Interestingly, we have also shown a direct 
correlation between the level of residual solvent, polymer Tg, and the amount of drug released.  
These data will be useful for designing future long-acting release 4HPR-PLGA systems or other 
hydrophobic drugs or those containing amide bonds loaded into PLGA. 
A2.2. Introduction 
Retinoids are a group of endogenous and exogenous molecules synthesized in vivo from 
carotenoid molecules or synthetically from Vitamin A (or retinol) and have important 
physiological roles including growth and development, reproduction, and cellular differentiation.  
Synthetic derivatives of Vitamin A have been utilized to treat a variety of skin disorders, and one 
of particular interest to us is fenretinide (4HPR), a highly active and promising therapeutic and 
chemopreventive agent for epithelial and neural origin cancers1.  It is known that retinoids, 
including 4HPR, are highly photo-sensitive leading to many types of isomerization reactions, 
which can be increased in the presence of organic solvents due electron transitions during 
conversion of singlet and triplet energy states2.  Retinoid structural rearrangement can also occur 
by reduction of the carbon-carbon double bonds in the presence of free radicals or light initiation. 
The propensity of retinoids to capture light is the property by which renders them useful for 
photon capture and light sensing in the eye’s opsin protein domains2.  
Due 4HPR’s lack of efficacy and dose-limiting toxicities by oral route, we have chosen to 
formulate 4HPR for local delivery using poly(lactic-co-glycolic acid) (PLGA)  implants for long-
acting release.  PLGA has been widely used as a choice polymer for controlled release drug 
delivery application due to its FDA approval, safe, predictable, and tailorable release properties 
based on ratio of lactide: glycolide monomers, molecular weight, and end-group capping.  The 
selection of the type of PLGA is largely dependent upon the duration of release (30 days to 9 




months) and the drug properties. The polyester undergoes hydrolysis into its lactic and glycolic 
acid monomers, giving rise to an acidic microenvironment and has shown to lead to autocatalyis 
of peptides3.  While PLGA is often utilized for stability enhancement of peptides or proteins, it is 
known that the hydrolysable ester bonds are subject to nucleophilic interactions with the 
encapsulated drugs. 
In our long-acting release 4HPR-PLGA millicylinder systems, we have found incomplete 
release of this hydrophobic drug even after 2 months in a solubilizing buffer.  The aim of this 
work is to address the reasons for incomplete release, which go beyond the drug’s obvious 
limited aqueous solubility, and addresses the drug-polymer interactions.  We suspect that 4HPR 
is interacting with PLGA similarly to peptides4, due to similar amide functional groups.  
Mechanisms of PLGA-peptide interactions that have been reported include acid-catalyzed 
reactions, such as deamidation and chain cleavage, drug-polymer acylation reaction and protein 
denaturation or degradation5,4,6,7.  4HPR is a weak acid, with a hydrolysable amide bond, which 
yields a reactive amino-phenol by-product. Results from our study shows that 4HPR does not 
appear to be hindering PLGA erosion, where nucleophilic attack of the amino-phenol would 
facilitate PLGA hydrolysis similarly to water. This paper considers the possible mechanisms of 
PLGA-drug interactions that causes incomplete drug release by inspection of 4HPR degradation 
products via mass spectrometry, carbonyl chemistry via FTIR spectroscopy, and π-π interactions 
via Raman spectroscopy.  Additionally, the effect of the protic acetone solvent used for 
millicylinder preparation was assessed.  These studies will help guide further preparation of 
4HPR-PLGA millicylindrical implants for long-acting release drug delivery for oral cancer 
chemoprevention. The utility of this research will also aid in troubleshooting PLGA delivery 




systems where loading amide, amine, or phenolic compounds have resulted in incomplete 
release. 
A2.3. Methods 
A2.3.1 4HPR in vitro release from PLGA millicylinders and PLGA Erosion 
 4HPR in vitro release from PLGA millicylinders was determined by placing one 
millicylinder (5-7 mg) in 5 mL Eppendorf tube containing 4 mL PBS pH 7.4 + 0.02% or 2% 
Tween 80, incubating at 37 °C on a shaking platform (200 rpm) and tubes protected from light 
by foil. The solutions were sampled by complete media replacement, 4HPR levels quantified by 
UPLC-UV, while 4HPR degradation products qualitatively determined by UPLC-MS.  PLGA 
implant erosion was performed after incubating implants in PBST 2%, and measuring PLGA 
mass loss after drying over 28 days.  A drug-loading and mass balance determination after in 
vitro release by digesting PLGA-4HPR millicylinders in THF, then precipitating PLGA with 
EtOH. 
A2.3.3 Identification of 4HPR Degradation products by LC-MS and MS/MS 
The extent of 4HPR degradation after in vitro release from PLGA millicylinder (10% 
4HPR+ 3% MgCO3) into PBST 2% was compared to the drug’s degradation in individual 
millicylinder components including PBST 2 % media, PBST 2% + 10% acetone, PBST 2% + 
PLGA + 10% acetone, PBST 2% + PLGA, PBST 2%+ PLGA + 10% acetone + 3% MgCO3.  
The solutions were analyzed by LC-MS using Waters Acquity UPLC-MS (quadrupole mass 
analyzer, QDa Acquity) system and Empower software under the following conditions:  Acquity 
BEH C18 2.1x100 mm column, mobile phase 80:20 ACN: 0.1% formic acid, isocratic flow rate 
0.65 mL/min, and total analysis time of 2 min.  MS was operated in both positive and negative 
ion mode, and 4HPR’s molecular ion [M+H+] m/z 392 was detected, and degradation products 




after in vitro release from 4HPR-PLGA millicylinders and buffers were identified based on 
literature mass spectra of retinoid molecules.  The MS/MS fragmentation was performed on ions 
observed in LC-MS using with Sciex 5500 Qtrap MS. 
A2.3.2 Microcalorimetry 
The amount of residual solvent trapped in PLGA-4HPR millicylinders after drying was 
determined by Thermogravimetric Analysis (TGA, Discovery, TA instruments).  The following 
temperature ramping profile was used:  10 °C/min until 300° C, then 20 °C/min till 600° C.  The 
percent mass loss after 150 °C was used to estimate both residual acetone and water removal 
during the TGA analysis.  The heating curves of the drug loaded (10, 20%, or 30% 4HPR) PLGA 
implants containing 3% MgCO3 were compared to no drug implants and starting materials.  
 The glass transition temperature (Tg) of the dried PLGA-4HPR millicylinders (prepared 
in previous reports, and could contain 5-30% 4HPR, 20% sodium deoxycholate, or 3-15% 
MgCO3) was measured to correlated with amount of 4HPR released in vitro release after 28 
days.  For the differential scanning calorimetry (DSC) analysis (Discovery, TA instruments), 2-3 
mg of the millicylinder was added to a hermetic pan, and samples were heated under modulating 
temperature from -10 °C to 70 °C, and Tg was determined.  
A2.3.4  FTIR and Raman Analysis of PLGA-4HPR Films 
PLGA-4HPR films were composed of 5% PLGA 503H + 4HPR (5, 10, 20 or 30%) + 3% 
MgCO3 dissolved in acetone and physical mixtures.  Individual FTIR spectra were acquired for 
acetone, 4HPR (solid), 4HPR (in acetone), PLGA, and PLGA + MgCO3. FTIR spectra were 
acquired with Perkin Elmer Spectrum BX spectrophotometer equipped ATR crystal accessory, 
20 uL of the polymer-drug solution dropped onto ATR, allowed to dry, then spectra acquired in 
400-4000 cm-1 range, 20 scans, and percent absorbance was reported. 




 Raman spectra was acquired of PLGA-4HPR films prepared as described in FTIR 
analysisby placing 50 μL of film, solid or solutions onto a silicon wafer and allowing to dry. 
Spectral acquisitions were performed using a WiTec Confocal Raman spectrometer, 532 nm 
laser in 400- 3500 cm-1 range, 20X objective, 35 accumulations per spectra, with 1 sec 
accumulation time. 
A2.4  Results and Discussion 
A2.4.1 4HPR-PLGA millicylinder in vitro release and polymer erosion 
4HPR was encapsulated in PLGA 503H millicylinders containing 3% MgCO3 for 
controlled release of 4HPR based on our previous work with formulating 4HPR into 
microspheres and ISFIs.8  The free-acid low molecular weight PLGA continuously erodes at 
physiological conditions to allow continuous release9. Also, we have found a positive effect upon 
addition of a poorly soluble basic salt (i.e. solubilizes upon pH lowering like antacids) on release 
of proteins and hydrophobic small molecules from PLGA millicylinders, which is attributed to 
pore formation and neutralization of PLGA monomers that have degraded within the bulk 
polymer10,11.  
The in vitro release of 4HPR from PLGA millicylinders was performed in both 
solubilizing (PBST 2%) and non-solubilizing (PBST 0.02%) buffers to determine if maintenance 
of sink conditions (with high level of solubilizer) could facilitate complete release of 
hydrophobic 4HPR from the implant. 4HPR solubility in PBS +0.02% and 2% Tween is 0.02 
and 500 μg/mL respectively. In Figure 1a, we observed that release is accelerated in presence of 
high levels of Tween solubilization, resulting in 40% vs. 4% 4HPR released by day 56 for PBST 
2% and PBST 0.02% respectively.  Clearly, the level of solubilization by Tween in the release 
media greatly dictates release of the hydrophobic drug. A mass balance for the PBST 2% media 
revealed an incomplete accounting of drug, such that 42 ± 4% 4HPR was released and 35 ± 3% 




4HPR was remaining in millicylinder, equating to 77 ± 4% 4HPR recovered.  The initial drug 
loading in the implant was close to 100%, indicating that the drug is stable initially inside of the 
PLGA, and therefore degradation must be occurring after being released from the implant into 
the aqueous media. The SEM of the implant cross-section (Fig. 1c) prior to in vitro release shows 
that 4HPR is soluble in the PLGA. This incomplete drug release is unusual given that PLGA 
503H typically is mostly eroded after 1 month, and after 2 months it should be completely 
hydrolyzed into its glycolic and lactic acid monomers.  It was suspected that 4HPR may be 
interacting with PLGA and inhibiting PLGA erosion, leading to a delayed release profile.  
However, this was not observed (Fig.  1b), where 10% and 20% 4HPR loaded implants 
containing 3% MgCO3 did not significantly alter polymer erosion compared to the PLGA+ 3% 
MgCO3 control, and by 28 days 50-60% PLGA had eroded.  We do see that the basic pore-
former MgCO3 significantly delayed erosion at 15% compared to 3%, likely due to electrostatic 
interactions between magnesium cations and PLGA’s carboxylate groups.  
 
Figure A2- 1:  a)  4HPR in vitro release from PLGA millicylinders (20% 4HPR + 3% MgCO3) in solubilizing 
PBST 2% and non-solubilizing PBST 0.02% media. B) Effect of drug loading and MgCO3 level on PLGA erosion 
in millicylinders in PBST 2%.  C) SEM of 10% 4HPR in PLG PLGA millicylinder +3% MgCO3 shows 4HPR 
solubility in the PLGA polymer phase. (Mean ± SE, n=3)  




A2.4.2 Mass Spectrometric analysis on 4HPR degradation in in vitro release media and 
PLGA implant 
 The mass balance showed that that ~25% of 4HPR degraded either within the PLGA 
matrix or in the aqueous release media after 2 months, therefore, the stability of 4HPR in the in 
vitro release media (PBST 2%) was evaluated and compared to the stability of 4HPR within the 
PLGA implant, and also in the presence of individual millicylinder components to delineate 
source of 4HPR degradation.  A qualitative LC-MS/MS analysis was performed to identify these 
degradation products, based on literature data. As shown in Table 1, the addition of acetone, 
PLGA, and MgCO3 to the PBST 2% media have little effect on the degradation compared to 
4HPR in the control PBST 2% solution.  However, substantial drug degradation occurs after 
4HPR is released from PLGA millicylinder, and after 1 week, the 4HPR peak was reduced to 
82%, while the peak at RT=0.9 increased to 17.2% of total chromatogram peak area. Yet, the 
drug was 100% stable within the PLGA.  These results show that 4HPR stability is compromised 
in presence of PLGA even early on in release profile, and the identification of degradation 
products in the release media (RT=0.9 and 1.7 min) will be helpful to determine what may be 












Table A2- 1. Evaluation of 4HPR degradation in dissolved in solubilizing media in presence of millicylinder 
components compared to 4HPR release from PLGA millicylinder and within the implant. 
 RT= 1.8(4HPR) RT= 1.7 
(4HPR cis) 
RT=0.9 
(retinoic acid  
oxidzation  & 
isomers) 
Media Composition D1 D7 D1 D7 D1 D7 
PBST 2% media only 
100% 96% - 0.3% - 3.8% 
PBST 2%+ acetone 
99% 97% 0.1% 0.3% 0.7% 2.6% 
PBST 2%+ acetone+ PLGA 100% 98% 0.1% 0.2% 0.4% 1.7% 
PBST 2%+ PLGA  99% 98% - 0.1% 1.4% 2.3% 
PBST 2%+ acetone+ PLGA+ MgCO3 99% 98% 0.1% 0.3% 0.4% 1.4% 
Release from PLGA implant, PBST 2% 95% 82% 0.8% 0.6% 4.4% 17.2% 
Extracted from PLGA implant -     100% - - - - 
*Days 1 and 7 reflect the extent of degradation at retention times (RT, min) in UPLC-UV % peak 
area percentages, 365 nm. 
Figure 2 shows UPLC-UV (365nm) chromatogram traces with 3 abundant peaks present 
at RT’s ~1.8 (parent 4HPR), 1.7, and 0.9 min, which are indicative are indicative of the parent 
retinoid structure, and abundant ions identified by MS of 4HPR in PBST 2%, 4HPR release from 
PLGA millicylinders in PBST 2%, and 4HPR extracted from PLGA millicylinders.  Reference 
LC-MS/MS spectra of 4HPR and its oxidized/metabolic derivatives have previously been 
reported, and served as a reference for identification12,13.  Per AIST database, 4HPR’s most 
abundant MS/MS ions include m/z 283 (after neutral loss of 4-amino-phenol), m/z 270 (minus 
C-H), and m/z 255 (minus CH3), while the oxidization on the hexenyl ring (after loss of 4-amino-
phenol) yields ions m/z 281 and 253.  No p-amino-phenol fragment is detected in LC-MS 
extracted ion chromatogram, and therefore it is plausible that it is adhering to PLGA due to its 
strong nucleophilic character, whose attractions are favorable for 4HPR’s amide bonds cleavage, 
similar to those reported for PLGA and peptide interactions 4,7,5.  Additionally, the negative ion 
MS detected m/z 313 in only the 4HPR-PLGA millicylinder release, which is identified as 4-




oxo-retinoic acid.  The positive ion m/z 253 is only detected in the PBST release, and based on 
MS/MS fragments, does not appear to be 4HPR, but rather an isoprene unit (68 Da) with 4 CH2 
groups (14 Da). Positive ion m/z 461 and 483 are likely some adduct of 4HPR given its similar 
MS/MS fragmentation pattern as 4HPR. Further analysis of these interactions will be 
investigated through FTIR and Raman analysis in the following sections. 
 
Figure A2- 2 Qualitative LC-MS investigation of 4HPR degradation products after a) in vitro release from PLGA 
millicylinders compared to b) 4HPR in PBST, and c) stability in PLGA polymer matrix. Chromatogram traces at 
365 nm and mass spectra of positive ions at those peaks. The negative ion m/z 313 only detected in 4HPR-PLGA 
release sample. The suspected degradation products after 4HPR amide hydrolysis, p-aminophenol, was not detected 
A. 4HPR release from PLGA millicylinder in PBST, Day 7 
B.  4HPR in PBST (no PLGA) Day 7 
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in any sample (standard MS in (d)).  The suspected retinoic acid derivative degradation products at given RT’s 0.5, 
0.9, 1.7, and 1.8 min are shown in (e) and their presence in samples indicated. 
 
A2.4.3 FTIR analysis of 4HPR-acetone and 4HPR-PLGA interactions 
Fourier-Transformed Infrared (FTIR) spectroscopy is useful to assess functional groups 
that exhibit asymmetrical stretching giving rise to a net change in dipole moment, and ultimately 
ionic interactions, and is due to absorption of light by vibrating molecules. Raman spectroscopy 
is useful to assess functional groups that exhibit symmetrical stretching, polarization, covalent 
interactions, and the principle guiding the detection of these interactions is due to scattering 
(elastic and inelastic, stokes shift) of light by the vibrating molecules.  Coupled together, Raman 
and FTIR can be used in tandem to elucidate interactions. In both Raman and FTIR 
spectroscopy, molecular vibrations are influenced by neighboring atoms via vibronic coupling, 
potential energy surfaces, and masses of atoms.    
 It was suspected that interactions were occurring between PLGA, acetone, and 4HPR in 
the millicylinder (PLGA 503H + 20% 4HPR + 3% MgCO3 using acetone as carrier solvent) 
leading to slow drug release. The results from the FTIR analysis are shown in Fig. 3 and a 
detailed peak assignment can be referenced in supplemental material Table S1. It should be 
noted that electron withdrawing groups can shift the frequency higher and conjugation shifts the 
frequency lower.  It was suspected that protic polar acetone carrier solvent was a player in the 
chemistry occurring within these PLGA-4HPR films, yet it is also known that organic solvents 
can accelerate 4HPR’s photo-degradation. In Fig. 3a, the FTIR of 4HPR solid is compared to that 
of 4HPR dissolved in acetone (which was allowed to evaporate prior to analysis).  Acetone 
(characteristic ketone peak at 1709 and 1749 cm-1) altered 4HPR’s (dry) spectra, and split 
4HPR’s carbonyl region peak from amide at 1630 cm-1 into 1606 and 1641 cm-1, indicating 
4HPR and acetone’s solvate interactions at 4HPR’s carbonyl. This solvent effect on 4HPR is also 




observed in the PLGA-4HPR-MgCO3 acetone film when compared to the physical mixture (see 
Supplemental Table S1). 
Next, the interactions between PLGA and 4HPR in the PLGA-4HPR-MgCO3 acetone 
films were examined (Fig 3b). The MgCO3 did not alter the spectra of the PLGA films (data not 
shown).  The acid end-capped PLGA’s characteristics FTIR peaks include C-H stretches at 2950 
cm-1 and an intense C=O stretch at 1749 cm-1 from the carbonyls on lactic and glycolic acid 
monomers.  PLGA does not contain any peaks in the 1600-1500 cm-1 region, where 4HPR has 
strong absorptions due to amide and ring bonds.  4HPR has characteristic peaks at 3500 and 
3300 (N-H stretch, 2° amide), 1629 (C=O, strong, amide), 1575 (C=C ring stretch), 1543 and 
1505 cm-1 (N-H bending).  The most significant change in 4HPR’s spectra in the presence of 
PLGA is the disappearance of peaks at 1311 and 1245 cm-1, corresponding to C-O from phenol 
or acyl C-O, suggesting that either 4HPR’s phenolic group is interacting with PLGA. When 
examining 4HPR’s characteristic 1500-1600 region in PLGA, we see slight blue shifts, 
potentially due to H-bonding.  Also in the 4HPR-PLGA films, 4HPR’s N-H stretching peaks at 
3300, 3500 cm-1 are much less intense, possibly due to either dilution by PLGA matrix that 
masks this N-H bond, or due to hydrogen bonding between PLGA and/or acetone.  4HPR’s 
effect on PLGA’s FTIR spectra was examined (PLGA vs. 4HPR-PLGA) show identical traces, 
except in the aforementioned 1500-1600 range, indicating that PLGA structure was not altered 
by 4HPR. To conclude, the results from this FTIR analysis suggests that acetone interacts with 
4HPR at its carbonyl group, and PLGA is interacting 4HPR’s phenolic group. Further 
investigation into 4HPR’s π-electron chemistry will be investigated by Raman spectroscopy in 
the following section. 





Figure A2- 3 FTIR spectra depicting carbonyl chemistry of 4HPR interactions with (a) acetone and (b)  PLGA by 
comparing 4HPR spectra in acetone, PLGA 503H in acetone and PLGA 503H + 20% 4HPR+ 3% MgCO3 film in 
acetone. Spectral differences are noted with arrows. 
A2.4.4  Raman Spectra show 4HPR’s π-electrons not altered in PLGA matrix 
Raman spectroscopy is a useful tool to measure π-π interactions between substances, due 
to the intensities of C=C bonds, and is often used in tandem with FTIR for structural elucidation. 
4HPR’s conjugated retinoid backbone contains a large cloud of π-electrons that could interact 
with PLGA. To test this, Raman spectra of both 4HPR and PLGA +20% 4HPR + 3% MgCO3 
film were compared as shown in Figure 4.  There is no difference in the spectra, and therefore it 
can be concluded that 4HPR’s backbone is not reactive toward neither PLGA nor magnesium 

















































Figure A2- 4. Raman spectra of 4HPR (red) and PLGA +20% 4HPR + 3% MgCO3 film (black) shows that 4HPR’s 
conjugated π electrons are not interacting with PLGA. 
A2.4.5 Microcalorimetric analysis reveals residual acetone trapped in PLGA millicylinder 
affects 4HPR release 
 
 As deduced from the FTIR analysis, the protic acetone solvent used during millicylinders 
preparation may have contributed to the drug-polymer interactions. TGA was used to measure 
the amount of residual acetone remaining in the PLGA-4HPR and PLGA millicylinders after 
drying.  Melting thermograms (Fig.5 a-c, Table 2) show solvate entrapment within PLGA 
millicylinders, which could not escape until heated to 150 ˚C, well above acetone’s boiling 
temperature, suggesting that acetone is either interacting with the millicylinder components, or 
the diffusion from bulk matrix is very slow.  Here, all 4HPR (10,20,30%) PLGA + 3% MgCO3 
milliyclinders had residual solvent levels near 3-4%, while the no drug PLGA + 3% MgCO3 
millicylinder contained 5.8% residual solvent.  Since both drug loaded and unloaded implants 
had similar levels of residual solvent, we suspect that acetone entrapment is likely due to its slow 
diffusion through the bulk PLGA millicylinder, rather than complexation with 4HPR-PLGA. 
Nonetheless, the presence of acetone in the implants may accelerate the drug degradation 





























process, and potentially alter the chemistry occurring within the bulk implant, or act as a polymer 
plasticizer. 
It is known that the glass transition temperature (Tg) of a polymeric substance affects the 
drug release rate.14, 15  The percent 4HPR release by day 28 was plotted as a function of the 
implant Tg for all of our PLGA 503H formulations (Fig. 5d), and found that more drug was 
released at lower Tgs. This can be attributed to greater mobility of polymer chains, which allows 
for faster drug diffusion through the polymer matrix. Also, we had suspected that residual 
acetone or water could be trapped inside millicylinder prior to the start of release study and may 
influence the Tg.  We found that there was an exponential relationship between the percent of 
residual solvent in implant and the Tg, with greater solvent yielding lower Tg’s (Fig. 5e).  
Although all implants were subject to the same drying methods, the differences in residual 
solvent level may be due to solvate formations with agents within the millicylinder.  





Figure A2- 5. Microcalorimetric measurements by TGA and DSC reveal effects of formulation variables 
on Tms and Tgs of 4HPR PLGA (503H) millicylinders containing 3% MgCO3.  A, b,c ) TGA analysis of 
PLGA-4HPR millicylinders and starting materials depicting residual solvent entrapments, a) at full 
temperature range, b) zoomed into 25-175 °C for residual solvent determination, c) effect of 
4HPR loading in PLGA implants on solvent entrapment. See Table 2 for mass loss weights at 
150 °C. d,e) DSC data correlating the dependence of Tg of PLGA in millicylinder implants 
(which could contain up to 15% MgCO3 and 20% NaDC and 10-30% 4HPR) with d) percent 
4HPR released after 28 days in vitro, and e) The effect of residual solvent initially present in 
implants on Tg.  
 
Table A2- 2. TGA analysis of 4HPR-PLGA millicylinders for residual solvent initially present 
Compounds/ formulations Weight % remain @150 °C % Residual Solvent 
4HPR 99.7 0.3 
4HPR+acetone 99.9 0.1 
PLGA 98.7 1.3 
PLGA +3% MgCO3 millicylinder 94.2 5.8 
PLGA+ 10% 4HPR +3% MgCO3 millicylinder 95.8 4.2 
PLGA+ 20% 4HPR +3% MgCO3 millicylinder 96.6 3.4 

































































   
A2.4.6 Comprehensive Deductions of 4HPR Behavior in PLGA implants 
In this paper, we have shown that 4HPR release from PLGA millicylinders is faster in 
presence of solubilizers, and that 4HPR does not appear to be altering PLGA erosion, but rather 
the magnesium ions from the basic MgCO3 salt slow the erosion. PLGA is solubilizing and 
stabilizing 4HPR inside the millicylinder, yet once released into aqueous media 4HPR degrades 
by hydrolysis of the amide linkage into the retinoid backbone and phenol molecules. To tease out 
what may be catalyzing this degradation, we incubated 4HPR in solubilizing media in presence 
of various millicylinder components, and the UPLC analysis revealed that release from PLGA 
millicylinder, not acetone or other millicylinder components, was responsible for the 
degradation. Despite the presence of sink conditions, only 50% 4HPR released after 2 months, a 
release that is inconsistent with the typical PLGA 503H erosion patterns. To address this, we 
considered the potential interactions between 4HPR, 4HPR degradation products, acetone, 
MgCO3, and PLGA. We have shown in the FTIR spectra that 4HPR’s carbonyl region is altered 
in presence of acetone, indicating solvate-drug interactions near the amide bond.  We also see 
differences in 4HPR’s FTIR spectra in the presence of PLGA, namely the disappearance of 
peaks in the 1300 cm-1 region, likely due to interactions with 4HPR’s phenol group and PLGA 
carboxyl groups.  The Raman analysis revealed that 4HPR’s π-electrons are not altered by 
PLGA.  The microcalorimetric analysis showed that residual solvent (acetone or water) was 
trapped in the PLGA-4HPR millicylinder and this increased level of residual solvent increased 
its PLGA’s Tg, leading to a greater amount of drug released after 28 days.  Further chemical 
explanations proceed. 




It is known that PLGA is subject to hydrolysis due to nuclephilic attack of water on the 
ester carbon, resulting in the formation of a primary alcohol and carboxylic acid5.  Further 
explanations of PLGA autocatalysis and mechanisms of drug release can be referenced 
elsewhere5, 16,17. First, the most obvious reactive group is 4HPR’s phenolic group, or its 
degradation product, 4-amino-phenol after hydrolysis of 4HPR’s amide bond.  This contains a 
nucleophilic hydroxyl group and a basic amino group, where in a neutral environment the amine 
is more reactive, while in both acidic and basic environment the hydroxyl is more reactive.  
Given that PLGA’s microclimate pH is near 3.518  the chemistry is more likely to occur with the 
hydroxyl group nucleophilic attack on PLGA’s carboxylate group, as shown in Figure 8.  The 
basic salt MgCO3 may play a role in activating either 4HPR (pKa 9.75) or its amino-phenol’s 
nucleophilic reactivity, by abstraction of the acidic hydrogen on the hydroxyl group. Yet in the 
FTIR spectra, MgCO3 did not alter the spectra of the PLGA films indicating a chemical reaction 
had not occurred, yet ionic pairing could exist between PLGA’s carboxylate groups and 
magnesium ions, as evident in Figure 1b, where elevated levels of MgCO3 decreased PLGA 
erosion.  To summarize these experimental outcomes to describe 4HPR’s behavior in PLGA 
(depicted in Fig. 6): 
• Incomplete 4HPR release from PLGA after 2 months indicate PLGA-4HPR 
interactions are more favorable than 4HPR’s partition into a solubilizing tween 
micelle 
• PLGA environment is acidic, and typical erosion pattern not affected by presence of 
4HPR, but rather presence of the basic pore-forming salt MgCO3. 




• Indeed the PLGA polymer is stabilizing 4HPR, however, it degrades upon release 
into the aqueous media into retinoic acid isomerization products, which have lower 
affinity for PLGA than 4HPR. 
• FTIR analysis revealed PLGA interacting with 4HPR carbonyl or phenol, as evident 
by disappearance of C-O peak, and blue shifts of 4HPR’s amide region indicate 
hydrogen bonding with PLGA. 
• Residual acetone solvent is trapped within PLGA-4HPR millicylinder prior to release 
studies, and greater levels lead to faster drug release likely due to plasticization of 
PLGA.  
• This residual acetone solvent interacts with 4HPR’s carbonyl via hydrogen bonding, 
as evident by FTIR, making it more electron withdrawing, further activating the 
hydrolysis of the amide bond. 
• 4HPR’s suspected degradation product, p-amino-phenol, is acting as nucleophile for 
PLGA hydrolysis and is also a driving force for 4HPR’s amide hydrolysis.  Lack of 
detection of p-amino-phenol in release media and presence of cleaved retinoic acid 
by-products confirms this premise. 









We have utilized PLGA to formulate long-acting release depots to locally deliver 4HPR.  
The prolonged drug release in vitro (2+ months) in a solubilizing buffer was uncharacteristic of 
the selected PLGA’s typical erosion pattern.  The polymer was stabilizing 4HPR, however the 
drug release from the PLGA indicated degradation by LC-MS, and mass balance accounted for 
roughly 20% in the release media.  Here we have elucidated 4HPR’s interactions with PLGA 
similar to peptides’ acylation reaction with PLGA, including hydrolysis of 4HPR’s amide bond 
into retinoic acid isomerization products. Future work for utilizing the favorable PLGA polymer 
for controlled release 4HPR delivery may involve investigation of stability enhancement of 




4HPR by inclusion of different salts, solvent systems, or increasing stability of amide bond by 
bioisosteres conversions. 
  





Table A2- 3. FTIR Peak Assignments for 4HPR and 4HPR-PLGA Films 
  
4HPR, solid 4HPR in acetone PLGA 503H, in acetone PLGA- 4HPR +3% 
MgCO3 Films 
PLGA- 4HPR +3% 
MgCO3 Physical Mixture 
Acetone 
cm-1 Assignment cm-1 Assignment cm-1 Assignment cm-1 Assignment cm-1 Assignment cm-1 Assign. 
3500, 
3200 
N-H stretch, amide,          
2 indicates 1° amine 
Same as solid, 












      3414 O-H 
stretch 
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2930 C-H Stretch (alkane) 2998 C-H stretch 
(alkane) 
2950 C-H stretch 
(alkane) 
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C=O stretch,  None at 1709, therefore 




1629 C=O, amide 1641 Acetone is 
splitting 
  1641 C=O, amide 1652    
  1606   1606 N-H Bend, 1° 
amines 
Doesn’t split in physical 
mix  
  
1575 C=C stretch, amide 
 
    1571 C=C stretch, 
amide 
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1546 N-H bend, amide     1541 N-H bend 1557    





1505    
1440 -C-C stretch (in ring), 
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1393   
1363 
 
1313 C-O, phenol, or acyl    Absent Absent                Absent Absent    
1241 C-O stretch (ROH, 
COOH 
 Absent Absent   Absent Absent  1223  
















   
    1086  1083   1083  1093  
967 
956 
=C-H bend (alkenes)       968    
831    867  867  832  903  
740 C-H Rock (alkanes)   712 C-H Rock 
(alkanes) 
712 C-H Rock 
(alkanes) 
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531 
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